Quick viewing(Text Mode)

Benzoyl Peroxide and Tea Tree Oil in Acne Compositions

Benzoyl Peroxide and Tea Tree Oil in Acne Compositions

Science IP Order: 3550000

Client Reference: 3456-789

Benzoyl Peroxide and in Compositions

Prepared for Dr. Jane Doe

Imaginary Pharmaceuticals

January 9, 2013

Science IP ® 2540 Olentangy River Road Columbus, Ohio 43202 Telephone: 866-360-0814 Fax: 614-447-5443 [email protected]

CONFIDENTIAL

Table of Contents

Click (or Ctrl-click) page number to jump to a section Original Search Request 3 Science IP’s Understanding of the Request 3 Science IP Search Results 4 Research Summary 4 Discussion of Search Strategy 4 Detailed Results 5 Patent References 5 Non-Patent References 139 Science IP Search Documentation 149 Search Strategy 149 Sources Used 156

Primary Searcher: Sharilyn Woods

Disclaimer Copyright©2013. American Chemical Society (ACS). All Rights Reserved. Except for distribution to Customer’s immediate client, any distribution of this report in any form without prior written permission from ACS is prohibited.

The information contained herein has been obtained from sources believed to be reliable. Science IP, Chemical Abstracts Service (CAS), and American Chemical Society (ACS) disclaim all warranties as to accuracy, completeness or adequacy of such information; and shall have no liability for errors, omissions or inadequacies in the information contained herein or the interpretation thereof.

Science IP does not provide legal advice. For legal advice, please review with your legal counsel.

Page 2 of 158

Science IP Order: 3550000 Client Reference: 3456-789

Original Search Request

Conduct a search of the literature and patents for references to acne compositions containing benzoyl peroxide and tea tree oil. Remove the duplicates.

Science IP’s Understanding of the Request

Search the literature and patents for references containing benzoyl peroxide and tea tree oil in acne compositions. Remove the duplicates

Page 3 of 158

Science IP Order: 3550000 Client Reference: 3456-789

Science IP Search Results

Research Summary A search was conducted in the Chemical Abstracts database for benzoyl peroxide by CAS Registry Number and by names collected from the Chemical Abstracts Registry and combined with references to tea tree oil or melaleuca. These references were then combined with terms for acne or anti-acne, and 28 references were retrieved.

A search was conducted in the Derwent World Patents Index for benzoyl peroxide by Derwent Registry Number and by names and combined with the results for tea tree oil by Derwent Registry Number and by names. These references were then combined with terms for acne or anti-acne, and 33 references were retrieved.

A search was conducted in the fulltext patent databases (US, EP, FR, GB, DE, WO, AU, CA, CN and JP), and three different approaches were used to help target the results. Benzoyl peroxide was searched within 250 words of tea tree oil within 250 words of the acne terms. Benzoyl peroxide was searched within 250 words of tree oil and then combined with terms for acne or anti-acne. The third approach was for all of the concepts to be limited to the title, abstract or claims. The three approaches retrieved 311 references.

Other bibliographic patent databases were searched for benzoyl peroxide and tea tree oil and acne terms, and 49 references were retrieved.

STNIndex which is an index to more than 120 databases on STN was searched to identify which databases might contain references on our search topic. Nine additional databases were identified and searched, and 41 references were retrieved.

The duplicates were removed, and 199 patent references and 42 non-patent literature references were retrieved. These references can be found below in the Detailed Results section with the bibliographic citation, abstracts and either hit indexing or keywords in context displayed.

Please let me know if you have any questions.

Discussion of Search Strategy

The scope of each database searched is shown in the Sources Used section at the end of the report. If additional information about the databases is desired, please contact the searcher.

Answers resulting from text search strategies are general and it is likely that some answers will not be of interest.

Return to Table of Contents

Page 4 of 158

Science IP Order: 3550000 Client Reference: 3456-789

Detailed Results Hypertext links have been added to selected patent numbers. Links for US documents open the corresponding Google Patents web page. Links for AU, CA, DE, EP, FR, GB, and WO documents open the corresponding page at the Espacenet web site. A patent family link has been added to USPATFULL and USPAT2 citations. Patents for other patent authorities (and non-patent records) are available, via CAS Fulltext Options, by clicking the ‘Full-text’ link above the patent titles.

Patent References For this sample report, only the 26 references from HCAPLUS, the first 7 references from USPATFULL, the first 4 references from PCTFull, and the reference from IFIPAT are displayed below.

L56 ANSWER 1 OF 199 HCAPLUS COPYRIGHT 2013 ACS on STN ACCESSION NUMBER: 2012:1402229 HCAPLUS Full-text DOCUMENT NUMBER: 157:530072 TITLE: Treatment of inflammatory and infectious skin disorders INVENTOR(S): Taylor, Emma PATENT ASSIGNEE(S): University of California, USA SOURCE: PCT Int. Appl., 48pp. LANGUAGE: English PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE ------WO 2012129499 A1 20120927 WO 2012-US30335 20120323 PRIORITY APPLN. INFO.: US 2011-466510P P 20110323 AB Disclosed herein is a compn. comprising of and/or derivs. thereof and/or functionally related compds. and benzoyl peroxide and/or derivs. thereof and/or functionally related compds. for the treatment of acne and other inflammatory or infectious skin disorders. Also disclosed are methods of treating acne and other inflammatory and infectious skin disorders using the compns. described herein. Efficacy of a combination benzoyl peroxide and resvetraol against of Pityrosporum acnes acnes was shown. IPCI A61K0009-06 [I,A]; A61K0009-20 [I,A]; A61K0031-03 [I,A]; A61K0031-075 [I,A]; A61K0031-085 [I,A]; A61P0031-00 [I,A]; A61P0017-10 [I,A] IPCR A61K0009-06 [I,A]; A61K0009-20 [I,A]; A61K0031-03 [I,A]; A61K0031-075 [I,A]; A61K0031-085 [I,A]; A61P0017-10 [I,A]; A61P0031-00 [I,A] CC 63-6 (Pharmaceuticals) Section cross-reference(s): 1 ST inflammatory infectious skin disorder treatment benzoyl peroxide resvetraol IT Essential oils RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Melaleuca; treatment of inflammatory and infectious skin disorders) IT Acne (vulgaris; treatment of inflammatory and infectious skin disorders) IT 52-01-7, 68-26-8, 69-72-7, , biological studies 79-14-1, Glycolic acid, biological studies 94-36-0, Benzoyl peroxide, biological studies 112-38-9, 114-07-8, 123-99-9, , biological studies 127-56-0, Sulfacetamide 130-26-7, 302-79-4, 501-36-0, Resveratrol 501-36-0D, Resveratrol, derivs. 537-42-8 537-42-8, Pterostilbene 777-11-7,

Page 5 of 158

Science IP Order: 3550000 Client Reference: 3456-789

Haloprogin 1397-89-3, 1400-61-9, 1404-04-2, 1404-26-8, Polymyxin B 1405-87-4, 1406-18-4, Vitamin E 2398-96-1, 4759-48-2, Isotretinoin 7704-34-9, Sulfur, biological studies 12650-69-0, 18323-44-9, 22199-08-2, sulfadiazine 22255-22-7 22916-47-8, 23593-75-1, 27208-80-6, trans-Piceid 29342-05-0, 38963-95-0, Resveratroloside 42438-89-1 53515-95-0 62218-08-0, ε-Viniferin 62218-13-7, α-Viniferin 65277-42-1, 65472-88-0, 86386-73-4, 91161-71-6, 99592-32-2, 101828-21-1, 106685-40-9, Adapalene 118292-40-3, Tazarotene) 145356-39-4 148766-36-3, cis-Piceid 150258-83-6 204076-78-8 224452-66-8, 1093198-85-6 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (treatment of inflammatory and infectious skin disorders)

Page 6 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 2 OF 199 HCAPLUS COPYRIGHT 2013 ACS on STN ACCESSION NUMBER: 2012:1117168 HCAPLUS Full-text DOCUMENT NUMBER: 157:338049 TITLE: Oil compositions for treatment of dermatological disorders INVENTOR(S): Edelson, Jonathan; Kotyla, Timothy; Theobald, Klaus PATENT ASSIGNEE(S): Anterios, Inc., USA SOURCE: PCT Int. Appl., 73pp. LANGUAGE: English PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE ------WO 2012103037 A1 20120802 WO 2012-US22278 20120123 US 20120328549 A1 20121227 US 2012-356634 20120123 PRIORITY APPLN. INFO.: US 2011-435752P P 20110124 AB The present invention provides oil compns. and assocd. methods and reagents, useful for the treatment and/or prevention of dermatol. conditions. The compns. comprise an oil agent including oils contg. a medium-chain triglyceride, a surfactant, a , and a least one inactive agent. The oil agents inhibit activity of sweat and/or sebaceous glands, show antiperspirant and/or deodorant activity and can be used to treat or prevent certain clin. conditions assocd. with sweat, such as, for example, , and bromhidrosis. The oil compns. provided are formulated for and achieve transdermal delivery, for example by topical administration. For example, antiperspirant effects of topical Labrafac Lipopihle WL 1349 was demonstrated in subjects with excessive sweating and may be used effectively in treating hyperhidrosis. IPCI A61P0017-10 [I,A]; A61K0031-20 [I,A] IPCR A61P0017-10 [I,A]; A61K0031-20 [I,A] CC 63-6 (Pharmaceuticals) Section cross-reference(s): 1, 62 IT Essential oils RL: COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Melaleuca alternifolia; oil compns. for treatment and/or prevention of dermatol. conditions) IT Dermatological agents (anti-acne agents; oil compns. for treatment and/or prevention of dermatol. conditions) IT Acne Alopecia Antibacterial agents Antiperspirants Burn Dermatological agents Eczema Human Hyperhidrosis Jatropha curcas Lupus erythematosus Oral drug delivery systems Personal deodorants Pharmaceutical creams Pharmaceutical gels Pharmaceutical injections Pharmaceutical ointments Pharmaceutical powders Prophylaxis Psoriasis

Page 7 of 158

Science IP Order: 3550000 Client Reference: 3456-789

Raynaud disease Seborrhea Skin, neoplasm Skin disease Skin hyperpigmentation Skin Sunscreens Surfactants Sweat gland Topical drug delivery systems Transdermal drug delivery systems (oil compns. for treatment and/or prevention of dermatol. conditions) IT 60-54-8, 68-26-8, Retinol 94-36-0, Benzoyl peroxide, biological studies 110-40-7, Diethyl sebacate 114-07-8, Erythromycin 123-95-5, Butyl stearate 143-28-2, Oleyl 302-79-4, Tretinoin 1327-41-9, Aluminum chlorohydrate 3380-34-5, 4759-48-2, Isotretinoin 7429-90-5D, Aluminum, compd. with zirconium 7440-67-7D, Zirconium, compd. with aluminum 7446-70-0, Aluminum chloride, biological studies 7784-25-0, Ammonium alum 9005-65-6, Polysorbate 80 9006-65-9, Dimethicone 10284-64-7, Aluminum dichlorohydrate 18323-44-9, Clindamycin 18472-51-0, gluconate 34513-50-3, Octyldodecanol 53026-85-0, Aluminum Chlorohydrex 106685-40-9, Adapalene 107231-12-9, Botulinum toxin 118292-40-3, Tazarotene 134375-99-8, Aluminum Zirconium Trichlorohydrex Gly 134910-86-4, Aluminum Zirconium Tetrachlorohydrex Gly 173763-15-0, Aluminum sesquichlorohydrate 773082-14-7, Aluminum dichlorohydrex RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (oil compns. for treatment and/or prevention of dermatol. conditions)

Page 8 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 3 OF 199 HCAPLUS COPYRIGHT 2013 ACS on STN ACCESSION NUMBER: 2012:640420 HCAPLUS Full-text DOCUMENT NUMBER: 156:597448 TITLE: High lubrication shaving aid comprising surfactants and organic polyhalogenic post-foaming agents INVENTOR(S): Kulesza, John E. PATENT ASSIGNEE(S): USA SOURCE: PCT Int. Appl., 23pp. LANGUAGE: English PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE ------WO 2012057782 A1 20120503 WO 2010-US54705 20101029 PRIORITY APPLN. INFO.: WO 2010-US54705 20101029 AB A shaving aid compn. is provided comprising a hydrophilic surfactant, such as triethanolamine stearate, at 5-20% by wt., an org. polyhalogenic agent at 3-10% by wt. that both promotes post application foaming, increases lubricity, and reduces skin irritation. The shaving aid is optionally used to deliver one or more therapeutics to the skin of a subject and is therefore operable to prevent or treat a , such as acne. Shaving compns. comprising triethanolamine stearate surfactant and CF-61 and CF-76 post-foaming agents were exemplified. Inclusion of 5% benzoyl peroxide reduced acne vulgaris and pseudofolliculitis barbaein humans. IPCI A61K0008-36 [I,A]; A61K0008-30 [I,A]; A61K0008-67 [I,A]; A61K0008-02 [I,A]; A61Q0019-00 [I,A] IPCR A61K0008-36 [I,A]; A61K0008-02 [I,A]; A61K0008-30 [I,A]; A61K0008-67 [I,A]; A61Q0019-00 [I,A] CC 62-4 (Essential Oils and Cosmetics) Section cross-reference(s): 63 IT Essential oils RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses) (Melaleuca alternifolia; high lubrication shaving compns. comprising surfactants, org. polyhalogenic post-foaming agents and therapeutic agents for preventing or treating skin condition) IT Dermatological agents (anti-acne agents; high lubrication shaving compns. comprising surfactants, org. polyhalogenic post-foaming agents and therapeutic agents for preventing or treating skin condition) IT Acne (vulgaris; high lubrication shaving compns. comprising surfactants, org. polyhalogenic post-foaming agents and therapeutic agents for preventing or treating skin condition) IT 57-11-4, Stearic acid, biological studies 57-55-6, Propylene glycol, biological studies 69-72-7, Salicylic acid, biological studies 94-36-0, Benzoyl peroxide, biological studies 102-71-6, Triethanolamine, biological studies 108-46-3, Resorcinol, biological studies 3380-34-5, Triclosan 4568-28-9, Triethanolamine stearate 9002-88-4, Polyethylene 9003-39-8, Povidone 11103-57-4, 25322-68-3, PEG 36653-82-4, 37321-65-6, Propylene glycol stearate 59409-41-5 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses) (high lubrication shaving compns. comprising surfactants, org. polyhalogenic post-foaming agents and therapeutic agents for preventing or treating skin condition)

Page 9 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 4 OF 199 HCAPLUS COPYRIGHT 2013 ACS on STN ACCESSION NUMBER: 2012:533474 HCAPLUS Full-text DOCUMENT NUMBER: 156:515812 TITLE: Treatment of acne by stem cell conditioned media INVENTOR(S): Riordan, Neil H.; Riordan, Tiemey M. PATENT ASSIGNEE(S): Aidan Research and Consulting, Llc., USA SOURCE: PCT Int. Appl., 51pp. LANGUAGE: English PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE ------WO 2012047733 A2 20120412 WO 2011-US54094 20110929 WO 2012047733 A3 20120621 US 20120195969 A1 20120802 US 2011-249145 20110929 PRIORITY APPLN. INFO.: US 2010-387885P P 20100929 AB The present invention relates to methods and topical compns. for treatment of acne or acneform conditions, particularly, but not limited to acne vulgaris, with products generated from culture of stem or progenitor cells. For example, mesenchymal stem cells, obtained from placenta using collagenase and phosphate- buffered saline (PBS), were suspended in α-MEM culture media supplemented with fetal bovine serum (FBS) and , and the culture medium was changed every 2-3 days. Upon confluence, cells were trypsinized, washed, and cultured in Roswell Park Memorial Institute (RPMI) media without red or FBS for 24 h. The conditioned media was collected and sterile filtered to exclude cells and cellular debris. The media was then mixed at a 1:1 vol. ratio with a moisturizing cream and used for topical treatment of a female with history of severe acne. After 3 days 18 of the inflammatory lesions and 1 of the noninflammatory lesions had resolved. At the end of 10 days only 2 noninflammatory lesions remained on the patient's face. IPCI A61K0035-12 [I,A]; A61K0038-18 [I,A]; A61K0038-19 [I,A]; A61K0031-185 [I,A]; A61K0031-07 [I,A]; A61P0017-00 [I,A] IPCR A61K0035-12 [I,A]; A61K0031-07 [I,A]; A61K0031-185 [I,A]; A61K0038-18 [I,A]; A61K0038-19 [I,A]; A61P0017-00 [I,A] CC 63-6 (Pharmaceuticals) Section cross-reference(s): 1, 9, 62 ST stem cell conditioned culture media topical acne IT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (3CB2; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT ATP-binding cassette transporters RL: BSU (Biological study, unclassified); BIOL (Biological study) (ABCG2, biomarker; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (ASMA, biomarker; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (BLB; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Fats and Glyceridic oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Bois; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT CD antigens RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD133; topical compns. comprising conditioned media of cultured stem

Page 10 of 158

Science IP Order: 3550000 Client Reference: 3456-789

cells for treatment of acne) IT CD antigens RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD29, biomarker; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT CD antigens RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD54, biomarker; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT CD antigens RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD63, biomarker; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT CD antigens RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD9, biomarker; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT CD antigens RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD90, biomarker; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT CXC chemokine receptors RL: BSU (Biological study, unclassified); BIOL (Biological study) (CXCR4, biomarker; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (Cripto, biomarker; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (C1-12; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Alcohols RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (C16-18, cetostearyl alc.; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT inhibitors (DNA methyltransferase inhibitors; topical compns. comprising conditioned media of cultured stem cells for treatment of acne ) IT Hematopoietin receptors RL: BSU (Biological study, unclassified); BIOL (Biological study) (FLT3 receptors, ; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Histocompatibility antigens RL: BSU (Biological study, unclassified); BIOL (Biological study) (HLA, class I, biomarker; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Intercellular adhesion molecules RL: BSU (Biological study, unclassified); BIOL (Biological study) (ICAM-1, biomarker; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Proteins RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses) (Kirre; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Fats and Glyceridic oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

Page 11 of 158

Science IP Order: 3550000 Client Reference: 3456-789

(Kuki nut; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Antigens RL: BSU (Biological study, unclassified); BIOL (Biological study) (Ly-6A, biomarker; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (MEPE, biomarker; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Marhoram; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Melaleuca; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (Muashi-1; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Transcription factors RL: BSU (Biological study, unclassified); BIOL (Biological study) (NANOG, biomarker; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Octamer transcription factors RL: BSU (Biological study, unclassified); BIOL (Biological study) (Oct-3, biomarker; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (PODXL (podocalyxin-like protein), biomarker; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Paired box transcription factors RL: BSU (Biological study, unclassified); BIOL (Biological study) (Pax6; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (RC-2; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (SH-3, biomarker; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (SH-4, biomarker; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Transcription factor SOX RL: BSU (Biological study, unclassified); BIOL (Biological study) (SOX2, biomarker; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Antigens RL: BSU (Biological study, unclassified); BIOL (Biological study) (SSEA-3 (stage-specific embryonic antigen 3), biomarker; topical compns. comprising conditioned media of cultured stem cells for treatment of acne)

Page 12 of 158

Science IP Order: 3550000 Client Reference: 3456-789

IT Antigens RL: BSU (Biological study, unclassified); BIOL (Biological study) (SSEA-4 (stage-specific embryonic antigen 4), biomarker; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Antigens RL: BSU (Biological study, unclassified); BIOL (Biological study) (STRO-1, biomarker; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (Tra-1-60, biomarker; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (Tra-1-81, biomarker; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Umbilical cord (Warton's jelly; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Wnt proteins RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses) (Wnt-3A; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Keloid (acne; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Wnt proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (agonists; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Fats and Glyceridic oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (allspice; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Fats and Glyceridic oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (almond; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Proteins RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses) (angiopoietin-like 2; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Proteins RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses) (angiopoietin-like 3; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Fats and Glyceridic oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (animal; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (anise; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Dermatological agents (anti-acne agents; topical compns. comprising conditioned

Page 13 of 158

Science IP Order: 3550000 Client Reference: 3456-789

media of cultured stem cells for treatment of acne) IT Fats and Glyceridic oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (apricot kernel; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Solvents (aprotic; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Fats and Glyceridic oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (argan; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Fats and Glyceridic oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (avocado; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (basil, Ocimum basilicum; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (bergamot; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Fats and Glyceridic oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (berry; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Activated leukocyte cell adhesion molecules CD34 antigens CD44 antigens Endoglins Melanoma cell adhesion molecules Vascular cell adhesion molecule 1 Vimentins c-Kit proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (biomarker; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (cassia; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (cedarwood; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (celery seed; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (chamomile; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Fats and Glyceridic oils

Page 14 of 158

Science IP Order: 3550000 Client Reference: 3456-789

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (chili; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (cinnamon; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (clary sage; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Stem cell (cloned; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (clove; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combination with; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Acne (; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Culture media (conditioned; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (cumin; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Skin (dermis; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Stem cell (embryonic; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Skin (epidermis; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (eucalyptus; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Tooth (exfoliated, stem cells derived from; topical compns. comprising conditioned media of cultured stem cells for treatment of acne ) IT Blood serum (fetal bovine serum (FBS); topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Fats and Glyceridic oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (fish; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Hair (follicle, stem cells of; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Essential oils

Page 15 of 158

Science IP Order: 3550000 Client Reference: 3456-789

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (geranium; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (ginger; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Amino acid transporters RL: BSU (Biological study, unclassified); BIOL (Biological study) (glutamate-aspartate transporter; topical compns. comprising conditioned media of cultured stem cells for treatment of acne ) IT Fats and Glyceridic oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (gourd; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Fats and Glyceridic oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (grape seed; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (grapefruit; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Fats and Glyceridic oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (hazelnut; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Fats and Glyceridic oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (hemp seed; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Lanolin RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (hydrogenated; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (hyssop; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Controlled-release drug delivery systems (immediate-release; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (jasmine; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (juniper; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (laurel leaf; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (lavender; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils

Page 16 of 158

Science IP Order: 3550000 Client Reference: 3456-789

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (lemon; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (lemongrass; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (lime; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Alcohols RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (linear, esters, ceraphyls; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Fats and Glyceridic oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (macadamia nut; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (manuka; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Triglycerides RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (medium-chain; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Stem cell (mesenchymal stem cell; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Fats and Glyceridic oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (mustard; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Perfumes (myrrh; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Stem cell (neural; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (nutmeg; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Biomarkers (of stem cells; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Resins RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (olibanum; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (orange, sweet; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (oregano; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Solvents

Page 17 of 158

Science IP Order: 3550000 Client Reference: 3456-789

(org.; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Transcription factors RL: BSU (Biological study, unclassified); BIOL (Biological study) (p27rex-1, biomarker; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (patchouli; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Physiological saline solutions (phosphate-buffered; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Sebaceous gland (pilosebaceous; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pine leaf; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Fats and Glyceridic oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pine seed; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Fats and Glyceridic oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (poppyseed; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Glycoproteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (prominin 1; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Solvents (protic; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Fats and Glyceridic oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pumpkin seed; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Endometrium (regenerative cells of; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Fats and Glyceridic oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (rice bran; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (rose; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (rosemary; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

Page 18 of 158

Science IP Order: 3550000 Client Reference: 3456-789

(rosewood; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (sage, Salvia officinalis; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (sandalwood; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (sassafras; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Fats and Glyceridic oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (sesame; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Hedgehog protein RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses) (sonic; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (sour orange neroli; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (sour orange; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (spearmint; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Embryo, animal (stem cell; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Adipose tissue Endothelium Heart Intestine Kidney Liver Osteoblast Osteoclast Parthenogenesis (stem cells derived from; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Cord blood Placenta (stem cells of; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Fats and Glyceridic oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (teaseed; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (thyme, Thymus vulgaris; topical compn. derived from conditioned media

Page 19 of 158

Science IP Order: 3550000 Client Reference: 3456-789

of cultured stem cells for treatment of acne) IT Combination chemotherapy Controlled-release drug delivery systems Cosmetic liquids Cosmetic packs Pharmaceutical carriers Pharmaceutical emulsions Pharmaceutical excipients Pharmaceutical gels Pharmaceutical ointments Pharmaceutical patches Topical drug delivery systems (topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Canola oil Coconut oil Corn oil Cottonseed oil Essential oils Essential oils Hydrocarbon oils Hydrocarbon oils Isoalkanes Jojoba oil Linseed oil Oils Olive oil Palm kernel oil Palm oil Paraffin oils Peanut oil Petrolatum Polysiloxanes Rape oil Safflower oil Soaps Soybean oil Sunflower oil RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Acne Animal tissue culture Anti-inflammatory agents Chelating agents Fever and Hyperthermia Hematopoietic precursor cell Histone deacetylase inhibitors Human Hypoxia Nonpolar solvents Polar solvents Scar Stem cell Surfactants Thickening agents (topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Nestins

Page 20 of 158

Science IP Order: 3550000 Client Reference: 3456-789

RL: BSU (Biological study, unclassified); BIOL (Biological study) (topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Bone morphogenetic protein 2 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses) (topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Fibronectins RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses) (topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Growth factors, animal RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses) (topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Hepatocyte growth factor RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses) (topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Interleukin 11 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses) (topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Interleukin 5 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses) (topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Interleukin 6 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses) (topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Leukemia inhibitory factor RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses) (topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Transforming growth factor β RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses) (topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Alcohols RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Glycols RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Polyoxyalkylenes RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (topical compns. comprising conditioned media of cultured stem cells for treatment of acne)

Page 21 of 158

Science IP Order: 3550000 Client Reference: 3456-789

IT Alcohols RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (trihydric; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Fats and Glyceridic oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (truffle; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Bombesin receptors RL: BSU (Biological study, unclassified); BIOL (Biological study) (type BB2, biomarker; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Collagens RL: BSU (Biological study, unclassified); BIOL (Biological study) (type I, biomarker; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (valerian; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Fats and Glyceridic oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (vegetable; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Acne (vulgaris; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT Fats and Glyceridic oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (walnut kernel oil; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Vitamins RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (water-insol.; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Fats and Glyceridic oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (wheat germ; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (wintergreen; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (ylang-ylang; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT Integrins RL: BSU (Biological study, unclassified); BIOL (Biological study) (β1, biomarker; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT 9001-78-9, Alkaline phosphatase 9027-73-0, CD73 9028-86-8, dehydrogenase 9054-63-1, CD13 antigen 120178-12-3, Telomerase reverse transcriptase RL: BSU (Biological study, unclassified); BIOL (Biological study) (biomarker; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT 69-72-7, Salicylic acid, biological studies 94-36-0, Benzoyl peroxide, biological studies RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

Page 22 of 158

Science IP Order: 3550000 Client Reference: 3456-789

(combination with; topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT 9037-42-7, DNA methyltransferase RL: BSU (Biological study, unclassified); BIOL (Biological study) (inhibitor; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT 9076-57-7, Histone deacetylase, inhibitor RL: BSU (Biological study, unclassified); BIOL (Biological study) (inhibitors; topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT 50-21-5D, , C12-15 alkyl esters 50-70-4, , biological studies 60-29-7, , biological studies 60-33-3, , biological studies 64-18-6, , biological studies 64-19-7, , biological studies 67-64-1, Acetone, biological studies 67-66-3, , biological studies 67-68-5, Dimethyl sulfoxide, biological studies 68-12-2, , biological studies 71-23-8, n-Propanol, biological studies 71-36-3, n-Butanol, biological studies 71-43-2, Benzene, biological studies 75-05-8, Acetonitrile, biological studies 75-09-2, Dichloromethane, biological studies 102-76-1, Triacetin 108-88-3, Toluene, biological studies 109-99-9, Tetrahydrofuran, biological studies 110-27-0, Isopropyl myristate 110-54-3, Hexane, biological studies 111-02-4, 112-10-7, Isopropyl stearate 112-80-1, Oleic acid, biological studies 118-60-5, Octyl salicylate 122-62-3, Dioctyl sebacate 123-91-1, 1,4-Dioxane, biological studies 123-95-5, Butyl stearate 134-09-8, Menthyl anthranilate 141-78-6, Ethyl , biological studies 143-28-2, 540-10-3, Cetyl palmitate 1323-03-1, Myristyl lactate 3687-46-5, Decyl oleate 6283-92-7, Lauryl lactate 6938-94-9, Diisopropyl adipate 8013-52-3, Industrial methylated spirit 16958-85-3, Octyl palmitate 25265-75-2, Butylene glycol 27458-93-1, Isostearyl alcohol 27841-06-1 29710-31-4, Cetyl octanoate 31807-55-3, Isododecane 35274-05-6, Cetyl lactate 42233-08-9, Tridecyl behenate 58958-60-4, Isostearyl neopentanoate 90052-75-8, Octyldodecyl stearoyl stearate 97338-28-8 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (topical compn. derived from conditioned media of cultured stem cells for treatment of acne) IT 9001-12-1, Collagenase 9014-42-0, Thrombopoietin 9061-61-4, Nerve growth factor 11096-26-7, Erythropoietin 62683-29-8, Colony-stimulating factor 67763-96-6, IGF-1 83869-56-1, Granulocyte-macrophage colony-stimulating factor 106096-93-9, BFGF 143011-72-7, Granulocyte colony-stimulating factor 1199555-26-4, α-MEM RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses) (topical compns. comprising conditioned media of cultured stem cells for treatment of acne) IT 56-81-5, , biological studies 57-55-6, Propylene glycol, biological studies 59-52-9, 60-00-4, Ethylenediaminetetraacetic acid, biological studies 64-17-5, , biological studies 67-56-1, , biological studies 67-63-0, , biological studies 107-15-3, Ethylenediamine, biological studies 637-12-7, Aluminum stearate 7664-38-2D, , di- and trialkyl esters 25322-68-3, RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (topical compns. comprising conditioned media of cultured stem cells for treatment of acne)

Page 23 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 5 OF 199 HCAPLUS COPYRIGHT 2013 ACS on STN ACCESSION NUMBER: 2012:431190 HCAPLUS Full-text DOCUMENT NUMBER: 156:432088 TITLE: Pharmaceutical or cosmetic compositions comprising benzoyl peroxide INVENTOR(S): Levin, Daniel; Harms, Arthur PATENT ASSIGNEE(S): Norac Pharma, USA SOURCE: PCT Int. Appl., 69pp. LANGUAGE: English PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE ------WO 2012037000 A1 20120322 WO 2011-US51153 20110912 US 20120064135 A1 20120315 US 2011-210855 20110816 PRIORITY APPLN. INFO.: US 2010-383149P P 20100915 US 2010-389456P P 20101004 US 2011-210855 A 20110816 AB The present invention relates to the prepn. of compns. comprising benzoyl peroxide, with or without other addnl. active ingredients. The process involves introducing benzoyl peroxide, along with any other active ingredients present, into a fatty substance that contains and protects the ingredients that would otherwise be unstable when in contact with one another. The compn. is designed to allow all ingredients to become available for skin contact or skin absorption when the fatty substance softens and/or melts as the compn. is applied to the skin. The benzoyl peroxide may be pre-micronized to a particle distribution size of about d90 of 0.1 to 150 µ, preferably d90 of 10 to 15 µ. Further, pharmaceutical or cosmetic ingredients may be contained within the fatty substances, with or without, benzoyl peroxide therein or may be present outside of the fatty substance but elsewhere within formulated pharmaceutical or cosmetic products using the active ingredients protected by the fatty substance. These compns. are useful in aq.-based formulations to treat diseases by topical, transdermal and/or s.c. administration. Thus, a formulation contained tretinoin 0.1, benzoyl peroxide 15.0, water 49.25, xanthan gum 0.3, Polyoxyl 40 stearate 5.0, stearic acid 17.0, stearyl alc. 3.0, iso-Pr myristate 10.0, BHT 0.1, and sorbic acid 0.2 g. IPCI A01N0031-00 [I,A]; A61K0031-075 [I,A] IPCR A01N0031-00 [I,A]; A61K0031-075 [I,A] CC 63-6 (Pharmaceuticals) Section cross-reference(s): 62 ST pharmaceutical cosmetic benzoyl peroxide IT Resins RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Manila elemi; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Essential oils RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Melaleuca; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Fats and Glyceridic oils RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (animal; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Skin disease (bacterial; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Materials

Page 24 of 158

Science IP Order: 3550000 Client Reference: 3456-789

(fatty; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Shear (high; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Fats and Glyceridic oils RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (hydrogenated; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Carboxylic acids RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (hydroxy; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Fats and Glyceridic oils RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (kokum; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Fats and Glyceridic oils RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (mango kernel; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Fluidization (microfluidization; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Acne Animal virus Antibiotics Antitumor agents Antiviral agents Beeswax Butter Ceiba pentandra Controlled-release drug delivery systems Cosmetics and Personal care products Drug delivery systems Emulsifying agents Fungi Fungicides Grease (food-derived) Mammary gland, neoplasm Melanoma Melting point Neoplasm Particle size distribution Rosacea Skin Stability Tinea pedis Topical drug delivery systems Transdermal drug delivery systems Vitiligo Wart Witch hazel (pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Alkanes

Page 25 of 158

Science IP Order: 3550000 Client Reference: 3456-789

Carnauba wax Castor oil Coal tar Cocoa butter Coconut oil Cottonseed oil Estrogens Fats and Glyceridic oils Glucocorticoids Glycerides Hydrocarbon oils Jojoba oil Lanolin Lard Olive oil Palm oil Paraffin oils Petroleum Polyesters Polyoxyalkylenes Progestogens Retinoids Tallow Triglycerides Vitamins RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Resins RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (podophyllum; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Polyethers RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (polyester-, block, diblock; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Polyesters RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (polyether-, block, diblock; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Pharmaceutical injections (s.c. injections; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Fats and Glyceridic oils RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (shea butter; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Tinea (skin disease) (tinea unguium; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Fats and Glyceridic oils RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);

Page 26 of 158

Science IP Order: 3550000 Client Reference: 3456-789

USES (Uses) (vegetable; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Fats and Glyceridic oils RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (wheat germ; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Antibiotics (β-lactam; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT 9004-95-9, Ethoxylated cetyl alcohol RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Brij C 10, Brij 52; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT 9002-92-0, Ethoxylated lauryl alcohol RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Brij L 23; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT 50-18-0 50-23-7 50-24-8 50-78-2 50-81-7, L-Ascorbic acid, biological studies 51-21-8 56-25-7 57-10-3, Hexadecanoic acid, biological studies 57-10-3D, Hexadecanoic acid, esters 57-11-4, Octadecanoic acid, biological studies 57-11-4D, Octadecanoic acid, esters 57-62-5 59-05-2 60-54-8 67-45-8 68-26-8, Retinol 69-72-7, biological studies 70-10-0 76-25-5 77-52-1 79-14-1, biological studies 94-36-0, biological studies 97-00-7 106-79-6 108-46-3, 1,3-Benzenediol, biological studies 111-01-3 111-46-6, biological studies 112-37-8, Undecanoic acid 112-53-8, 1- 112-86-7 112-95-8, Eicosane 114-07-8, Erythromycin 123-76-2 124-18-5, Decane 124-94-7 126-07-8 130-26-7 143-07-7, Dodecanoic acid, biological studies 154-21-2 302-79-4, 334-48-5, Decanoic acid 338-98-7 356-12-7 378-44-9 472-15-1 508-02-1 536-59-4 538-24-9 544-63-8, Tetradecanoic acid, biological studies 564-25-0 593-45-3, Octadecane 626-86-8 629-94-7, Heneicosane 777-11-7 859-18-7 1143-38-0 1314-13-2, oxide (ZnO), biological studies 1397-89-3, Amphotericin B 1400-61-9, Nystatin 1403-66-3, 1404-04-2, Neomycin 1404-26-8, Polymyxin B 1405-87-4, Bacitracin 1406-16-2, Vitamin D 1406-18-4, Vitamin E 2022-85-7 2098-66-0 2135-17-3 2152-44-5 2398-96-1 3055-97-8 3093-35-4 3116-76-5 4419-39-0 4759-48-2 5593-20-4 5633-20-5 6713-27-5 7681-93-8 7704-34-9, Sulfur, biological studies 7733-02-0 7761-88-8, silver(1+) salt (1:1), biological studies 9004-98-2, Brij 98 9005-00-9, Brij S10 10118-90-8 10540-29-1 11056-06-7, Bleomycin 11103-57-4, Vitamin A 11111-12-9, Cephalosporin 12001-76-2, Vitamin B 12650-69-0 15387-18-5 18323-44-9 21462-39-5 22832-87-7 22916-47-8 23214-92-8 23593-75-1 24169-02-6 24729-96-2 25036-49-1 25322-68-3 27196-00-5, Tetradecanol 27523-40-6 28069-65-0 29342-05-0 30303-65-2, Docosanol 33069-62-4 39809-25-1 55079-83-9 56049-79-7 56093-45-9, 56420-45-2 59277-89-3 60628-96-8 61318-91-0 64872-76-0 65277-42-1 65899-73-2 67392-87-4 67915-31-5 78613-35-1 80474-14-2 84625-61-6 85213-14-5, -dipropylene glycol-phthalic anhydride-trimethylolpropane alternating copolymer 86386-73-4 90566-53-3 91161-71-6 99011-02-6 101530-10-3 101828-21-1 104227-87-4 104987-11-3 105102-22-5 106685-40-9 107868-30-4 112809-51-5 114977-28-5 118292-40-3 120511-73-1 124832-26-4 130726-68-0 137071-32-0 137234-62-9 153559-49-0 171228-49-2 184475-35-2 918504-65-1 1006879-72-6

Page 27 of 158

Science IP Order: 3550000 Client Reference: 3456-789

RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmaceutical or cosmetic compns. comprising benzoyl peroxide)

Page 28 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 6 OF 199 HCAPLUS COPYRIGHT 2013 ACS on STN ACCESSION NUMBER: 2012:379957 HCAPLUS Full-text DOCUMENT NUMBER: 156:431081 TITLE: Antiaging and wrinkle treatment methods using nanoemulsion compositions INVENTOR(S): Baker, James R., Jr.; Ciotti, Susan M. PATENT ASSIGNEE(S): NanoBio Corporation, USA SOURCE: U.S. Pat. Appl. Publ., 40pp. LANGUAGE: English PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE ------US 20120064136 A1 20120315 US 2011-229080 20110909 PRIORITY APPLN. INFO.: US 2010-381833P P 20100910 AB The present invention relates to methods for treating, preventing, minimizing, and/or diminishing signs of aging in the skin comprising administering to the subject in need thereof a nanoemulsion compn. The nanoemulsion comprises at least one drug or non-drug active agent, an active agent having antiaging and/or anti-wrinkle properties, an active cosmetic substance, an antiviral agent, an anti-acne active agent, or any combination thereof. For example, skin permeation of two different active ingredients, benzoyl peroxide or adapalene from nanoemulsion were evaluated in vitro in a skin model. There was an increase in the delivery of the second active incorporated in the nanoemulsion to the epidermis and dermis, as compared to a com. prepn. INCL 424401000; 424400000; 424059000; 424062000; 514569000; 514714000; 514159000; 977788000; 977906000; 977926000 IPCI A61K0008-06 [I,A]; A61K0008-92 [I,A]; A61K0031-192 [I,A]; A61K0031-327 [I,A]; A61K0031-60 [I,A]; A61Q0017-04 [I,A]; A61Q0019-08 [I,A]; A61Q0019-00 [I,A]; A61Q0019-02 [I,A]; A61P0017-00 [I,A]; A61P0017-10 [I,A]; A61P0031-12 [I,A]; A61P0017-02 [I,A]; A61K0009-107 [I,A]; B82Y0005-00 [N,A] IPCR A61K0008-06 [I,A]; A61K0008-92 [I,A]; A61K0009-107 [I,A]; A61K0031-192 [I,A]; A61K0031-327 [I,A]; A61K0031-60 [I,A]; A61P0017-00 [I,A]; A61P0017-02 [I,A]; A61P0017-10 [I,A]; A61P0031-12 [I,A]; A61Q0017-04 [I,A]; A61Q0019-00 [I,A]; A61Q0019-02 [I,A]; A61Q0019-08 [I,A]; B82Y0005-00 [N,A] NCL 424/401.000; 424/059.000; 424/062.000; 424/400.000; 514/159.000; 514/569.000; 514/714.000; 977/788.000; 977/906.000; 977/926.000 CC 62-4 (Essential Oils and Cosmetics) Section cross-reference(s): 63 IT Essential oils RL: COS (Cosmetic use); NANO (Nanomaterial); BIOL (Biological study); USES (Uses) (Melaleuca alternifolia; antiaging and wrinkle treatment methods using nanoemulsion compns.) IT Essential oils RL: COS (Cosmetic use); NANO (Nanomaterial); BIOL (Biological study); USES (Uses) (Melaleuca; antiaging and wrinkle treatment methods using nanoemulsion compns.) IT Dermatological agents (anti-acne agents; antiaging and wrinkle treatment methods using nanoemulsion compns.) IT Acne Aftershaves Antiaging cosmetics Antioxidants Antiviral agents Barrier cosmetics

Page 29 of 158

Science IP Order: 3550000 Client Reference: 3456-789

Bath preparations Bile Chelating agents Controlled-release drug delivery systems Cosmetic aerosols Cosmetic creams Cosmetic emulsions Cosmetic foams Cosmetic gels Cosmetic liquids Cosmetic lotions Cosmetic nanoemulsions Cosmetic ointments Cosmetic powders Cosmetic sprays Deodorants Foundations (cosmetics) Human Humectants Hydration, physiological Melasma Nonpolar solvents Pharmaceutical capsules Pharmaceutical microcapsules Polar solvents Scar Sebaceous gland Skin cleansers Skin conditioners Skin emollients Skin hyperpigmentation Skin-lightening cosmetics Sunscreens Suntanning products Surfactants Topical drug delivery systems Viscosity Wrinkle-preventing cosmetics (antiaging and wrinkle treatment methods using nanoemulsion compns.) IT 50-00-0D, Formaldehyde, polymers with alkoxylated alkylphenol 50-21-5, Lactic acid, biological studies 50-21-5D, Lactic acid, C12-15 alkyl esters 50-70-4, Sorbitol, biological studies 50-81-7, Ascorbic acid, biological studies 52-51-7, Bronopol 55-56-1, Chlorohexidine 56-40-6, Glycine, biological studies 56-40-6D, Glycine, alkyldimethyl derivs. 56-81-5, Glycerol, biological studies 56-81-5D, Glycerol, monoesters 56-81-5D, Glycerol, monoesters with lanolin fatty acids 57-09-0, Hexadecyltrimethylammonium bromide 57-55-6, Propylene glycol, biological studies 57-88-5, , biological studies 59-02-9, α- 59-50-7, Chlorocresol 59-52-9, Dimercaprol 60-00-4, Edetic acid, biological studies 60-29-7, Diethyl ether, biological studies 60-33-3, Linoleic acid, biological studies 62-76-0, Sodium 64-17-5, Ethanol, biological studies 64-18-6, Formic acid, biological studies 64-19-7, Acetic acid, biological studies 65-85-0, Benzoic acid, biological studies 67-56-1, Methanol, biological studies 67-63-0, Isopropyl alcohol, biological studies 67-64-1, Acetone, biological studies 67-66-3, Chloroform, biological studies 67-68-5, Dimethyl sulfoxide, biological studies 68-12-2, Dimethylformamide, biological studies 68-26-8, Retinol 68-26-8D, Vitamin A, derivs. 69-72-7, Salicylic acid, biological studies

Page 30 of 158

Science IP Order: 3550000 Client Reference: 3456-789

69-93-2, Uric acid, biological studies 70-18-8, Glutathione, biological studies 71-23-8, n-Propanol, biological studies 71-36-3, n-Butanol, biological studies 71-43-2, Benzene, biological studies 73-31-4, Melatonin 75-05-8, Acetonitrile, biological studies 75-09-2, Dichloromethane, biological studies 76-22-2, Camphor 77-86-1, Tris buffer 77-92-9, Citric acid, biological studies 78-70-6, 79-09-4, , biological studies 81-23-2, Dehydrocholic acid 81-25-4, Cholic acid 83-44-3, Deoxycholic acid 83-46-5, β-Sitosterol 87-69-4, L-(+)-, biological studies 89-78-1, 89-83-8, 94-36-0, Benzoyl peroxide, biological studies 97-78-9, N-Lauroylsarcosine 100-51-6, Benzyl alcohol, biological studies 100-95-8 102-71-6, Triethanolamine, biological studies 102-76-1, Triacetin 103-47-9, CHES 106-22-9, 106-23-0, 106-24-1, 106-25-2, Nerol 107-15-3, Ethylenediamine, biological studies 108-88-3, Toluene, biological studies 108-95-2, Phenol, biological studies 109-99-9, Tetrahydrofuran, biological studies 110-27-0, Isopropyl myristate 110-44-1, Sorbic acid 110-54-3, Hexane, biological studies 110-85-0, , biological studies 111-02-4, Squalene 111-42-2, Diethanolamine, biological studies 112-10-7, Isopropyl stearate 112-80-1, Oleic acid, biological studies 115-69-5, 2-Amino-2-methyl-1,3-propanediol 116-31-4, 118-60-5 121-44-8, Triethylamine, biological studies 121-54-0, 2-[2-[p-Diisobutylphenoxy]ethoxy]ethyl dimethylbenzylammonium chloride 122-18-9, Benzyldimethylhexadecylammonium chloride 122-62-3, Dioctyl sebacate 122-99-6, Phenoxyethanol 123-03-5, 123-46-6, Girard-T reagent 123-91-1, 1,4-Dioxane, biological studies 123-95-5, Butyl stearate 124-03-8, Ethylhexadecyldimethylammonium bromide 124-68-5, 2-Amino-2-methyl-1-propanol 126-92-1, Sodium octyl sulfate 127-08-2, acetate 127-09-3, Sodium acetate 128-13-2, Ursodeoxycholic acid 128-37-0, Butylated hydroxytoluene, biological studies 134-03-2, Sodium ascorbate 134-09-8, Menthyl anthranilate 137-16-6, N-Lauroylsarcosine sodium salt 137-66-6, Ascorbyl palmitate 138-86-3, 139-07-1, Dodecyl dimethyl benzylammonium chloride 139-08-2, Benzyldimethyltetradecylammonium chloride 139-88-8, Niaproof 4 141-43-5, Monoethanolamine, biological studies 141-53-7, 141-78-6, Ethyl acetate, biological studies 142-50-7, Nerolidol 142-72-3, acetate 142-91-6, Isopropyl palmitate 143-28-2, Oleyl alcohol 143-62-4, Digitoxigenin 144-02-5, Sodium 5,5-diethylbarbiturate 144-55-8, Sodium carbonate (NaHCO3), biological studies 145-42-6, Sodium taurocholate 150-25-4, BICINE 151-21-3, Sodium lauryl sulfate, biological studies 275-51-4, Azulene 288-32-4, , biological studies 298-14-6, Potassium bicarbonate 302-95-4, Sodium deoxycholate 303-98-0, Coenzyme Q10 304-59-6, Potassium sodium tartrate 361-09-1, Sodium cholate 471-34-1, carbonate, biological studies 474-25-9, Chenodeoxycholic acid 489-84-9, Guaiazulene 497-19-8, Sodium carbonate, biological studies 501-36-0, Resveratrol 502-61-4, Farnesene 512-85-6, 515-69-5, 525-79-1, Kinetin 529-05-5, Chamazulene 536-59-4, 540-10-3, Cetyl palmitate 540-69-2, Ammonium formate 540-84-1, Isooctane 541-02-6, Decamethylcyclopentasiloxane 541-05-9, Hexamethylcyclotrisiloxane 546-80-5, Thujone 553-08-2, 556-33-2 556-50-3 556-67-2, Octamethylcyclotetrasiloxane 577-11-7, Triton GR-5M 584-08-7, Potassium carbonate 590-29-4, Potassium formate 631-61-8, Ammonium acetate 638-11-9, Isopropyl n-butyrate 866-83-1 866-84-2 868-18-8 877-24-7 1066-33-7, Ammonium bicarbonate 1119-94-4, Dodecyltrimethylammonium bromide 1119-97-7, Trimethyl(tetradecyl)ammonium bromide 1132-61-2, MOPS 1135-40-6, CAPS 1185-53-1, Trizma hydrochloride 1200-22-2, 1303-96-4,

Page 31 of 158

Science IP Order: 3550000 Client Reference: 3456-789

Sodium tetraborate decahydrate 1310-73-2, Sodium hydroxide, biological studies 1323-03-1, Myristyl lactate 1323-38-2, Glyceryl monoricinoleate 1323-42-8 1323-83-7, Glyceryl distearate 1330-85-4 1338-39-2, Sorbitan monolaurate 1338-41-6, Sorbitan monostearate 1338-43-8, Sorbitan monooleate 1406-18-4, Vitamin E 1643-20-5, N,N-Dimethyldodecylamine N-oxide 2044-56-6, Lithium dodecyl sulfate 2281-11-0 2311-46-8, Isopropyl n-hexanoate 2311-59-3, Isopropyl n-decanoate 2386-53-0, Sodium 1-dodecanesulfonate 2386-54-1, Sodium 1-butanesulfonate 2420-29-3, Hexaethylene glycol monooctadecyl ether 2646-38-0, Chenodeoxycholic acid sodium salt 2832-45-3, Sodium hexanesulfonate 3012-65-5, Ammonium citrate dibasic 3055-94-5, Triethylene glycol monododecyl ether 3055-95-6, Pentaethylene glycol monododecyl ether 3055-96-7, Hexaethylene glycol monododecyl ether 3055-97-8, Heptaethylene glycol monododecyl ether 3055-98-9, Octaethylene glycol monododecyl ether 3055-99-0, Nonaethylene glycol monododecyl ether 3164-29-2 3245-38-3, Deoxycholic acid methyl ester 3687-46-5, Decyl oleate 3700-67-2, Dimethyldioctadecylammonium bromide 4263-52-9, Sodium 2-bromoethanesulfonate 4292-10-8 4478-97-1, Pentaethylene glycol monohexadecyl ether 4484-59-7, Triethylene glycol monohexadecyl ether 4602-84-0, Farnesol 4669-23-2, Triethylene glycol monodecyl ether 4719-04-4 4759-48-2, Isotretinoin 5157-04-0, Hexaethylene glycol monotetradecyl ether 5168-91-2, Hexaethylene glycol monohexadecyl ether 5204-74-0, Triethylammonium acetate 5274-68-0, Tetraethylene glycol monododecyl ether 5300-03-8, 5324-84-5, 1-Octanesulfonic acid sodium salt 5392-40-5, 5538-94-3, Dioctyl dimethylammonium chloride 5625-37-6, PIPES 5698-39-5, Octaethylene glycol monohexadecyl ether 5703-94-6, Tetraethylene glycol monodecyl ether 5785-44-4 6009-70-7, Ammonium oxalate monohydrate 6009-98-9, Taurochenodeoxycholic acid sodium salt 6080-58-6 6106-24-7, biological studies 6108-17-4, Lithium acetate dihydrate 6131-90-4, Sodium acetate trihydrate 6131-98-2, Sodium bitartrate monohydrate 6132-02-1, Sodium carbonate decahydrate 6132-04-3 6153-56-6, dihydrate 6229-23-8 6283-92-7, Lauryl lactate 6381-59-5 6381-92-6, Ethylenediaminetetraacetic acid disodium salt dihydrate 6487-48-5, Potassium oxalate monohydrate 6829-55-6D, Tocotrienol, derivs. 6850-27-7, Trimethylammonium acetate 6850-28-8, TRIS-acetate 6938-94-9, Diisopropyl adipate 6976-37-0, Bis-TRIS 7173-51-5, 1-Decanaminium-N-decyl-N,N-dimethyl-chloride RL: COS (Cosmetic use); NANO (Nanomaterial); BIOL (Biological study); USES (Uses) (antiaging and wrinkle treatment methods using nanoemulsion compns.)

Page 32 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 7 OF 199 HCAPLUS COPYRIGHT 2013 ACS on STN ACCESSION NUMBER: 2012:378908 HCAPLUS Full-text DOCUMENT NUMBER: 156:401359 TITLE: Pharmaceutical or cosmetic compositions comprising benzoyl peroxide INVENTOR(S): Levin, Daniel; Harms, Arthur PATENT ASSIGNEE(S): Norac Pharma, USA SOURCE: U.S. Pat. Appl. Publ., 23pp. LANGUAGE: English PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE ------US 20120064135 A1 20120315 US 2011-210855 20110816 WO 2012037000 A1 20120322 WO 2011-US51153 20110912 PRIORITY APPLN. INFO.: US 2010-383149P P 20100915 US 2010-389456P P 20101004 US 2011-210855 A 20110816 AB The present invention relates to the prepn. of compns. comprising benzoyl peroxide, with or without other addnl. active ingredients. The process involves introducing benzoyl peroxide, along with any other active ingredients present, into a fatty substance that contains and protects the ingredients that would otherwise be unstable when in contact with one another. The compn. is designed to allow all ingredients to become available for skin contact or skin absorption when the fatty substance softens and/or melts as the compn. is applied to the skin. The benzoyl peroxide may be pre-micronized to a particle distribution size of about d90 of 0.1 to 150 µ, preferably d90 of 10 to 15 µ. Further, pharmaceutical or cosmetic ingredients may be contained within the fatty substances, with or without, benzoyl peroxide therein or may be present outside of the fatty substance but elsewhere within formulated pharmaceutical or cosmetic products using the active ingredients protected by the fatty substance. These compns. are useful in aq.-based formulations to treat diseases by topical, transdermal and/or s.c. administration. Thus, a formulation contained tretinoin 0.1, benzoyl peroxide 15.0, water 49.25, xanthan gum 0.3, Polyoxyl 40 stearate 5.0, stearic acid 17.0, stearyl alc. 3.0, iso-Pr myristate 10.0, BHT 0.1, and sorbic acid 0.2 g. INCL 424401000; 514714000; 424400000; 514337000; 514559000; 514024000; 514029000; 514646000; 514569000; 514772000 IPCI A61K0008-11 [I,A]; A61K0008-38 [I,A]; A61K0009-00 [I,A]; A61K0031-4436 [I,A]; A61K0031-203 [I,A]; A61K0031-7056 [I,A]; A61K0031-7048 [I,A]; A61K0031-136 [I,A]; A61K0031-192 [I,A]; A61K0047-44 [I,A]; A61P0031-00 [I,A]; A61P0031-10 [I,A]; A61P0031-12 [I,A]; A61P0035-00 [I,A]; A61Q0019-00 [I,A]; A61P0031-04 [I,A]; A61P0017-00 [I,A]; A61P0017-10 [I,A]; A61K0031-327 [I,A] IPCR A61K0008-11 [I,A]; A61K0008-38 [I,A]; A61K0009-00 [I,A]; A61K0031-136 [I,A]; A61K0031-192 [I,A]; A61K0031-203 [I,A]; A61K0031-327 [I,A]; A61K0031-4436 [I,A]; A61K0031-7048 [I,A]; A61K0031-7056 [I,A]; A61K0047-44 [I,A]; A61P0017-00 [I,A]; A61P0017-10 [I,A]; A61P0031-00 [I,A]; A61P0031-04 [I,A]; A61P0031-10 [I,A]; A61P0031-12 [I,A]; A61P0035-00 [I,A]; A61Q0019-00 [I,A] NCL 424/401.000; 424/400.000; 514/024.000; 514/029.000; 514/337.000; 514/559.000; 514/569.000; 514/646.000; 514/714.000; 514/772.000 CC 63-6 (Pharmaceuticals) Section cross-reference(s): 62 ST pharmaceutical cosmetic benzoyl peroxide IT Resins RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Manila elemi; pharmaceutical or cosmetic compns. comprising benzoyl peroxide)

Page 33 of 158

Science IP Order: 3550000 Client Reference: 3456-789

IT Essential oils RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Melaleuca; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Fats and Glyceridic oils RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (animal; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Skin disease (bacterial; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Materials (fatty; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Shear (high; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Fats and Glyceridic oils RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (hydrogenated; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Carboxylic acids RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (hydroxy; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Fats and Glyceridic oils RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (kokum; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Fats and Glyceridic oils RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (mango kernel; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Fluidization (microfluidization; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Acne Animal virus Antibiotics Antitumor agents Antiviral agents Beeswax Butter Ceiba pentandra Cosmetics and Personal care products Drug delivery systems Emulsifying agents Fungi Fungicides Grease (food-derived) Mammary gland, neoplasm Melanoma Melting point Neoplasm

Page 34 of 158

Science IP Order: 3550000 Client Reference: 3456-789

Particle size distribution Rosacea Skin Stability Tinea pedis Topical drug delivery systems Transdermal drug delivery systems Vitiligo Wart Witch hazel (pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Alkanes Carnauba wax Castor oil Coal tar Cocoa butter Coconut oil Corticosteroids Cottonseed oil Estrogens Fats and Glyceridic oils Glucocorticoids Glycerides Hydrocarbon oils Jojoba oil Lanolin Lard Olive oil Palm oil Paraffin oils Petroleum Polyesters Polyoxyalkylenes Progestogens Retinoids Steroids Tallow Triglycerides Vitamins RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Resins RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (podophyllum; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Polyethers RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (polyester-, block, diblock; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Polyesters RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (polyether-, block, diblock; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Pharmaceutical injections

Page 35 of 158

Science IP Order: 3550000 Client Reference: 3456-789

(s.c. injections; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Fats and Glyceridic oils RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (shea butter; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Nail disease Tinea (skin disease) (tinea unguium; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Fats and Glyceridic oils RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (vegetable; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Fats and Glyceridic oils RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (wheat germ; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT Antibiotics (β-lactam; pharmaceutical or cosmetic compns. comprising benzoyl peroxide) IT 50-18-0, 50-23-7, Hydrocortisone 50-24-8, 50-78-2, Acetylsalicylic acid 50-81-7, , biological studies 51-21-8, Fluorouracil 56-25-7, Cantharidin 57-10-3, Palmitic acid, biological studies 57-10-3D, Palmitic acid, esters 57-11-4, Stearic acid, biological studies 57-11-4D, Stearic acid, esters 57-62-5, 59-05-2, Methotrexate 60-54-8, Tetracycline 67-45-8, 68-26-8, Retinol 69-72-7, Salicylic acid, biological studies 70-10-0, 76-25-5, acetonide 77-52-1, 79-14-1, Glycolic acid, biological studies 94-36-0, Benzoyl peroxide, biological studies 97-00-7, 2,4-Dinitrochlorobenzene 106-79-6, Dimethyl sebacate 108-46-3, Resorcinol, biological studies 111-01-3, 111-46-6, Diethylene glycol, biological studies 112-37-8, Undecanoic acid 112-53-8, 1-Dodecanol 112-86-7, Erucic acid 112-95-8, Eicosane 114-07-8, Erythromycin 123-76-2, Levulinic acid 124-18-5, Decane 124-94-7, Triamcinolone 126-07-8, 130-26-7, Clioquinol 143-07-7, Lauric acid, biological studies 154-21-2, 302-79-4, Retinoic acid 334-48-5, Decanoic acid 338-98-7, Isoflupredone acetate 356-12-7, Fluocinonide 378-44-9, 472-15-1, 508-02-1, 536-59-4, Perillyl alcohol 538-24-9, Trilaurin 544-63-8, Myristic acid, biological studies 564-25-0, 593-45-3, Octadecane 626-86-8, Adipic acid monoethyl ester 629-94-7, Heneicosane 777-11-7, 859-18-7, Lincomycin hydrochloride 1143-38-0, Anthralin 1314-13-2, Zinc oxide, biological studies 1397-89-3, Amphotericin B 1400-61-9, Nystatin 1403-66-3, Gentamycin 1404-04-2, Neomycin 1404-26-8, Polymyxin B 1405-87-4, Bacitracin 1406-16-2, Vitamin D 1406-18-4, Vitamin E 2022-85-7, 2098-66-0, 2135-17-3, Flumethasone 2152-44-5, Betamethasone 17-valerate 2398-96-1, Tolnaftate 3055-97-8, Heptaethylene glycol monododecyl ether 3093-35-4, Halcinonide 3116-76-5, 4419-39-0, Beclomethasone 4759-48-2, Isotretinoin 5593-20-4, Betamethasone dipropionate 5633-20-5, Oxybutynin 6713-27-5, 7681-93-8, 7704-34-9, Sulfur, biological studies 7733-02-0, Zinc sulfate 7761-88-8, , biological studies 10118-90-8, 10540-29-1, 11056-06-7, Bleomycin 11103-57-4,

Page 36 of 158

Science IP Order: 3550000 Client Reference: 3456-789

Vitamin A 11111-12-9, Cephalosporin 12001-76-2, Vitamin B 12650-69-0, Mupirocin 15387-18-5, Fezatione 18323-44-9, Clindamycin 21462-39-5, Clindamycin hydrochloride 22832-87-7, Miconazole nitrate 22916-47-8, Miconazole 23214-92-8, Doxorubicin 23593-75-1, Clotrimazole 24169-02-6, nitrate 24729-96-2, Clindamycin phosphate 25036-49-1, Poly(Diethylene glycol adipate) 25322-68-3, Polyethylene glycol 27196-00-5, Tetradecanol 27523-40-6, 28069-65-0, Cuprimyxin 29342-05-0, Ciclopirox 30303-65-2, Docosanol 33069-62-4, 39809-25-1, Penciclovir 55079-83-9, Acitretin 56049-79-7, Diethylene glycol monotetradecyl ether 56093-45-9, Selenium sulfide 56420-45-2, Epirubicin 59277-89-3, Acyclovir 60628-96-8, 61318-91-0, nitrate 64872-76-0, 65277-42-1, Ketoconazole 65899-73-2, 67392-87-4, 67915-31-5, 78613-35-1, 80474-14-2, propionate 84625-61-6, 85213-14-5 86386-73-4, Fluconazole 90566-53-3, Fluticasone 91161-71-6, Terbinafine 99011-02-6, Imiquimod 101530-10-3, Lanoconazole 101828-21-1, Butenafine 104227-87-4, Famciclovir 104987-11-3, 105102-22-5 106685-40-9, Adapalene 107868-30-4, Aromasin 112809-51-5, Letrozole 114977-28-5, 118292-40-3, Tazarotene 120511-73-1, Anastrazole 124832-26-4, Valaciclovir 130726-68-0, 137071-32-0, 137234-62-9, 153559-49-0, Bexarotene 171228-49-2, 184475-35-2, Gefitinib 918504-65-1, Vemurafenib 1006879-72-6 RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmaceutical or cosmetic compns. comprising benzoyl peroxide)

Page 37 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 8 OF 199 HCAPLUS COPYRIGHT 2013 ACS on STN ACCESSION NUMBER: 2011:692804 HCAPLUS Full-text DOCUMENT NUMBER: 155:22429 TITLE: Surfactant-free, water-free, foamable compositions and breakable foams and their uses INVENTOR(S): Tamarkin, Dov; Gazal, Elana; Papiashvili, Irakliy; Hazot, Yohan; Schuz, David; Keynan, Rita PATENT ASSIGNEE(S): Foamix Ltd., Israel SOURCE: PCT Int. Appl., 88pp. LANGUAGE: English PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE ------WO 2011064631 A1 20110603 WO 2010-IB2613 20101001 GB 2474930 A 20110504 GB 2010-16546 20101001 GB 2474930 B 20120704 CA 2776471 A1 20110603 CA 2010-2776471 20101001 CA 2776482 A1 20111110 CA 2011-2776482 20110504 WO 2011138678 A2 20111110 WO 2011-IB1374 20110504 US 20110281827 A1 20111117 US 2011-100724 20110504 PRIORITY APPLN. INFO.: US 2009-248144P P 20091002 US 2010-322148P P 20100408 US 2010-331126P P 20100504 US 2010-349911P P 20100531 US 2010-380568P P 20100907 US 2010-385385P P 20100922 US 2010-388884P P 20101001 WO 2010-IB2612 A 20101001 WO 2010-IB2613 W 20101001 WO 2010-IB2617 A 20101001 WO 2011-IB1374 W 20110504 AB A substantially surface active agent-free and foam adjuvant- free compn. which includes a hydrophobic solvent, a wax and a propellant. A substantially surface active agent-free and foam adjuvant- free compn., further comprising, a tetracycline antibiotic, or one or more other active agents. A method of treatment, using a substantially surface active agent- free and substantially foam adjuvant-free compn. For example, a foamable compn. of the present invention was fomrulated from heavy mineral oil 79, paraffin 51-53 20, minocycline hydrochloride 1, and propellant AP-70 8 part. IPCI A61K0009-12 [I,A] IPCR A61K0009-12 [I,A] CC 63-6 (Pharmaceuticals) Section cross-reference(s): 5, 62 IT Essential oils RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Melaleuca; surfactant-free, water-free, foamable compns. and breakable foams and their uses) IT Dermatological agents (anti-acne agents; surfactant-free, water-free, foamable compns. and breakable foams and their uses) IT Acne (comedo; surfactant-free, water-free, foamable compns. and breakable foams and their uses) IT Abscess Acaricides Acne Allergy inhibitors Alopecia

Page 38 of 158

Science IP Order: 3550000 Client Reference: 3456-789

Analgesics Anti-infective agents Anti-inflammatory agents Antiaging cosmetics Antibacterial agents Antibiotics Antidandruff hair preparations Antidepressants Antihistamines agents Antioxidants Antiproliferative agents Antitumor agents Antiviral agents Astringents Atopic dermatitis Beeswax Blister Bullous pemphigoid Burn Cellulitis Cholesteatoma Corn Cosmetic foams Decubitus ulcer Dermatological agents Ectodermal dysplasia Eczema Erysipelas Erythema nodosum Erythroderma Foams Fungicides Furunculosis Hair growth inhibitors Hair growth stimulants Herpes Herpes labialis Human Human herpesvirus 3 Hyperhidrosis Hypnotics and Sedatives Hypolipemic agents Ichthyosis Immunomodulators Immunostimulants Immunosuppressants Impetigo Injury Insect repellents Insecticides Kaposi sarcoma Keratosis Lubricants Lymphadenitis Mastocytosis

Page 39 of 158

Science IP Order: 3550000 Client Reference: 3456-789

Measles Melanoma Mucosal drug delivery systems Myositis Natural products, pharmaceutical Necrosis Neurodermatitis Nonsteroidal anti-inflammatory drugs Ophthalmic drug delivery systems Oxidizing agents Parasiticides Pediculus humanus capitis Pemphigus Pharmaceutical foams Pigmentation disorders Pityriasis lichenoides Pityriasis rosea Pruritus Psoriasis Purpura (disease) Radical scavengers Rhus toxicodendron Rubella Scar Scleroderma Skin Skin, neoplasm Skin disease Skin infection Skin rash Skin ulcer Skin-lightening cosmetics Staphylococcal scalded-skin syndrome Sunburn Sunscreens Sunspots Suntanning products Tinea (skin disease) Tinea pedis Toxic epidermal necrolysis Transdermal drug delivery systems UV stabilizers Urticaria Varicella Vasoconstrictors Vasodilators Vitiligo Wound healing promoters Wrinkle-preventing cosmetics Zea mays (surfactant-free, water-free, foamable compns. and breakable foams and their uses) IT Acne (vulgaris; surfactant-free, water-free, foamable compns. and breakable foams and their uses) IT 50-81-7, Vitamin C, biological studies 57-83-0, , biological studies 58-95-7, Tocopheryl acetate 65-85-0D, Benzoic acid, C12-15 alkyl derivs. 68-26-8, Vitamin A 74-98-6, Propane, biological studies 75-28-5, Isobutane 94-36-0, Benzoyl peroxide

Page 40 of 158

Science IP Order: 3550000 Client Reference: 3456-789

, biological studies 103-23-1, Diethylhexyl adipate 104-76-7D, 2-Ethylhexanol, coco fatty acyl derivs. 106-97-8, Butane, biological studies 110-27-0, Isopropyl myristate 110-36-1, Butyl myristate 112-10-7, Isopropyl stearate 115-83-3, Pentaerythrityl tetrastearate 122-62-3, Dioctyl sebacate 123-95-5, Butyl stearate 124-07-2D, Octanoic acid, C12-15 alkyl derivs. 126-30-7D, Neopentylglycol, dicaprylate/dicaprate 137-58-6, 140-25-0, Benzyl laurate 142-91-6, Isopropyl palmitate 149-57-5D, 2-Ethylhexanoic acid, C16-18 alkyl derivs. 293-51-6, Cyclotetrasiloxane 295-01-2, Cyclohexasiloxane 538-23-8, Glyceryl trioctanoate 540-10-3, Cetyl palmitate 540-97-6, Dow corning 246 556-67-2, Dow corning 244 564-25-0, Doxycycline 620-67-7, Glycerol triheptanoate 629-70-9, Cetyl acetate 1190-63-2, Hexadecyl stearate 1323-03-1, Myristyl lactate 2599-01-1, Cetyl myristate 2915-57-3, Di-2-ethylhexyl succinate 3234-85-3, Myristyl myristate 3687-45-4, Oleyl oleate 3687-46-5, Decyl oleate 6144-28-1D, Bis(octyldodecylstearoyl) 6221-95-0, Myristyl propionate 6283-92-7, Lauryl lactate 6309-51-9, Isoamyl laurate 6938-94-9, Diisopropyl adipate 7384-98-7, Propylene glycol dicaprylate 7425-14-1, 2-Ethylhexyl 2-ethylhexanoate 7491-02-3, Diisopropyl sebacate 7735-26-4, Diethyleneglycol dioctanoate 9003-13-8, Polypropylene glycol butyl ether 9003-27-4, Polyisobutylene 9005-12-3, Methylphenylpolysiloxane 9006-65-9, Dimethicone 9035-85-2, PolyPropylene glycol hexadecyl ether 9064-14-6, PolyPropylene glycol lauryl ether 10118-90-8, Minocycline 10233-13-3, Isopropyl laurate 10401-55-5, Cetyl ricinoleate 11103-57-4, Vitamin A 12001-76-2, Vitamin B 12001-79-5, Vitamin K 13552-80-2, Glyceryl triundecanoate 13614-98-7, Minocycline hydrochloride 14303-70-9, Propyl myristate 15763-02-7, Dioctyl malate 17673-56-2, Oleyl erucate 17955-88-3, Caprylyl methicone 22047-49-0, Ethylhexyl stearate 25231-21-4, PolyPropylene glycol stearyl ether 25322-69-4D, PolyPropylene glycol, alkyl ethers 25339-09-7, Isocetyl stearate 26896-18-4D, Isononanoic acid, C16-18 alkyl derivs. 27841-06-1, Neopentylglycol dicaprate 29710-25-6, 2-Ethylhexyl hydroxystearate 29710-31-4, Cetyl octanoate 29759-38-4, Tetrafluoroethane 29806-73-3, 2-Ethylhexyl palmitate 31161-71-4, Benzyl myristate 31692-79-2, Dimethiconol 31807-55-3, Isododecane 32222-06-3, Calcitriol 34316-64-8, Hexyl laurate 34513-50-3, Octyl dodecanol 34689-06-0, Stearyl caprate 34962-91-9, Isodecyl 2-ethylhexanoate 35274-05-6, Cetyl lactate 36078-10-1, Dodecyl oleate 36148-84-2 36311-34-9, Isohexadecanol 36311-34-9D, Isocetyl alcohol, lanolate 37220-82-9, Glyceryl oleate 37286-64-9, PolyPropylene glycol methyl ether 41395-89-5, Isodecyl isononanoate 41669-30-1, Isostearyl isostearate 41755-60-6, Benzyl palmitate 42131-25-9, Isononyl isononanoate 42131-27-1, Isotridecyl isononanoate 42131-28-2, Isostearyl lactate 42175-36-0, Oleyl lactate 42233-14-7, Arachidyl behenate 42557-10-8 52581-71-2 52663-48-6, Stearyl propionate 53824-77-4, Propylene glycol dicaprate 56235-92-8, Di-2-ethylhexyl malate 57569-76-3 58958-60-4, Isostearyl neopentanoate 59130-69-7, Cetyl 2-ethylhexanoate 59231-34-4, Isodecyl oleate 59587-44-9, 2-Ethylhexyl pelargonate 60908-77-2, Isohexadecane 63793-60-2, PolyPropylene glycol myristyl ether 65591-14-2, Arachidyl propionate 66009-41-4, Stearyl heptanoate 68171-33-5, Isopropyl isostearate 71566-49-9, 2-Ethylhexyl isononanoate 72269-52-4 72576-80-8, Isostearyl palmitate 83919-23-7, furoate 84605-09-4 90052-75-8, Octyldodecyl stearoyl stearate 93385-14-9, Triisocetyl citrate 93596-79-3 93682-38-3, Isostearyl malate 94247-28-6, Isocetyl behenate 94248-76-7, Isocetyl octanoate 97338-28-8 111517-88-5, Propylene glycol ricinoleate 113431-53-1 125804-07-1 125804-08-2, 2-Octyldodecyl behenate 125804-16-2, Isostearyl behenate 125804-18-4, Tridecyl isononanoate 127358-80-9, Isostearyl linoleate 127770-27-8, Isocetyl palmitate 135326-54-4,

Page 41 of 158

Science IP Order: 3550000 Client Reference: 3456-789

Propylene glycol myristyl ether acetate 138208-67-0, Isohexyl decanoate 138208-68-1, Isocetyl salicylate 144610-93-5, Myristyl neopentanoate 156048-34-9, Dimethylsilanediol-diphenylsilanediol copolymer 159317-32-5, Isostearyl glycolate 163564-45-2, Isostearyl isononanoate 172670-81-4, Isononyl octanoate 190282-37-2, Diethyleneglycol diisononanoate 195868-36-1, Phenyl trimethicone 308122-33-0, 2-Octyldodecyl hydroxystearate 383419-35-0 1008098-31-4 1286715-16-9 1286715-17-0 1287647-89-5 RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (surfactant-free, water-free, foamable compns. and breakable foams and their uses)

Page 42 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 9 OF 199 HCAPLUS COPYRIGHT 2013 ACS on STN ACCESSION NUMBER: 2011:436533 HCAPLUS Full-text DOCUMENT NUMBER: 154:469599 TITLE: Topical tetracycline compositions comprising hydrophobic oils and viscosity-modifying agents INVENTOR(S): Tamarkin, Dov; Gazal, Elana; Papiashvili, Irakliy; Hazot, Yohan; Schuz, David; Keynan, Rita PATENT ASSIGNEE(S): Foamix Ltd., Israel SOURCE: PCT Int. Appl., 82pp. LANGUAGE: English PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE ------WO 2011039638 A2 20110407 WO 2010-IB2617 20101001 WO 2011039638 A3 20110526 CA 2776474 A1 20110407 CA 2010-2776474 20101001 GB 2474930 A 20110504 GB 2010-16546 20101001 GB 2474930 B 20120704 EP 2482788 A2 20120808 EP 2010-819992 20101001 CN 102686205 A 20120919 CN 2010-80054424 20101001 CA 2776482 A1 20111110 CA 2011-2776482 20110504 WO 2011138678 A2 20111110 WO 2011-IB1374 20110504 US 20110281827 A1 20111117 US 2011-100724 20110504 MX 2012003985 A 20120625 MX 2012-3985 20120402 PRIORITY APPLN. INFO.: US 2009-248144P P 20091002 US 2010-322148P P 20100408 US 2010-331126P P 20100504 US 2010-349911P P 20100531 US 2010-380568P P 20100907 US 2010-385385P P 20100922 US 2010-388884P P 20101001 WO 2010-IB2612 A 20101001 WO 2010-IB2613 A 20101001 WO 2010-IB2617 W 20101001 WO 2011-IB1374 W 20110504 AB A topical therapeutic hydrophobic breakable compn. includes a carrier comprising (a) about 60% to 99% by wt. of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alc., a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the compn. The viscosity of the compn. is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic, and is higher than the viscosity of the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents,. The amt. of viscosity modifying agents can optionally be reduced by at least an amt. by wt. that would have increased the viscosity of the carrier without the tetracycline antibiotic by at least 30%. The tetracycline is chem. stable in the compn. for at least 6 mo, wherein more than about 90% of the tetracycline has not broken down. When the compn. is packaged in an aerosol container to which is added a liquefied or compressed gas propellant, the compn. affords upon release from the container a breakable foam of at least good quality that breaks easily upon application of shear force. Thus, a mineral oil-based oleaginous formulation with improved viscosity contained minocycline HCl, a mixt. of heavy and light mineral oils, cyclomethicone, stearyl alc., beeswax, stearic acid, hydrogenated castor oil, behenyl alc., cetostearyl alc., and silica. The formulation viscosity was directly related to the concn. of the tetracycline, reaching a plateau when the active ingredient is present at a concn. of about 0.50%. IPCI A61K0031-65 [I,A]; A61K0008-02 [I,A] IPCR A61K0031-65 [I,A]

Page 43 of 158

Science IP Order: 3550000 Client Reference: 3456-789

CC 63-6 (Pharmaceuticals) Section cross-reference(s): 1 IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Melaleuca alternifolia; topical tetracycline compns. with carriers contg. hydrophobic oils and viscosity-modifying agents) IT Dermatological agents (anti-acne agents; topical tetracycline compns. with carriers contg. hydrophobic oils and viscosity-modifying agents) IT Acne (comedo; topical tetracycline compns. with carriers contg. hydrophobic oils and viscosity-modifying agents) IT Acne (nodular papulopustular acne; topical tetracycline compns. with carriers contg. hydrophobic oils and viscosity-modifying agents) IT AIDS (disease) Abscess Acaricides Acne Allergy inhibitors Alopecia Anal disease Analgesics Anti-infective agents Anti-inflammatory agents Antibacterial agents Antibiotics Antidepressants Antihistamines Antimicrobial agents Antiproliferative agents Antitumor agents Antiviral agents Anus neoplasm Astringents Atopic dermatitis Barrier cosmetics Beeswax Blepharitis Blindness Blister Bullous pemphigoid Callosity Cataract Cellulitis Cervix, neoplasm Chlamydia infection Cholesteatoma Combination chemotherapy Condyloma acuminatum Conjunctivitis Constipation Crohn disease Decubitus ulcer Disinfectants Drug bioavailability Drug toxicity Drugs

Page 44 of 158

Science IP Order: 3550000 Client Reference: 3456-789

Ear disease Ectodermal dysplasia Eczema Endometritis Erysipelas Erythema nodosum Erythroderma Eye disease Eye disease Female reproductive system disease Folliculitis Fungicides Furunculosis Giant cell arteritis Glaucoma HIV infection Hair growth stimulants Hemorrhoid Hepatitis B Herpes Herpes labialis Hirsutism Human herpesvirus 3 Human herpesvirus 3 Human papillomavirus Hydrophobicity Hyperhidrosis Hypnotics and Sedatives Hypolipemic agents Ichthyosis Immunomodulators Immunostimulants Immunosuppressants Impetigo Insect repellents Insecticides Iritis Kaposi sarcoma Keratoconus Lichen planus Lubricants Lyme disease Lymphadenitis Macular degeneration Mastocytosis Measles Melanoma Molluscum contagiosum virus Mouth disease Myasthenia gravis Neurodermatitis Nevus Nonsteroidal anti-inflammatory drugs Nose disease Oophoritis Oxidizing agents Pediculus humanus capitis Pemphigus Pesticides Pharmaceutical aerosols

Page 45 of 158

Science IP Order: 3550000 Client Reference: 3456-789

Pharmaceutical carriers Pharmaceutical foams Photosensitivity disorders Photosensitizers, pharmaceutical Pigmentation disorders Pityriasis lichenoides Pityriasis rosea Propellants (sprays and foams) Prophylaxis Pruritus Pruritus Psoriasis Pterygium Purpura (disease) Radical scavengers Reproductive system, neoplasm Respiratory system disease Retinal detachment Rhus toxicodendron Rosacea Rubella Sarcoidosis Scabies Scar Scar Scleritis Scleroderma Seborrhea Sinusitis Skin, neoplasm Skin disease Skin rash Skin ulcer Skin-lightening cosmetics Staphylococcal scalded-skin syndrome Staphylococcal scalded-skin syndrome Sunburn Sunless tanning products Tinea (skin disease) Tinea pedis Topical drug delivery systems Toxic epidermal necrolysis Trachoma Transdermal drug delivery systems Urticaria Uveitis Vagina, neoplasm Vaginal disease Varicella Varicella Vasoconstrictors Vasodilators Viscosity Vision disorders Vitiligo Vulva disease Wart Wound healing promoters Wrinkle-preventing cosmetics (topical tetracycline compns. with carriers contg. hydrophobic oils and

Page 46 of 158

Science IP Order: 3550000 Client Reference: 3456-789

viscosity-modifying agents) IT Acne (vulgaris; topical tetracycline compns. with carriers contg. hydrophobic oils and viscosity-modifying agents) IT 50-81-7, Vitamin C, biological studies 57-10-3, Hexadecanoic acid, biological studies 57-11-4, Octadecanoic acid, biological studies 57-83-0, Progesterone, biological studies 57-88-5, Cholesterol, biological studies 58-95-7, Tocopheryl acetate 65-85-0D, Benzoic acid, alkyl esters 94-36-0, Benzoyl peroxide, biological studies 103-23-1, Diethylhexyl adipate 104-76-7D, 2-Ethylhexanol, coco fatty acid esters 106-14-9, 12-Hydroxystearic acid 109-36-4, Octyl stearate 110-27-0, Isopropyl myristate 110-36-1, Butyl myristate 112-10-7, Isopropyl stearate 112-53-8, Lauryl alcohol 112-72-1, Myristyl alcohol 112-85-6, Docosanoic acid 112-92-5, 115-83-3, Pentaerythrityl tetrastearate 122-62-3, Dioctyl sebacate 123-95-5, Butyl stearate 124-07-2D, Octanoic acid, alkyl esters 140-25-0, Benzyl laurate 142-91-6, Isopropyl palmitate 143-07-7, Dodecanoic acid, biological studies 149-57-5D, Ethylhexanoic acid, cetearyl esters 506-12-7, Heptadecanoic acid 506-30-9, Eicosanoic acid 506-46-7, Hexacosanoic acid 506-48-9, Octacosanoic acid 506-50-3, Triacontanoic acid 506-51-4, Tetracosanol 506-52-5, Hexacosanol 538-23-8, Glyceryl trioctanoate 540-10-3, Cetyl palmitate 544-63-8, Tetradecanoic acid, biological studies 557-59-5, Tetracosanoic acid 557-61-9, Octacosanol 593-50-0, Triacontanol 620-67-7, Glycerol triheptanoate 629-70-9, Cetyl acetate 629-96-9, 661-19-8, Behenyl alcohol 1190-63-2, Hexadecyl stearate 1323-03-1, Myristyl lactate 1406-16-2, Vitamin D 2599-01-1, Cetyl myristate 2915-57-3 3234-85-3, Myristyl myristate 3625-52-3, Dotriacontanoic acid 3687-45-4, Oleyl oleate 3687-46-5, Decyl oleate 6221-95-0, Myristyl propionate 6283-92-7, Lauryl lactate 6309-51-9, Isoamyl laurate 6938-94-9, Diisopropyl adipate 7138-40-1, Heptacosanoic acid 7384-98-7, Propylene glycol dicaprylate 7425-14-1 7491-02-3, Diisopropyl sebacate 7631-86-9, Silicon dioxide, biological studies 7735-26-4, Diethylene glycol dioctanoate 9003-13-8, Polypropylene glycol butyl ether 9003-27-4, Polyisobutylene 9006-65-9, Dimethicone 9035-85-2, Polypropylene glycol cetyl ether 9064-14-6, Polypropylene glycol lauryl ether 10233-13-3, Isopropyl laurate 10401-55-5, Cetyl ricinoleate 11103-57-4, Vitamin A 12001-76-2, Vitamin B 12001-79-5, Vitamin K 13552-80-2, Glyceryl triundecanoate 14303-70-9, Propyl myristate 15763-02-7, Dioctyl malate 16958-85-3, Octyl palmitate 17673-56-2, Oleyl erucate 22047-49-0, Ethylhexyl stearate 25231-21-4, Polypropylene glycol stearyl ether 25322-69-4D, Polypropylene glycol, alkyl ethers 25339-09-7, Isocetyl stearate 25496-72-4, Glyceryl oleate 26896-18-4D, Isononanoic acid, cetearyl esters 27841-06-1, Neopentyl glycol dicaprate 27841-06-1D, Neopentylglycol dicaprate, mixed esters with neopentylglycol and octanoic acid 28484-70-0, 1-Tetratriacontanol 29710-25-6, 2-Ethylhexyl hydroxystearate 29710-31-4, Cetyl octanoate 29806-73-3, 2-Ethylhexyl palmitate 30399-84-9, Isostearic acid 31161-71-4, Benzyl myristate 31335-74-7D, Neopentylglycol dicaprylate, mixed esters with neopentylglycol and octanoic acid 31807-55-3, Isododecane 34316-64-8, Hexyl laurate 34513-50-3, Octyldodecanol 34689-06-0, Stearyl caprate 34962-91-9 35274-05-6, Cetyl lactate 36078-10-1, Dodecyl oleate 36653-82-4, Cetyl alcohol 37286-64-9, Polypropylene glycol methyl ether 38232-03-0, Tritriacontanoic acid 38232-04-1, Tetratriacontanoic acid 38232-05-2, Pentatriacontanoic acid 41395-89-5, Isodecyl isononanoate 41669-30-1, Isostearyl isostearate 41755-60-6, Benzyl palmitate 42131-25-9, Isononyl isononanoate 42131-27-1, Isotridecyl isononanoate 42131-28-2, Isostearyl lactate 42175-36-0, Oleyl lactate 42233-14-7, Arachidyl behenate 42557-10-8 51744-92-4, α-Tocopheryl linoleate 52581-71-2 52663-48-6,

Page 47 of 158

Science IP Order: 3550000 Client Reference: 3456-789

Stearyl propionate 53824-77-4, Propylene glycol dicaprate 56235-92-8 57569-76-3, Glycereth-7 triacetate 58958-60-4, Isostearyl neopentanoate 59130-69-7, Cetyl 2-ethylhexanoate 59231-34-4, Isodecyl oleate 59587-44-9, 2-Ethylhexyl pelargonate 60908-77-2, Isohexadecane 63793-60-2, Polypropylene glycol myristyl ether 65591-14-2, Arachidyl propionate 66009-41-4, Stearyl heptanoate 68171-33-5, Isopropyl isostearate 71566-49-9, 2-Ethylhexyl isononanoate 72269-52-4 72576-80-8, Isostearyl palmitate 83826-43-1, Octyldodecyl myristate 84605-09-4 90052-75-8, Octyldodecyl stearoyl stearate 93385-14-9, Triisocetyl citrate 93596-79-3, Polypropylene glycol isocetyl ether 93682-38-3, Isostearyl malate 93705-18-1 94247-28-6, Isocetyl behenate 97338-28-8 102767-64-6, Propellant A 46 111517-88-5, Propylene glycol ricinoleate 113431-53-1, Diisostearyl fumarate 125804-07-1 125804-08-2 125804-16-2, Isostearyl behenate 125804-18-4, Tridecyl isononanoate 127358-80-9, Isostearyl linoleate 127770-27-8, Isocetyl palmitate 135326-54-4, Propylene glycol myristyl ether acetate 138208-67-0, Isohexyl decanoate 138208-68-1, Isocetyl salicylate 144610-93-5, Myristyl neopentanoate 159317-32-5, Isostearyl glycolate 163564-45-2, Isostearyl isononanoate 172670-81-4, Isononyl octanoate 190282-37-2, Diethylene glycol diisononanoate 195868-36-1, Phenyl trimethicone 308122-33-0, 2-Octyldodecyl hydroxystearate 1008098-31-4, Isostearyl citrate 1186139-12-7 1257338-52-5, Schercemol DISD 1286715-16-9 1286715-17-0 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (topical tetracycline compns. with carriers contg. hydrophobic oils and viscosity-modifying agents)

Page 48 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 10 OF 199 HCAPLUS COPYRIGHT 2013 ACS on STN ACCESSION NUMBER: 2011:436527 HCAPLUS Full-text DOCUMENT NUMBER: 154:469598 TITLE: Surfactant-free, water-free foamable tetracycline compositions, breakable foams and gels and their uses INVENTOR(S): Tamarkin, Dov; Gazal, Elana; Papiashvili, Irakliy; Hazot, Yohan; Schuz, David; Keynan, Rita PATENT ASSIGNEE(S): Foamix Ltd., Israel SOURCE: PCT Int. Appl., 138pp. LANGUAGE: English PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE ------WO 2011039637 A2 20110407 WO 2010-IB2612 20101001 WO 2011039637 A3 20110630 CA 2776366 A1 20110407 CA 2010-2776366 20101001 GB 2474930 A 20110504 GB 2010-16546 20101001 GB 2474930 B 20120704 AU 2010302350 A1 20120524 AU 2010-302350 20101001 CA 2776482 A1 20111110 CA 2011-2776482 20110504 WO 2011138678 A2 20111110 WO 2011-IB1374 20110504 US 20110281827 A1 20111117 US 2011-100724 20110504 PRIORITY APPLN. INFO.: US 2009-248144P P 20091002 US 2010-322148P P 20100408 US 2010-331126P P 20100504 US 2010-349911P P 20100531 US 2010-380568P P 20100907 US 2010-385385P P 20100922 US 2010-388884P P 20101001 WO 2010-IB2612 W 20101001 WO 2010-IB2613 A 20101001 WO 2010-IB2617 A 20101001 WO 2011-IB1374 W 20110504 AB A surfactant-free oleaginous foamable compn. comprising a hydrophobic solvent, a petrolatum, a , a fatty alc., a fatty acid and/or a wax and/or shea butter, with and without a propellant is provided. A substantially surface active agent-free compn. further comprises a tetracycline antibiotic, or a vitamin D deriv., or one or more other active agents. A method of using a substantially surface active agent-free compn. for intradermal delivery of the active agent into the skin with minimal or negligible transdermal delivery for treatment, among others, eye and dermatol. or mucosal disorders is described. A minocycline oleaginous compn. contg. soybean oil, octyldodecanol, medium-chain triglycerides oil and coconut oil was proposed. IPCI A61K0009-12 [I,A] IPCR A61K0009-12 [I,A] CC 63-6 (Pharmaceuticals) Section cross-reference(s): 1 IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Melaleuca; surfactant- and water-free foamable compns., breakable foams and gels, and therapeutic uses thereof) IT Dermatological agents (anti-acne agents; surfactant- and water-free foamable compns., breakable foams and gels, and therapeutic uses thereof) IT Acne (nodular papulopustular; surfactant- and water-free foamable compns., breakable foams and gels, and therapeutic uses thereof) IT AIDS (disease) Abscess

Page 49 of 158

Science IP Order: 3550000 Client Reference: 3456-789

Acaricides Acinetobacter Acne Albinism Allergy Allergy inhibitors Alopecia Anal disease Analgesics Anthelmintics Anti-infective agents Anti-inflammatory agents Antibacterial agents Antibiotics Antidepressants Antihistamines Antimicrobial agents Antioxidants Antiproliferative agents Antitumor agents Antiviral agents Anus neoplasm Arthralgia Arthritis Aspergillus niger Astringents Atopic dermatitis Bacterial infection Bacteroides Barrier cosmetics Beeswax Blister Bullous pemphigoid Candida albicans Cellulitis Cervix, neoplasm Chlamydia infection Cholesteatoma Constipation Crohn disease Decubitus ulcer Dermatomycosis Drug toxicity Drugs Dysmenorrhea Dysplastic nevus Ear disease Ectodermal dysplasia Eczema Endometriosis Endometritis Erysipelas Erythema nodosum Erythroderma Escherichia coli Female reproductive system, neoplasm Female reproductive system disease Folliculitis Fungicides Furunculosis

Page 50 of 158

Science IP Order: 3550000 Client Reference: 3456-789

Gestational trophoblastic disease HIV infection Haemophilus Hair growth stimulants Hemorrhoid Hepatitis B Herpes Herpes labialis Herpes simplex Human herpesvirus 3 Human papillomavirus Hyperhidrosis Hyperkeratosis Hypnotics and Sedatives Hypolipemic agents Ichthyosis Immunomodulators Immunostimulants Immunosuppressants Impetigo Inflammation Insect repellents Insecticides Kaposi sarcoma Keloid Lichen planus Lubricants Lymphadenitis Lymphogranuloma venereum Mastocytosis Measles Melanoma Melasma Molluscum contagiosum virus Myalgia Mycobacterium leprae Neisseria meningitidis Neoplasm Neurodermatitis Nocardia Nonsteroidal anti-inflammatory drugs Nose disease Oophoritis Ophthalmic drug delivery systems Osteoarthritis Ovary, neoplasm Oxidizing agents Pain Parasitic infection Parasiticides Pediculus humanus capitis Pemphigus Pesticides Pharmaceutical carriers Pharmaceutical foams Photosensitizers, pharmaceutical Pigmentation disorders Pityriasis lichenoides Pityriasis rosea

Page 51 of 158

Science IP Order: 3550000 Client Reference: 3456-789

Premenstrual syndrome Preservatives Propellants (sprays and foams) Prophylaxis Propionibacterium acnes Pruritus Pseudomonas aeruginosa Psoriasis Purpura (disease) Radical scavengers Respiratory system disease Rhus diversiloba Rhus toxicodendron Rubella Scabies Scar Scleroderma Sexual disorders Sexually transmitted diseases Skin disease Skin ulcer Skin-lightening cosmetics Stability Staphylococcal scalded-skin syndrome Staphylococcus aureus Streptococcus Streptococcus pyogenes Sunburn Sunless tanning products Surfactants Tinea (skin disease) Tinea pedis Toxic epidermal necrolysis Trichomonas vaginalis Urticaria Uterine cervicitis Vagina, neoplasm Vaginal disease Varicella Vasoconstrictors Vasodilators Vesiculobullous Viral infection Vitiligo Vulva disease Wound Wound healing promoters (surfactant- and water-free foamable compns., breakable foams and gels, and therapeutic uses thereof) IT Acne (vulgaris; surfactant- and water-free foamable compns., breakable foams and gels, and therapeutic uses thereof) IT 50-81-7, Vitamin C, biological studies 57-11-4, Stearic acid, biological studies 57-50-1D, Sucrose, stearic acid esters 57-88-5, Cholesterol, biological studies 58-95-7, Tocopheryl acetate 65-85-0D, Benzoic acid, alkyl esters 75-28-5, Isobutane 94-36-0, Benzoyl peroxide, biological studies 103-23-1, Diethylhexyl adipate 109-36-4, Octyl stearate 110-27-0, Isopropyl myristate 110-36-1, Butyl myristate 112-10-7, Isopropyl stearate 112-72-1, Myristyl alcohol 112-92-5, Stearyl alcohol 115-83-3, Pentaerythrityl tetrastearate

Page 52 of 158

Science IP Order: 3550000 Client Reference: 3456-789

122-62-3, Dioctyl sebacate 123-95-5, Butyl stearate 124-07-2D, Octanoic acid, alkyl esters 140-25-0, Benzyl laurate 142-91-6, Isopropyl palmitate 149-57-5D, Ethylhexanoic acid, cetearyl esters 293-51-6, Cyclotetrasiloxane 294-40-6, Cyclopentasiloxane 295-01-2, Cyclohexasiloxane 443-48-1, 538-23-8, Glyceryl trioctanoate 540-10-3, Cetyl palmitate 540-97-6, Dow Corning 246 Fluid 556-67-2, Dow Corning 244 Fluid 564-25-0, Doxycycline 620-67-7, Glycerol triheptanoate 629-70-9, Cetyl acetate 661-19-8, Behenyl alcohol 1190-63-2, Hexadecyl stearate 1323-03-1, Myristyl lactate 1406-16-2, Vitamin D 2152-44-5, Betamethasone valerate 2599-01-1, Cetyl myristate 2915-57-3 3234-85-3, Myristyl myristate 3687-45-4, Oleyl oleate 3687-46-5, Decyl oleate 6221-95-0, Myristyl propionate 6283-92-7, Lauryl lactate 6309-51-9, Isoamyl laurate 6938-94-9, Diisopropyl adipate 7384-98-7, Propylene glycol dicaprylate 7425-14-1 7491-02-3, Diisopropyl sebacate 7735-26-4, Diethylene glycol dioctanoate 9003-13-8, Polypropylene glycolbutyl ether 9003-27-4, Polyisobutylene 9006-65-9, Dimethicone 9006-65-9D, Dimethicone, PEG/PPG derivs. 9035-85-2, PPG cetyl ether 9064-14-6, Polypropylene glycol lauryl ether 10118-90-8, Minocycline 10233-13-3, Isopropyl laurate 10401-55-5, Cetyl ricinoleate 11103-57-4, Vitamin A 12001-76-2, Vitamin B 12001-79-5, Vitamin K 13552-80-2, Glyceryl triundecanoate 13614-98-7, Minocycline hydrochloride 14303-70-9, Propyl myristate 15763-02-7, Dioctyl malate 16958-85-3, Octyl palmitate 17673-56-2, Oleyl erucate 17955-88-3, Caprylyl methicone 22047-49-0, Ethylhexyl stearate 22204-53-1, 24390-14-5, Doxycycline hyclate 25231-21-4, Polypropylene glycol stearyl ether 25322-69-4D, Polypropylene glycol, alkyl ethers 25339-09-7, Isocetyl stearate 26896-18-4D, Isononanoic acid, cetearyl esters 27841-06-1, Neopentyl glycol dicaprate 29710-25-6 29710-31-4, Cetyl octanoate 29806-73-3 30399-84-9, Isostearic acid 31161-71-4, Benzyl myristate 31335-74-7, Neopentyl glycol dicaprylate 31692-79-2, Dimethiconol 31807-55-3, Isododecane 32222-06-3, Calcitriol 34316-64-8, Hexyl laurate 34513-50-3, Octyldodecanol 34689-06-0, Stearyl caprate 34962-91-9 35274-05-6, Cetyl lactate 36078-10-1, Dodecyl oleate 36148-84-2 36311-34-9, Isohexadecanol 36653-82-4, Cetyl alcohol 37220-82-9, Glyceryl oleate 37286-64-9, Polypropylene glycol methyl ether 41395-89-5, Isodecyl isononanoate 41669-30-1, Isostearyl isostearate 41755-60-6, Benzyl palmitate 42131-25-9, Isononyl isononanoate 42131-27-1, Isotridecyl isononanoate 42131-28-2, Isostearyl lactate 42175-36-0, Oleyl lactate 42233-14-7, Arachidyl behenate 42557-10-8 52581-71-2 52663-48-6 53824-77-4, Propylene glycol dicaprate 56235-92-8 57569-76-3 58958-60-4, Isostearyl neopentanoate 59130-69-7 59231-34-4, Isodecyl oleate 59587-44-9 60908-77-2, Isohexadecane 63793-60-2, Polypropylene glycol myristyl ether 65591-14-2, Arachidyl propionate 66009-41-4, Stearyl heptanoate 68171-33-5, Isopropyl isostearate 71566-49-9 72269-52-4 72576-80-8, Isostearyl palmitate 83826-43-1, Octyldodecyl myristate 83919-23-7, Mometasone furoate 84605-09-4 90052-75-8, Octyldodecyl stearoyl stearate 91161-71-6, Terbinafine 93385-14-9, Triisocetyl citrate 93596-79-3 93682-38-3, Isostearyl malate 94247-28-6, Isocetyl behenate 97338-28-8 111517-88-5, Propylene glycol ricinoleate 112965-21-6, Calcipotriol 113431-53-1 125804-07-1 125804-08-2, 2-Octyldodecyl behenate 125804-16-2 125804-18-4, Tridecyl isononanoate 127358-80-9, Isostearyl linoleate 127770-27-8, Isocetyl palmitate 135326-54-4, Propylene glycol myristyl ether acetate 138208-67-0, Isohexyl decanoate 138208-68-1, Isocetyl salicylate 144610-93-5 156048-34-9 159317-32-5, Isostearyl glycolate 163564-45-2, Isostearyl isononanoate 172670-81-4, Isononyl octanoate 190282-37-2, Diethylene glycol diisononanoate 195868-36-1, Phenyltrimethicone 308122-33-0, 2-Octyldodecyl hydroxystearate 383419-35-0 1008098-31-4 1286715-16-9 1286715-17-0 1287647-89-5

Page 53 of 158

Science IP Order: 3550000 Client Reference: 3456-789

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (surfactant- and water-free foamable compns., breakable foams and gels, and therapeutic uses thereof)

Page 54 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 11 OF 199 HCAPLUS COPYRIGHT 2013 ACS on STN ACCESSION NUMBER: 2010:969294 HCAPLUS Full-text DOCUMENT NUMBER: 153:295963 TITLE: Nanoemulsion compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof INVENTOR(S): Sutcliffe, Joyce A.; Ciotti, Susan M.; Baker, James R., Jr. PATENT ASSIGNEE(S): NanoBio Corporation, USA SOURCE: PCT Int. Appl., 92pp. LANGUAGE: English PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE ------WO 2010087964 A2 20100805 WO 2010-US236 20100128 WO 2010087964 A3 20110616 CA 2750233 A1 20100805 CA 2010-2750233 20100128 US 20100226983 A1 20100909 US 2010-656421 20100128 EP 2391342 A2 20111207 EP 2010-703377 20100128 PRIORITY APPLN. INFO.: US 2009-147960P P 20090128 WO 2010-US236 W 20100128 AB The present invention relates to methods for treating and preventing acne or Propionibacterium acnes infection in a subject comprising topically administering to the subject in need thereof an anti-acne nanoemulsion compn. Thus, nanoemulsions comprised, in an aq. medium, soybean oil, Tween 20 as a nonionic surfactant, ethanol, cetylpyridinium chloride (CPC) as a cationic surfactant, EDTA, and water, and optionally, a thickening agent for the gel formulation. The nanoemulsions showed relevant microbiol. and bactericidal activity against a collection of recent clin. isolates of P. acnes, including multidrug-resistant strains. Combinations of the nanoemulsion with 0.5% benzoyl peroxide or 2% salicylic acid were as effective as nanoemulsion alone. IPCI A61K0009-107 [I,A]; A61K0009-00 [I,A]; A61K0008-06 [I,A] IPCR A61K0009-107 [I,A]; A61K0008-06 [I,A]; A61K0009-00 [I,A] CC 63-6 (Pharmaceuticals) Section cross-reference(s): 1 ST antibacterial nanoemulsion topical acne Propionibacterium infection IT Fats and Glyceridic oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Chile oil; nanoemulsion compns. for treatment and prevention of acne) IT Alcohols RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (C1-12; nanoemulsion compns. for treatment and prevention of acne) IT Alcohols RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (C11-15-secondary, ethoxylated; nanoemulsion compns. for treatment and prevention of acne) IT Fats and Glyceridic oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Kuki nut oil; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

Page 55 of 158

Science IP Order: 3550000 Client Reference: 3456-789

(Marhoram flower oil; nanoemulsion compns. for treatment and prevention of acne) IT Polysiloxanes RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Me Ph; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Melaleuca; nanoemulsion compns. for treatment and prevention of acne) IT Bacterial infection (Propionibacterium acnes; nanoemulsion compns. for treatment and prevention of acne) IT RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Quillaja bark; nanoemulsion compns. for treatment and prevention of acne) IT Amides Carbohydrates Waxes RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (alkoxylated; nanoemulsion compns. for treatment and prevention of acne) IT RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (alkyl, ethoxylated; nanoemulsion compns. for treatment and prevention of acne) IT Betaines RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (alkyl; nanoemulsion compns. for treatment and prevention of acne) IT Quaternary ammonium compounds RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (alkylbenzyldimethyl, chlorides; nanoemulsion compns. for treatment and prevention of acne) IT Quaternary ammonium compounds RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (alkylbenzyldimethyl; nanoemulsion compns. for treatment and prevention of acne) IT Quaternary ammonium compounds RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (alkyltrimethyl, chlorides; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (allspice oil; nanoemulsion compns. for treatment and prevention of acne) IT Fats and Glyceridic oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

Page 56 of 158

Science IP Order: 3550000 Client Reference: 3456-789

(almond; nanoemulsion compns. for treatment and prevention of acne) IT Fats and Glyceridic oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (animal; nanoemulsion compns. for treatment and prevention of acne) IT Polyelectrolytes Surfactants (anionic; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (anise; nanoemulsion compns. for treatment and prevention of acne) IT Fats and Glyceridic oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (apricot kernel; nanoemulsion compns. for treatment and prevention of acne) IT Solvents (aprotic; nanoemulsion compns. for treatment and prevention of acne) IT Fats and Glyceridic oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (avocado; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (basil, Ocimum basilicum; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (bay leaf oil; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (bergamot; nanoemulsion compns. for treatment and prevention of acne) IT Fats and Glyceridic oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (berry oil; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (camphor; nanoemulsion compns. for treatment and prevention of acne) IT Antiflatulents (carminatives; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

Page 57 of 158

Science IP Order: 3550000 Client Reference: 3456-789

(cassia bark oil; nanoemulsion compns. for treatment and prevention of acne) IT Polyelectrolytes Surfactants (cationic; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (cedarwood; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (celery seed; nanoemulsion compns. for treatment and prevention of acne) IT Polysiloxanes RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (cetyl Me, di-Me, cetyl dimethicone; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (chamomile; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (cinnamon; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (clary sage; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (clove; nanoemulsion compns. for treatment and prevention of acne) IT Monoglycerides RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (coco monoglycerides; nanoemulsion compns. for treatment and prevention of acne) IT Amides RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (coco, N-(hydroxyethyl), ethoxylated; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (cumin; nanoemulsion compns. for treatment and prevention of acne) IT Cyclosiloxanes RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (di-Me; nanoemulsion compns. for treatment and prevention of

Page 58 of 158

Science IP Order: 3550000 Client Reference: 3456-789

acne) IT Quaternary ammonium compounds RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (dialkyldimethyl, chlorides; nanoemulsion compns. for treatment and prevention of acne) IT Fatty acids RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (esters, Ceraphyls; nanoemulsion compns. for treatment and prevention of acne) IT Carboxylic acids Fatty acids RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (esters; nanoemulsion compns. for treatment and prevention of acne) IT Castor oil Fatty acids Lanolin RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (ethoxylated; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (eucalyptus; nanoemulsion compns. for treatment and prevention of acne) IT Fats and Glyceridic oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (fish; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (geranium; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (ginger; nanoemulsion compns. for treatment and prevention of acne) IT Fats and Glyceridic oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (gourd oil; nanoemulsion compns. for treatment and prevention of acne) IT Fats and Glyceridic oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (grape seed; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (grapefruit; nanoemulsion compns. for treatment and prevention of acne) IT Fats and Glyceridic oils

Page 59 of 158

Science IP Order: 3550000 Client Reference: 3456-789

RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (hazelnut; nanoemulsion compns. for treatment and prevention of acne) IT Fats and Glyceridic oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (hemp oil; nanoemulsion compns. for treatment and prevention of acne) IT Castor oil RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (hydrogenated, ethoxylated; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (hyssop oil; nanoemulsion compns. for treatment and prevention of acne) IT Controlled-release drug delivery systems (immediate-release; nanoemulsion compns. for treatment and prevention of acne) IT Propionibacterium acnes (infection; nanoemulsion compns. for treatment and prevention of acne) IT Surfactants (ionic; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (jasmine; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (juniper; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (lavender; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (lemon; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (lemongrass; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (lime; nanoemulsion compns. for treatment and prevention of acne) IT Fats and Glyceridic oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study);

Page 60 of 158

Science IP Order: 3550000 Client Reference: 3456-789

USES (Uses) (macadamia nut; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (manuka oil; nanoemulsion compns. for treatment and prevention of acne) IT Triglycerides RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (medium-chain; nanoemulsion compns. for treatment and prevention of acne) IT Fats and Glyceridic oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (mustard; nanoemulsion compns. for treatment and prevention of acne) IT Perfumes (myrrh; nanoemulsion compns. for treatment and prevention of acne) IT Acne Antibacterial agents Bile Buffers Chelating agents Controlled-release drug delivery systems Human Nonpolar solvents Pharmaceutical nanoemulsions Polar solvents Preservatives Prophylaxis Sebaceous gland Sebum Stability Surfactants Topical drug delivery systems Viscosity (nanoemulsion compns. for treatment and prevention of acne) IT Canola oil Coconut oil Corn oil Cottonseed oil Cyclosiloxanes Essential oils Glycols Hydrocarbon oils Isoalkanes Jojoba oil Linseed oil Oils Olive oil Palm oil Paraffin oils Peanut oil Petrolatum Phenolic resins Phosphates

Page 61 of 158

Science IP Order: 3550000 Client Reference: 3456-789

Polyesters Polymers Polyoxyalkylenes Polysiloxanes Quaternary ammonium compounds Rape oil Safflower oil Soybean oil Steroids Sulfates Sunflower oil RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (nanoemulsion compns. for treatment and prevention of acne) IT Retinoids RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (nanoemulsion compns. for treatment and prevention of acne) IT Surfactants (nonionic; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (nutmeg; nanoemulsion compns. for treatment and prevention of acne) IT Chenopodium Valeriana (oil; nanoemulsion compns. for treatment and prevention of acne ) IT Resins RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (olibanum; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (orange, sweet; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (oregano; nanoemulsion compns. for treatment and prevention of acne) IT Solvents (org.; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (patchouli; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (peppermint; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils

Page 62 of 158

Science IP Order: 3550000 Client Reference: 3456-789

RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pine leaf; nanoemulsion compns. for treatment and prevention of acne) IT Fats and Glyceridic oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pine seed; nanoemulsion compns. for treatment and prevention of acne) IT Polyoxyalkylenes RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (polyester-; nanoemulsion compns. for treatment and prevention of acne) IT Polyesters RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (polyoxyalkylene-; nanoemulsion compns. for treatment and prevention of acne) IT Fats and Glyceridic oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (poppyseed; nanoemulsion compns. for treatment and prevention of acne) IT Solvents (protic; nanoemulsion compns. for treatment and prevention of acne) IT Fats and Glyceridic oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pumpkin seed; nanoemulsion compns. for treatment and prevention of acne) IT Fats and Glyceridic oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (rice bran; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (rose; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (rosemary; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (rosewood; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (sage, Salvia officinalis; nanoemulsion compns. for treatment and prevention of acne) IT Carboxylic acids Sulfonic acids RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study);

Page 63 of 158

Science IP Order: 3550000 Client Reference: 3456-789

USES (Uses) (salts; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (sandalwood; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (sassafras; nanoemulsion compns. for treatment and prevention of acne) IT Fats and Glyceridic oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (sesame; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (sour orange neroli; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (sour orange; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (spearmint; nanoemulsion compns. for treatment and prevention of acne) IT RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (tallow alkyl, 1,3-diaminopropane derivs., ethoxylated; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (tangerine peel oil; nanoemulsion compns. for treatment and prevention of acne) IT Fats and Glyceridic oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (teaseed; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (thyme, Thymus vulgaris; nanoemulsion compns. for treatment and prevention of acne) IT Pharmaceutical gels Topical drug delivery systems (topical gels; nanoemulsion compns. for treatment and prevention of acne) IT Alcohols RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

Page 64 of 158

Science IP Order: 3550000 Client Reference: 3456-789

(trihydric; nanoemulsion compns. for treatment and prevention of acne) IT Quaternary ammonium compounds RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (trimethoxysilyl; nanoemulsion compns. for treatment and prevention of acne) IT Fats and Glyceridic oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (truffle oil; nanoemulsion compns. for treatment and prevention of acne) IT Fats and Glyceridic oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (vegetable; nanoemulsion compns. for treatment and prevention of acne) IT Fats and Glyceridic oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (walnut kernel oil; nanoemulsion compns. for treatment and prevention of acne) IT Vitamins RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (water-insol.; nanoemulsion compns. for treatment and prevention of acne) IT Fats and Glyceridic oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (wheat germ; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (wintergreen; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (yarrow; nanoemulsion compns. for treatment and prevention of acne) IT Essential oils RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (ylang-ylang; nanoemulsion compns. for treatment and prevention of acne) IT Surfactants (zwitterionic; nanoemulsion compns. for treatment and prevention of acne) IT 60-54-8, Tetracycline 69-72-7, Salicylic acid, biological studies 94-36-0, Benzoyl peroxide, biological studies 114-07-8, Erythromycin 18323-44-9, Clindamycin RL: NANO (Nanomaterial); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (nanoemulsion compns. for treatment and prevention of acne) IT 50-21-5D, Lactic acid, C12-15 alkyl esters 50-70-4, Sorbitol, biological studies 50-81-7, Ascorbic acid, biological studies 52-51-7, Bronopol 55-56-1, Chlorohexidine 56-81-5, Glycerol, biological studies 56-81-5D, Glycerol, lanolin esters 56-81-5D, Glycerin, mono- and

Page 65 of 158

Science IP Order: 3550000 Client Reference: 3456-789

diesters 57-09-0, Hexadecyltrimethylammonium bromide 57-55-6, Propylene glycol, biological studies 57-88-5, Cholesterol, biological studies 59-02-9, α-Tocopherol 59-50-7, Chlorocresol 59-52-9, Dimercaprol 60-00-4, Ethylenediaminetetraacetic acid, biological studies 60-29-7, Diethyl ether, biological studies 60-33-3, Linoleic acid, biological studies 64-17-5, Ethanol, biological studies 64-18-6, Formic acid, biological studies 64-19-7, Acetic acid, biological studies 65-85-0, Benzoic acid, biological studies 67-56-1, Methanol, biological studies 67-63-0, Isopropyl alcohol, biological studies 67-64-1, Acetone, biological studies 67-66-3, Chloroform, biological studies 67-68-5, Dimethyl sulfoxide, biological studies 68-12-2, Dimethylformamide, biological studies 71-23-8, n-Propanol, biological studies 71-36-3, n-Butanol, biological studies 71-43-2, Benzene, biological studies 75-05-8, Acetonitrile, biological studies 75-09-2, Dichloromethane, biological studies 76-22-2, Camphor 77-92-9, Citric acid, biological studies 78-70-6, Linalool 81-23-2, Dehydrocholic acid 81-25-4, Cholic acid 83-44-3, Deoxycholic acid 83-46-5, β-Sitosterol 89-78-1, Menthol 89-83-8, Thymol 97-78-9, N-Lauroylsarcosine 100-51-6, Benzyl alcohol, biological studies 102-76-1, Triacetin 106-22-9, Citronellol 106-23-0, Citronellal 106-24-1, Geraniol 106-25-2, Nerol 107-15-3, Ethylenediamine, biological studies 108-88-3, Toluene, biological studies 108-95-2, Phenol, biological studies 109-76-2D, 1,3-Propanediamine, N-tallow derivs., ethoxylated 109-99-9, Tetrahydrofuran, biological studies 110-27-0, Isopropyl myristate 110-44-1, Sorbic acid 110-54-3, Hexane, biological studies 111-02-4, Squalene 112-10-7, Isopropyl stearate 112-80-1, Oleic acid, biological studies 118-60-5 121-54-0 122-18-9, Benzyldimethylhexadecylammonium chloride 122-62-3, Dioctyl sebacate 122-99-6, Phenoxyethanol 123-03-5, Cetylpyridinium chloride 123-46-6 123-91-1, 1,4-Dioxane, biological studies 123-95-5, Butyl stearate 124-03-8, Ethylhexadecyldimethylammonium bromide 126-73-8, Tri-n-butyl phosphate, biological studies 126-92-1, Sodium octyl sulfate 128-13-2, Ursodeoxycholic acid 128-37-0, Butylated hydroxytoluene, biological studies 134-03-2, Sodium ascorbate 134-09-8, Menthyl anthranilate 136-44-7, Glyceryl PABA 137-16-6, N-Lauroylsarcosine sodium salt 137-66-6, Ascorbyl palmitate 138-86-3, Limonene 139-07-1, Dodecyl dimethyl benzylammonium chloride 139-08-2, Benzyldimethyltetradecylammonium chloride 139-88-8, Niaproof 4 141-78-6, Ethyl acetate, biological studies 142-50-7, Nerolidol 142-91-6, Isopropyl palmitate 143-28-2, Oleyl alcohol 143-62-4, Digitoxigenin 145-42-6, Sodium taurocholate 151-21-3, Sodium lauryl sulfate, biological studies 275-51-4, Azulene 302-95-4, Sodium deoxycholate 360-65-6, Glycodeoxycholic acid 361-09-1, Sodium cholate 474-25-9, Chenodeoxycholic acid 475-31-0, Glycocholic acid 489-84-9, Guaiazulene 502-61-4, Farnesene 512-85-6, Ascaridole 515-69-5, Bisabolol 529-05-5, Chamazulene 536-59-4, Perillyl alcohol 540-10-3, Cetyl palmitate 540-84-1, Isooctane 541-02-6, Decamethylcyclopentasiloxane 541-05-9, Hexamethylcyclotrisiloxane 542-44-9, Glyceryl palmitate 546-80-5, Thujone 553-08-2, Thonzonium bromide 556-67-2, Octamethylcyclotetrasiloxane 577-11-7, Triton GR-5M 638-11-9, Isopropyl n-butyrate 863-57-0, Glycocholic acid sodium salt 1118-68-9D, alkyl derivs. 1119-94-4, Dodecyltrimethylammonium bromide 1119-97-7, Trimethyl(tetradecyl)ammonium bromide 1323-03-1, Myristyl lactate 1323-38-2, Glyceryl ricinoleate 1323-83-7, Glyceryl distearate 1330-85-4 1338-10-9 1338-39-2, Sorbitan monolaurate 1338-41-6, Sorbitan monostearate 1338-43-8, Sorbitan monooleate 1643-20-5, N,N-Dimethyldodecylamine N-oxide 2044-56-6, Lithium dodecyl sulfate 2281-11-0 2311-46-8, Isopropyl n-hexanoate 2311-59-3, Isopropyl n-decanoate 2386-53-0, Sodium 1-dodecanesulfonate 2386-54-1, Sodium 1-butanesulfonate 2420-29-3, Hexaethylene glycol monooctadecyl ether

Page 66 of 158

Science IP Order: 3550000 Client Reference: 3456-789

2646-38-0, Chenodeoxycholic acid sodium salt 2832-45-3, Sodium hexanesulfonate 3033-62-3D, alkyl derivs., chlorides 3055-94-5, Triethylene glycol monododecyl ether 3055-95-6, Pentaethylene glycol monododecyl ether 3055-96-7, Hexaethylene glycol monododecyl ether 3055-97-8, Heptaethylene glycol monododecyl ether 3055-98-9, Octaethylene glycol monododecyl ether 3055-99-0, Nonaethylene glycol monododecyl ether 3245-38-3, Deoxycholic acid methyl ester 3687-46-5, Decyl oleate 3700-67-2, Dimethyldioctadecylammonium bromide 4263-52-9, Sodium 2-bromoethanesulfonate 4292-10-8 4478-97-1, Pentaethylene glycol monohexadecyl ether 4484-59-7, Triethylene glycol monohexadecyl ether 4602-84-0, Farnesol 4669-23-2, Triethylene glycol monodecyl ether 4719-04-4 5157-04-0, Hexaethylene glycol monotetradecyl ether 5168-91-2, Hexaethylene glycol monohexadecyl ether 5274-68-0, Tetraethylene glycol monododecyl ether 5324-84-5, 1-Octanesulfonic acid sodium salt 5392-40-5, Citral 5538-94-3, Dioctyl dimethylammonium chloride 5698-39-5, Octaethylene glycol monohexadecyl ether 5703-94-6, Tetraethylene glycol monodecyl ether 6009-98-9, Taurochenodeoxycholic acid sodium salt 6283-92-7, Lauryl lactate 6938-94-9, Diisopropyl adipate 7173-51-5, 1-Decanaminium-N-decyl-N,N-dimethyl chloride 7281-04-1, Benzyldodecyldimethylammonium bromide 7664-38-2D, Phosphoric acid, di- and trialkyl esters 7681-57-4, Sodium metabisulfite 8050-81-5, Simethicone 9002-92-0, Polyoxyethylene lauryl ether 9002-93-1, Triton X-100 9003-11-6D, Ethylene oxide-propylene oxide copolymer, tetra-functional copolymers 9003-27-4, Polyisobutene 9003-35-4D, Phenol-formaldehyde copolymer, alkyl derivs., alkoxylated 9004-64-2, Klucel 9004-81-3, Polyoxyethylene laurate 9004-95-9, Brij 56 9004-98-2, Brij 92V 9004-99-3, Polyoxyethylene stearate 9005-00-9, Polyoxyethylene stearyl ether 9005-02-1, Polyoxyethylene dilaurate 9005-08-7, Polyoxyethylene distearate 9005-64-5 9005-65-6 9005-66-7 9005-67-8 9005-70-3, TWEEN 85 9005-71-4, TWEEN 65 9006-65-9, Dimethicone 9011-14-7D, Poly(methyl methacrylate), graft copolymers, PEO side chains-contg. 9014-93-1, Triton X-207 9016-45-9, Ethoxylated 9036-19-5, Igepal CA-630 10361-16-7 11024-24-1, Digitonin 11099-07-3, Glyceryl stearate 11105-10-5, Triton QS 15 11139-88-1, Glyceryl caprate 11140-02-6 11140-04-8, Glyceryl caprylate 12298-68-9, Lugol's solution 12441-09-7D, Sorbitan, esters, ethoxylated 13149-87-6 13177-41-8 13419-61-9, Sodium 1-decanesulfonate 14533-63-2, Sodium 1-propanesulfonate 14912-44-8, Ylangene 14933-08-5 14933-09-6 14974-53-9, Glyceryl thioglycolate 15163-36-7 15178-76-4 16409-34-0, Glycodeoxycholic acid sodium salt 16564-43-5, Glycochenodeoxycholic acid sodium salt 16958-85-3, Octyl palmitate 18449-82-6, Tetradecyl-β-D-maltoside 19327-38-9, Triethylene glycol monooctyl ether 19327-40-3, Pentaethylene glycol monooctyl ether 22767-49-3, Sodium pentanesulfonate 22767-50-6, Sodium 1-heptanesulfonate 23244-49-7, Pentaethylene glycol monodecyl ether 24233-81-6, Octaethylene glycol monodecyl ether 24634-61-5, Potassium sorbate 24938-91-8, Polyoxyethylene tridecyl ether 25013-16-5, Butylated hydroxyanisole 25155-18-4 25265-75-2, Butylene glycol 25301-02-4, Tyloxapol 25322-68-3D, fatty ethers 25496-72-4, Glyceryl oleate 25637-84-7, Glyceryl dioleate 26027-38-3, Nonoxynol-14 26266-57-9, Sorbitan monopalmitate 26266-58-0, Span 85 26403-72-5, Polyethylene glycol diglycidyl ether 26658-19-5, Span 65 26826-30-2, Triethylene glycol monotetradecyl ether 27306-76-9, Polyoxyethylene cetylstearyl ether RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (nanoemulsion compns. for treatment and prevention of acne) IT 27306-79-2, Polyoxyethylene myristyl ether 27321-96-6, Polyoxyethylene cholesteryl ether 27458-93-1, Isostearyl alcohol 27479-28-3, Quaternium 14 27638-00-2, Glyceryl dilaurate 27668-52-6 27841-06-1D,

Page 67 of 158

Science IP Order: 3550000 Client Reference: 3456-789

Neopentyl glycol dicaprate, cetol derivs. 27847-86-5, Octaethylene glycol monotetradecyl ether 28063-42-5, Glyceryl monoerucate 28854-76-4D, Aminopropionic acid*, N-alkyl derivs. 29710-31-4, Cetyl octanoate 29781-81-5, n-Decyl α-D-glucopyranoside 29836-26-8, Octyl-β-D-glucopyranoside 31692-79-2, Dimethiconol 31807-55-3, Isododecane 32426-11-2, Octyl decyl dimethylammonium chloride 34398-01-1 35192-74-6, Sodium 1-nonanesulfonate 35274-05-6, Cetyl lactate 35807-85-3, Tauroursodeoxycholic acid sodium salt 37211-53-3, Triton CF 21 37211-54-4, Triton CF 32 37220-82-9, Glyceryl oleate 37281-47-3, Triton DF 12 37318-95-9, Glyceryl laurate 37336-15-5, Resin Oil 37348-65-5, Glyceryl linoleate 38411-85-7, Sodium taurohyodeoxycholate 39034-24-7, Tetraethylene glycol monotetradecyl ether 39236-46-9, Imidazolidinyl urea 39840-09-0, Heptaethylene glycol monodecyl ether 40036-79-1, Heptaethylene glycol monotetradecyl ether 42233-08-9, Tridecyl behenate 42557-10-8 50996-85-5 51668-30-5 52623-95-7, Triton QS-44 52845-07-5, Isoeicosane 53563-63-6, Glyceryl dimyristate 55348-40-8, Triton X-200 58229-81-5, Triton DF 16 58958-60-4, Isostearyl neopentanoate 59979-06-5, Triton X 151 60828-78-6, Tergitol TMN 10 60908-77-2, Isohexadecane 61332-02-3, Glyceryl isostearate 64114-57-4 64936-82-9 64936-83-0 68207-00-1, Dodecylethyldimethylammonium bromide 69227-93-6, n-Dodecyl β-D-maltoside 69364-63-2, Polyoxyethylene isohexadecyl ether 70005-86-6, Undecyl β-D-glucopyranoside 71093-13-5, Pentaethylene glycol monooctadecyl ether 71611-21-7, W 1 (detergent) 72006-34-9, Polyhydroxystearic acid 72175-39-4 75621-03-3, CHAPS 82473-24-3, CHAPSO 82494-09-5, Decyl β-D-maltopyranoside 83826-43-1, Octyldodecyl myristate 85261-20-7, N-Decanoyl-N-methylglucamine 86674-95-5, Pentaethylene glycol monohexyl ether 90052-75-8 91490-94-7, Diisodecyl dimethylammonium chloride 94271-01-9 97338-28-8 98060-40-3 98064-96-1, n-Hexadecyl β-D-maltoside 100929-89-3, Glycolithocholic acid ethyl ester 104365-63-1, Glyceryl hydroxystearate 106392-12-5, Ethylene oxide-propylene oxide block copolymer 108084-06-6, Octylphenoxyethoxyethyl dimethyl benzylammonium chloride 110026-03-4, Taurodeoxycholic acid sodium salt monohydrate 114355-44-1, Poloxamer 182 Dibenzoate 115457-83-5, Methyl-6-O-(N-heptylcarbamoyl)-α-D- glucopyranoside 116183-64-3, n-Dodecyl α-D-maltoside 121309-88-4, Benzyltrimethylammonium tetrachloroiodate 134216-08-3, n-Dodecanoyl-N-methylglucamide 141265-32-9, N-Nonanoyl-N-methylglucamine 144975-21-3, Isotetracosane 153190-98-8, Poloxamer 105 Benzoate 195868-36-1, Phenyltrimethicone 283158-20-3 618113-48-7 691397-13-4, Poloxamer 188 697765-47-2, Ethylene oxide-propylene oxide diblock copolymer 1191416-21-3, Lauryl trimethicone 1192493-28-9 RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (nanoemulsion compns. for treatment and prevention of acne) IT 99-96-7D, 4-Hydroxybenzoic acid, esters RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (; nanoemulsion compns. for treatment and prevention of acne)

Page 68 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 12 OF 199 HCAPLUS COPYRIGHT 2013 ACS on STN ACCESSION NUMBER: 2009:1616001 HCAPLUS Full-text DOCUMENT NUMBER: 152:105038 TITLE: Nanoemulsions comprising drugs such as botulinum toxin for dermal delivery for treating skin diseases INVENTOR(S): Edelson, Jonathan; Kotyla, Timothy; Zhang, Boke PATENT ASSIGNEE(S): Anterios, Inc., USA SOURCE: PCT Int. Appl., 162pp. LANGUAGE: English PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE ------WO 2009158687 A1 20091230 WO 2009-US48972 20090626 AU 2009261995 A1 20091230 AU 2009-261995 20090626 CA 2726836 A1 20091230 CA 2009-2726836 20090626 KR 2011033243 A 20110330 KR 2011-7001737 20090626 EP 2310000 A1 20110420 EP 2009-771218 20090626 CN 102076333 A 20110525 CN 2009-80124419 20090626 JP 2011526302 T 20111006 JP 2011-516743 20090626 IL 209697 A 20121231 IL 2009-209697 20090626 MX 2010013562 A 20110215 MX 2010-13562 20101209 IN 2011CN00566 A 20111125 IN 2011-CN566 20110127 US 20110212157 A1 20110901 US 2011-509 20110506 PRIORITY APPLN. INFO.: US 2008-76065P P 20080626 WO 2009-US48972 W 20090626 AB The present invention describes systems and methods for treating disorders and/or conditions assocd. with the dermal level of the skin. Such disorders include acne, hyperhidrosis, bromhidrosis, chromhidrosis, rosacea, , dermal infection, and/or actinic keratosis. Methods generally involve administering nanoemulsions (e.g., nanoparticle compns.) comprising at least one therapeutic agent, such as botulinum toxin. In some embodiments, nanoemulsions are prepd., e.g., by high pressure microfluidization, and comprise a particle size distribution exclusively between 10 nm and 300 nm. IPCI A61K0009-51 [I,A]; A61K0031-48 [I,A] IPCR A61K0009-51 [I,A]; A61K0031-48 [I,A] CC 63-6 (Pharmaceuticals) Section cross-reference(s): 1 ST botulinum toxin nanoemulsion nanoparticle skin acne hyperhidrosis rosacea infection IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Melaleuca; nanoemulsions comprising drugs such as botulinum toxin for dermal delivery for treating skin diseases) IT Abrasives Acne Adsorption Aloe barbadensis Alopecia Antiandrogens Antibiotics Antiperspirants Antiviral agents Carica papaya Cavitation Clostridium botulinum Cosmetic sticks Cucurbita Detergents Eczema

Page 69 of 158

Science IP Order: 3550000 Client Reference: 3456-789

Human Hyperhidrosis Lupus erythematosus Nanoencapsulation Natural products, pharmaceutical Oral drug delivery systems Papaya Particle size distribution Permeation enhancers Personal deodorants Pharmaceutical aerosols Pharmaceutical creams Pharmaceutical gels Pharmaceutical injections Pharmaceutical nanoemulsions Pharmaceutical nanoparticles Pharmaceutical ointments Pharmaceutical patches Pharmaceutical powders Pharmaceutical sprays Polygonum multiflorum Psoriasis Raynaud disease Rosacea Serenoa repens Shampoos Silybum marianum Skin, neoplasm Skin emollients Skin hyperpigmentation Skin infection Stability Surfactants Topical drug delivery systems Transdermal drug delivery systems Urtica (nanoemulsions comprising drugs such as botulinum toxin for dermal delivery for treating skin diseases) IT 51-21-8, 5-Fluorouracil 52-01-7, Spironolactone 53-06-5, Cortisone 57-10-3, Palmitic acid, biological studies 57-88-5D, Cholesterol, esters 58-08-2, Caffeine, biological studies 59-05-2, Methotrexate 60-54-8, Tetracycline 63-89-8, Dipalmitoylphosphatidylcholine 66-97-7, Psoralen 67-71-0, Methylsulfonylmethane 67-97-0D, Vitamin D3, analogs 68-26-8, Retinol 69-72-7, Salicylic acid, biological studies 76-03-9, Trichloroacetic acid, biological studies 83-44-3, Deoxycholic acid 94-36-0, Benzoyl peroxide, biological studies 98-92-0, 110-27-0, Isopropyl myristate 110-40-7, Diethyl sebacate 112-80-1, Oleic acid, biological studies 114-07-8, Erythromycin 123-95-5, Butyl stearate 123-99-9, Azelaic acid, biological studies 124-22-1, Dodecylamine 124-30-1, Stearylamine 127-07-1, Hydroxyurea 143-27-1, Hexadecylamine 143-28-2, Oleyl alcohol 144-80-9, Sulfacetamide 154-42-7, Thioguanine 302-79-4, Tretinoin 382-67-2, Desoximetasone 443-48-1, Metronidazole 446-86-6, Azathioprine 475-31-0, Glycocholic acid 506-26-3, γ-Linolenic acid 538-23-8, Caprylic triglyceride 564-25-0, Doxycycline 599-79-1, Sulfasalazine 621-71-6, Capric triglyceride 1143-38-0, Dithranol 1190-63-2, Hexadecyl stearate 1323-38-2, Glyceryl ricinoleate 1327-41-9, Aluminum chlorohydrate 1338-39-2, Span 20 1403-66-3, Gentamicin 1405-87-4, Bacitracin 1406-05-9, Penicillin 1406-11-7, Polymyxin 2197-63-9, Dicetyl phosphate 3116-76-5, Dicloxacillin

Page 70 of 158

Science IP Order: 3550000 Client Reference: 3456-789

3380-34-5, Triclosan 4004-05-1, DOPE 4235-95-4, DOPC 4759-48-2, Isotretinoin 6990-06-3, 7429-90-5D, Aluminum, -zirconium compds. 7440-66-6, Zinc, biological studies 7440-67-7D, Zirconium, -aluminum compds. 7446-70-0, Aluminum chloride, biological studies 7704-34-9, Sulfur, biological studies 7784-25-0, Ammonium alum 9002-92-0 9004-99-3, Polyoxyethylene monostearate 9005-64-5, Polysorbate 20 9005-65-6, Polysorbate 80 9005-67-8, Polysorbate 60 9005-70-3, Polysorbate 85 9005-71-4, Polysorbate 65 9006-65-9, Dimethicone 10118-90-8, Minocycline 12441-09-7D, Sorbitan, fatty acid esters 12619-70-4, Cyclodextrin 12650-69-0, Mupirocin 15307-86-5, 15686-71-2, Cephalexin 18323-44-9, Clindamycin 18472-51-0, Chlorhexidine gluconate 23593-75-1, Clotrimazole 25301-02-4, Tyloxapol 25322-68-3, Polyethylene glycol 26266-58-0, Span 85 27220-47-9, Econazole 34513-50-3, Octyldodecanol 36653-82-4, Hexadecanol 38304-91-5, 52645-53-1, 56093-45-9, Selenium sulfide 59277-89-3, Acyclovir 59865-13-3, Cyclosporine 65277-42-1, Ketoconazole 65666-07-1, Silymarin 84625-61-6, Itraconazole 86386-73-4, Fluconazole 91161-71-6, Terbinafine 93384-43-1, Botulinum toxin type A 93384-44-2, Botulin B 93384-46-4, Botulin D 93384-47-5, Botulin E 98319-26-7, 99011-02-6, Imiquimod 104162-48-3, DOTMA 104227-87-4, Famciclovir 104987-11-3, Tacrolimus 106392-12-5, Poloxamer 106685-40-9, Adapalene 107231-12-9, Botulinum toxin 107231-13-0, Botulin C1 107231-14-1, Botulin C2 107231-15-2, Botulin F 107231-16-3, Botulin G 112965-21-6, Calcipotriol 118292-40-3, Tazarotene 124832-26-4, Valacyclovir 128794-94-5, Mycophenolate mofetil 134375-99-8, Aluminum Zirconium Trichlorohydrex Gly 134910-86-4, Aluminum Zirconium Tetrachlorohydrex Gly 137071-32-0, Pimecrolimus 164656-23-9, 170277-31-3, Infliximab 174722-31-7, Rituximab 185243-69-0, Etanercept 185463-23-4, DPPG 214745-43-4, Efalizumab 222535-22-0, Alefacept 252023-70-4, Surfactin 331731-18-1, Adalimumab 815610-63-0, Ustekinumab RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (nanoemulsions comprising drugs such as botulinum toxin for dermal delivery for treating skin diseases)

Page 71 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 13 OF 199 HCAPLUS COPYRIGHT 2013 ACS on STN ACCESSION NUMBER: 2009:1203732 HCAPLUS Full-text DOCUMENT NUMBER: 151:410849 TITLE: Anti-acne sunscreen composition containing avobenzone and oxybenzoneoxybenzone, octisalate, or octyl methoxycinnamate INVENTOR(S): Kunin, Audrey PATENT ASSIGNEE(S): Dermadoctor, Inc., USA SOURCE: U.S. Pat. Appl. Publ., 4 pp. LANGUAGE: English PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE ------US 20090246156 A1 20091001 US 2008-59761 20080331 PRIORITY APPLN. INFO.: US 2008-59761 20080331 AB The present invention is directed to compns. for anti-acne sunscreen. The sunscreen compn. has the unique ability to treat and prevent acne in addn. to screen both UVA and UVB radiation. In particular, the sunscreen compn. includes a sunscreen base, at least one UVA deactivator, at least one UVB deactivator, and at least one anti-acne agent. The UVA deactivator may be avobenzone and the UVB deactivator may be selected from one of the following oxybenzone, octisalate, octyl methoxycinnamate, or a mixt. thereof. No formulation example is presented. INCL 424060000; 424059000 IPCI A61K0008-33 [I,A]; A61K0008-30 [I,A]; A61Q0017-04 [I,A] IPCR A61K0008-33 [I,A]; A61K0008-30 [I,A]; A61Q0017-04 [I,A] NCL 424/060.000; 424/059.000 CC 62-4 (Essential Oils and Cosmetics) Section cross-reference(s): 63 ST anti acne sunscreen avobenzone oxybenzoneoxybenzone octisalate octyl methoxycinnamate IT Essential oils RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses) (Melaleuca alternifolia; anti-acne sunscreen compn. contg. avobenzone and oxybenzoneoxybenzone, octisalate, or octyl methoxycinnamate) IT Fats and Glyceridic oils RL: BSU (Biological study, unclassified); BIOL (Biological study) (almond, ethoxylated; anti-acne sunscreen compn. contg. avobenzone and oxybenzoneoxybenzone, octisalate, or octyl methoxycinnamate) IT Achillea Anacyclus pyrethrum Antibacterial agents Arnica montana Boswellia serrata Cosmetic creams Cosmetic gels Cosmetic liquids Cosmetic lotions Cosmetic ointments Cosmetic packs Cucumber Cucumis sativus 2 inhibitors Evodia rutaecarpa Filipendula Filipendula ulmaria Hamamelis virginiana

Page 72 of 158

Science IP Order: 3550000 Client Reference: 3456-789

Human Rumex crispus Salix alba Shampoos Skin cleansers Sunscreens Witch hazel (anti-acne sunscreen compn. contg. avobenzone and oxybenzoneoxybenzone, octisalate, or octyl methoxycinnamate) IT Soaps RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses) (anti-acne sunscreen compn. contg. avobenzone and oxybenzoneoxybenzone, octisalate, or octyl methoxycinnamate) IT Cyclosiloxanes RL: BSU (Biological study, unclassified); BIOL (Biological study) (di-Me; anti-acne sunscreen compn. contg. avobenzone and oxybenzoneoxybenzone, octisalate, or octyl methoxycinnamate) IT Essential oils RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses) (eucalyptus; anti-acne sunscreen compn. contg. avobenzone and oxybenzoneoxybenzone, octisalate, or octyl methoxycinnamate) IT Natural products, pharmaceutical (licorice; anti-acne sunscreen compn. contg. avobenzone and oxybenzoneoxybenzone, octisalate, or octyl methoxycinnamate) IT Cosmetics and Personal care products (patches, strips, serums, scrubs; anti-acne sunscreen compn. contg. avobenzone and oxybenzoneoxybenzone, octisalate, or octyl methoxycinnamate) IT Glycyrrhiza glabra (root ext.; anti-acne sunscreen compn. contg. avobenzone and oxybenzoneoxybenzone, octisalate, or octyl methoxycinnamate) IT Acne (treating agent; anti-acne sunscreen compn. contg. avobenzone and oxybenzoneoxybenzone, octisalate, or octyl methoxycinnamate) IT Proteins RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses) (α-binding; anti-acne sunscreen compn. contg. avobenzone and oxybenzoneoxybenzone, octisalate, or octyl methoxycinnamate) IT 52-01-7, Spironolactone 56-81-5, Glycerine, biological studies 57-55-6, Propylene glycol, biological studies 58-95-7, Tocopheryl acetate 79-10-7D, Acrylic acid, esters, polymers 94-13-3, 94-26-8, 99-76-3, 120-47-8, 122-99-6, Phenoxyethanol 139-33-3, Disodium EDTA 427-51-0, 500-38-9, Nordihydroguaiaretic acid 508-02-1, Oleanolic acid 1117-86-8, Caprylyl glycol 5451-09-2, Aminolevulinic acid hydrochloride 9067-32-7, Sodium hyaluronate 13311-84-7, 25265-75-2, Butylene glycol 25777-71-3 37318-79-9, Sorbitan oleate 98319-26-7, Finasteride 170277-31-3, Infliximab 185243-69-0, Etanercept 190085-41-7, Butyloctyl salicylate 331731-18-1, Adalimumab RL: BSU (Biological study, unclassified); BIOL (Biological study) (anti-acne sunscreen compn. contg. avobenzone and oxybenzoneoxybenzone, octisalate, or octyl methoxycinnamate) IT 67392-87-4, Drospirenone RL: BSU (Biological study, unclassified); COS (Cosmetic use); BIOL (Biological study); USES (Uses) (anti-acne sunscreen compn. contg. avobenzone and oxybenzoneoxybenzone, octisalate, or octyl methoxycinnamate) IT 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-78-2, Acetylsalicylic

Page 73 of 158

Science IP Order: 3550000 Client Reference: 3456-789

acid 53-03-2, Prednisone 53-06-5, Cortisone 57-13-6, Urea, biological studies 57-63-6, Ethinyl 59-05-2, Methotrexate 60-33-3, Linoleic acid, biological studies 60-54-8, Tetracycline 64-19-7, Acetic acid, biological studies 69-72-7, Salicylic acid, biological studies 79-14-1, Glycolic acid, biological studies 80-08-0, Atrisone 94-36-0, Benzoyl peroxide, biological studies 103-90-2, Acetaminophen 108-46-3, Resorcinol, biological studies 114-07-8, Erythromycin 117-39-5, 123-99-9, Azelaic acid, biological studies 144-80-9, Sulfacetamide 302-79-4, Tretinoin 443-48-1, Metronidazole 446-86-6, Azathioprine 564-25-0, Doxycycline 738-70-5, Trimethoprim 992-21-2, 1314-13-2, Zinc oxide, biological studies 2375-03-3, Solumedrol 4759-48-2, Isotretinoin 7704-34-9, Sulfur, biological studies 7733-02-0, Zinc sulfate 10043-01-3, Alum 10118-90-8, Minocycline 13463-41-7, Pyrithione zinc 18323-44-9, Clindamycin 22916-47-8, Miconazole 35891-70-4, Myriocin 53123-88-9, 59865-13-3, Cyclosporine 65277-42-1, Ketoconazole 83905-01-5, 99011-02-6, Imiquimod 104987-11-3, Tacrolimus 106685-40-9, Adapalene 162359-55-9, Fingolimod RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses) (anti-acne sunscreen compn. contg. avobenzone and oxybenzoneoxybenzone, octisalate, or octyl methoxycinnamate) IT 118-60-5, Octisalate 131-57-7, Oxybenzone 5466-77-3, Octyl methoxycinnamate 70356-09-1, Avobenzone RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (anti-acne sunscreen compn. contg. avobenzone and oxybenzoneoxybenzone, octisalate, or octyl methoxycinnamate) IT 521-18-6, 5α- RL: BSU (Biological study, unclassified); BIOL (Biological study) (inhibitors; anti-acne sunscreen compn. contg. avobenzone and oxybenzoneoxybenzone, octisalate, or octyl methoxycinnamate) IT 329900-75-6 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses) (inhibitors; anti-acne sunscreen compn. contg. avobenzone and oxybenzoneoxybenzone, octisalate, or octyl methoxycinnamate)

Page 74 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 14 OF 199 HCAPLUS COPYRIGHT 2013 ACS on STN ACCESSION NUMBER: 2009:676527 HCAPLUS Full-text DOCUMENT NUMBER: 151:24968 TITLE: Peptide-based antiacne reagents INVENTOR(S): O'Brien, John P.; Wang, Hong; Wilkins, Antoinette E. PATENT ASSIGNEE(S): E. I. du Pont de Nemours and Company, USA SOURCE: U.S. Pat. Appl. Publ., 31pp. LANGUAGE: English PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE ------US 20090143295 A1 20090604 US 2008-273778 20081119 PRIORITY APPLN. INFO.: US 2007-991261P P 20071130 AB Peptide-based antiacne reagents, formed by coupling a skin-binding peptide with an antiacne agent, are described. The skin-binding peptide portion of the peptide-based antiacne reagent binds strongly to the skin, thus keeping the antiacne agent coupled to the skin for a long lasting effect. Skin care compns. comprising the peptide-based antiacne reagents are also provided as well as a method of treating or preventing skin acne. INCL 514012000; 514773000; 514162000; 514718000; 514002000; 514013000; 514014000; 514015000 IPCI A61K0047-48 [I,A]; A61K0031-60 [I,A]; A61K0031-085 [I,A]; A61K0038-00 [I,A]; A61K0038-10 [I,A]; A61K0038-08 [I,A]; A61P0017-10 [I,A] IPCR A61K0047-48 [I,A]; A61K0031-085 [I,A]; A61K0031-60 [I,A]; A61K0038-00 [I,A]; A61K0038-08 [I,A]; A61K0038-10 [I,A]; A61P0017-10 [I,A] NCL 514/001.100; 514/162.000; 514/718.000; 514/773.000 CC 1-12 (Pharmacology) Section cross-reference(s): 62, 63 ST antiacne skin binding peptide antimicrobial acne IT Essential oils RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Melaleuca alternifolia; peptide-based antiacne reagents) IT DNA RL: BSU (Biological study, unclassified); BIOL (Biological study) (assocd. peptide-skin complexes; peptide-based antiacne reagents) IT Proteins RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (attacins; peptide-based antiacne reagents) IT Eubacteria Ribosome Yeast (display; peptide-based antiacne reagents) IT mRNA RL: ARU (Analytical role, unclassified); ANST (Analytical study) (display; peptide-based antiacne reagents) IT Keratins RL: BSU (Biological study, unclassified); BIOL (Biological study) (; peptide-based antiacne reagents) IT Peptides RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (lantibiotic; peptide-based antiacne reagents) IT Acne Antibiotics Antimicrobial agents

Page 75 of 158

Science IP Order: 3550000 Client Reference: 3456-789

Antimicrobial peptides Combinatorial library Cosmetics and Personal care products Dermatological agents Human Latex Peptide library Phage display Pharmaceutical capsules Protein sequences Topical drug delivery systems (peptide-based antiacne reagents) IT Polymers RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (peptide-based antiacne reagents) IT Antimicrobial peptides RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (peptide-based antiacne reagents) IT Bile salts RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (peptide-based antiacne reagents) IT Retinoids RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (peptide-based antiacne reagents) IT Sebaceous gland (sebocyte, sebostats; peptide-based antiacne reagents) IT Amino acids Amino acids RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (sulfur-contg.; peptide-based antiacne reagents) IT Amino acids RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (D-, sulfur-contg.; peptide-based antiacne reagents) IT 108433-95-0, Magainin II 115966-68-2 121798-56-9 142547-17-9 150398-24-6 155709-76-5 162096-67-5 207452-60-6 223762-50-3 230974-91-1 230974-92-2 313227-98-4 370102-12-8 466691-12-3 466691-39-4 470663-44-6 478181-94-1 506412-23-3 643745-56-6 684212-63-3 700814-11-5 700814-15-9 700814-18-2 700814-23-9 700814-26-2 700814-28-4 700814-30-8 700814-32-0 700814-35-3 700814-38-6 700814-41-1 700814-44-4 700814-47-7 700814-50-2 700814-52-4 700814-55-7 700814-57-9 700814-60-4 700814-65-9 700814-71-7 700814-76-2 846056-18-6 846056-19-7 846056-20-0 846056-21-1 846056-22-2 846056-23-3 847143-38-8 847143-41-3 847774-72-5 908606-19-9 908606-20-2 908606-21-3 908606-23-5 908606-24-6 908606-25-7 908606-26-8 908606-27-9 908606-28-0 908606-29-1 908606-30-4 908606-31-5 908606-32-6 911288-83-0 911288-84-1 911288-85-2 911288-86-3 911288-87-4 932013-55-3 932013-57-5 932013-58-6 932013-61-1 932013-62-2 932013-63-3 932013-64-4 932013-65-5 936251-53-5 936251-54-6 936251-55-7 936251-56-8 940910-74-7 1159631-98-7 1159631-99-8 1159632-00-4 1160082-33-6 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (amino acid sequence; peptide-based antiacne reagents)

Page 76 of 158

Science IP Order: 3550000 Client Reference: 3456-789

IT 9003-53-6, Polystyrene 9003-55-8, Styrene- copolymer 9011-14-7, Polymethylmethacrylate 9017-21-4, Polyvinyltoluene RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (peptide-based antiacne reagents) IT 52-90-4, Cysteine, occurrence 56-84-8, Aspartic acid, occurrence 56-87-1, , occurrence 107-21-1, , occurrence 141-43-5, Ethanol , occurrence 147-85-3, Proline, occurrence 9002-88-4, Polyethylene RL: OCU (Occurrence, unclassified); OCCU (Occurrence) (peptide-based antiacne reagents) IT 60-54-8, Tetracycline 94-36-0, Benzoyl peroxide, biological studies 98-92-0, Nicotinamide 101-20-2, 3,4,4'-Trichlorocarbanilide 114-07-8, Erythromycin 122-99-6, Phenoxyethanol 123-99-9, Azelaic acid, biological studies 141-78-6, Ethyl acetate, biological studies 302-79-4, Tretinoin 770-35-4, Phenoxyisopropanol 1200-22-2, Lipoic acid 2013-58-3, Meclocycline 3380-34-5, 2,4,4'-Trichloro-2'-hydroxy diphenyl ether 18323-44-9, Clindamycin 18472-51-0, Chlorhexidine gluconate 37231-28-0, Melittin 41593-38-8, Phenoxypropanol 68890-66-4, Octopirox 80802-79-5, Cecropin 97762-98-6, Brevinin 103220-14-0, Defensin 106685-40-9, Adapalene 113041-69-3, Magainin 118292-40-3, Tazarotene 123781-17-9, Histatin 162011-90-7, 384340-80-1, Novispirin G10 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (peptide-based antiacne reagents)

Page 77 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 15 OF 199 HCAPLUS COPYRIGHT 2013 ACS on STN ACCESSION NUMBER: 2007:1450137 HCAPLUS Full-text DOCUMENT NUMBER: 148:62071 TITLE: Anti-infection augmentation foamable compositions and kit and uses thereof INVENTOR(S): Tamarkin, Dov; Friedman, Doron; Eini, Meir PATENT ASSIGNEE(S): Foamix Ltd., Israel SOURCE: U.S. Pat. Appl. Publ., 43pp., Cont.-in-part of U.S. Ser. No. 448,490. LANGUAGE: English PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE ------US 20070292355 A1 20071220 US 2007-732547 20070404 WO 2004037225 A2 20040506 WO 2003-IB5527 20031024 WO 2004037225 A3 20041229 US 7820145 B2 20101026 US 2004-835505 20040428 US 20050031547 A1 20050210 US 20050069566 A1 20050331 US 2004-911367 20040804 CA 2776692 A1 20050303 CA 2004-2776692 20040820 US 7700076 B2 20100420 US 2004-922358 20040820 US 20050074414 A1 20050407 US 20100040561 A9 20100218 EP 2422768 A2 20120229 EP 2011-190124 20040820 EP 2422768 A3 20120509 AU 2004313285 A1 20050929 AU 2004-313285 20041216 ZA 2005007018 A 20080227 ZA 2005-7018 20041216 US 20050186142 A1 20050825 US 2005-41921 20050124 ZA 2005003298 A 20060830 ZA 2005-3298 20050425 US 20060140984 A1 20060629 US 2005-532618 20051222 AU 2006201878 A1 20070927 AU 2006-201878 20060504 US 20060269485 A1 20061130 US 2006-448490 20060607 AU 2006339311 A2 20070907 AU 2006-339311 20060607 AU 2006339311 A1 20070907 CA 2611577 A1 20070907 CA 2006-2611577 20060607 WO 2007099396 A2 20070907 WO 2006-IB3975 20060607 WO 2007099396 A3 20080313 EP 1919449 A2 20080514 EP 2006-847249 20060607 AU 2007355106 A1 20081218 AU 2007-355106 20071129 WO 2008152444 A2 20081218 WO 2007-IB4628 20071129 WO 2008152444 A3 20090618 EP 2097065 A2 20090909 EP 2007-874548 20071129 IL 198688 A 20121031 IL 2007-198688 20071129 IN 2007KN04925 A 20080704 IN 2007-KN4925 20071218 PRIORITY APPLN. INFO.: IL 2002-152486 A 20021025 US 2002-429546P P 20021129 US 2003-492385P P 20030804 US 2003-497648P P 20030825 WO 2003-IB5527 W 20031024 US 2003-530015P P 20031216 US 2004-835505 A2 20040428 US 2004-911367 A2 20040804 US 2004-922358 A2 20040820 US 2005-41921 A2 20050124 US 2005-688244P P 20050607 US 2005-532618 A2 20051222 US 2006-789186P P 20060404 US 2006-448490 A2 20060607 US 2006-861620P P 20061129

Page 78 of 158

Science IP Order: 3550000 Client Reference: 3456-789

US 2007-880434P P 20070112 CA 2004-2536482 A3 20040820 EP 2004-769356 A3 20040820 WO 2006-IB3975 W 20060607 WO 2007-IB4628 W 20071129 AB This invention relates to anti-infective foamable compn. and kits include a foamable carrier; a therapeutically safe and effective concn. of an anti- infective agent; an augmenting agent selected from the group consisting of a agent and a skin penetration enhancer; and a propellant. The compn. is housed in a container and upon release is expandable to form a breakable foam. The foamable carrier is selected to generate a foam of good or excellent quality in the presence of the augmenting agent and anti-infective agent. Methods for treating, alleviating or preventing a disorder of the skin, a body cavity or mucosal surface, wherein the disorder involves a fungal, bacterial, or viral infection as one of its etiol. factors, is described. Thus, foamable compn. was prepd. contg. PEG 400 91.65%, hydroxypropyl cellulose 0.475, steareth 2 1.88%, salicylic acid 5.0%, and ciclopiroxolamine 1.0%. INCL 424043000; 424725000; 514002000; 514220000; 514253090; 514263370; 514263400; 514027000; 514274000; 514307000 IPCI A61K0009-12 [I,A]; A61K0031-015 [I,A]; A61K0031-415 [I,A]; A61K0031-4164 [I,A]; A61K0031-425 [I,A]; A61K0031-433 [I,A]; A61K0031-44 [I,A]; A61K0031-497 [I,A]; A61P0011-00 [I,A]; A61P0035-00 [I,A]; A61P0031-18 [I,A]; A61P0031-12 [I,A]; A61P0031-10 [I,A]; A61P0027-16 [I,A]; A61P0017-00 [I,A]; A61K0031-505 [I,A]; A61K0031-52 [I,A]; A61K0031-522 [I,A]; A61K0031-551 [I,A]; A61K0031-70 [I,A]; A61K0036-00 [I,A]; A61K0038-00 [I,A] IPCR A61K0009-12 [I,A]; A61K0031-015 [I,A]; A61K0031-415 [I,A]; A61K0031-4164 [I,A]; A61K0031-425 [I,A]; A61K0031-433 [I,A]; A61K0031-44 [I,A]; A61K0031-497 [I,A]; A61K0031-505 [I,A]; A61K0031-52 [I,A]; A61K0031-522 [I,A]; A61K0031-551 [I,A]; A61K0031-70 [I,A]; A61K0036-00 [I,A]; A61K0038-00 [I,A]; A61P0011-00 [I,A]; A61P0017-00 [I,A]; A61P0027-16 [I,A]; A61P0031-10 [I,A]; A61P0031-12 [I,A]; A61P0031-18 [I,A]; A61P0035-00 [I,A] NCL 424/043.000; 424/725.000; 514/003.500; 514/003.700; 514/007.400; 514/009.400; 514/018.800; 514/027.000; 514/220.000; 514/253.090; 514/263.370; 514/263.400; 514/274.000; 514/307.000; 514/361.000; 514/365.000; 514/396.000; 514/406.000; 514/766.000 CC 63-6 (Pharmaceuticals) IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Melaleuca; anti-infection augmentation foamable compns. and kit and uses thereof) IT Dermatological agents (anti-acne agents; anti-infection augmentation foamable compns. and kit and uses thereof) IT Acne (vulgaris; anti-infection augmentation foamable compns. and kit and uses thereof) IT 50-21-5, Lactic acid, biological studies 50-70-4D, Sorbitol, ester 50-81-7, Ascorbic acid, biological studies 50-81-7D, Vitamin C, deriv. 51-17-2, 56-03-1, 56-81-5, Glycerol, biological studies 57-10-3, Hexadecanoic acid, biological studies 57-11-4, Stearic acid, biological studies 57-13-6, Urea, biological studies 57-50-1D, Sucrose, ester 57-55-6, Propylene glycol, biological studies 58-95-7, Tocopheryl acetate 61-57-4, 63-74-1, 67-68-5, Dimethyl sulfoxide, biological studies 68-12-2, Dimethylformamide, biological studies 68-26-8, Retinol 68-26-8D, Retinol, ascorbic acid derivs. 69-72-7, Salicylic acid, biological studies 76-30-2, Dihydroxytartaric acid 76-93-7, biological studies 77-92-9, Citric acid, biological studies 77-95-2, Quinic acid 79-09-4,

Page 79 of 158

Science IP Order: 3550000 Client Reference: 3456-789

Methylacetic acid, biological studies 79-14-1, Glycolic acid, biological studies 79-81-2, 80-08-0, 80-69-3, Tartronic acid 84-65-1, Anthraquinone 87-69-4, Tartaric acid, biological studies 87-73-0, Saccharic acid 90-64-2, Mandelic acid 94-36-0, Benzoyl peroxide, biological studies 103-82-2, Phenylacetic acid, biological studies 106-14-9, 12-Hydroxystearic acid 107-11-9, 107-21-1, Ethylene glycol, biological studies 107-41-5, Hexylene glycol 108-95-2, Phenol, biological studies 109-97-7, 110-15-6, , biological studies 110-27-0, Isopropyl myristate 110-91-8D, Morpholine, deriv. 110-94-1, 111-16-0, 111-20-6, , biological studies 111-46-6, Diethylene glycol, biological studies 112-53-8, Lauryl alcohol 112-72-1, Myristyl alcohol 112-85-6, Behenic acid 112-92-5, Stearyl alcohol 115-83-3, Pentaerythrityl tetrastearate 116-31-4, Retinal 120-62-7, Sulfoxide 122-32-7, Triolein 123-86-4, Butyl acetate 123-99-9, Azelaic acid, biological studies 124-04-9, Adipic acid, biological studies 124-07-2D, Caprylic acid, dialkylamino , biological studies 126-07-8D, Griseofulvin, deriv. 126-30-7D, Neopentyl glycol, dicaprylate/dicaprate derivs. 127-17-3, Pyruvic acid, biological studies 127-19-5, Dimethylacetamide 127-40-2, 127-47-9, Retinyl acetate 138-39-6, Mafenide 138-86-3, Limonene 141-78-6, Ethyl acetate, biological studies 141-82-2, , biological studies 142-91-6, Isopropyl palmitate 143-07-7, Lauric acid, biological studies 144-68-3D, , deriv. 147-73-9, Erythraric acid 148-79-8, Thiabendazole 288-13-1, Pyrazole 288-32-4, Imidazole, biological studies 288-42-6, Oxazole 288-47-1, 289-06-5, Thiadiazole 289-07-6, 1,2,3,4-Thiatriazole 289-95-2, Pyrimidine 302-79-4, Retinoic acid 320-77-4, Isocitric acid 432-70-2, α 443-48-1, Metronidazole 473-81-4, 502-65-8, 505-48-6, 505-52-2, 1,13-Tridecanedioic acid 506-30-9, Arachidic acid 506-48-9, Octacosanoic acid 515-30-0, Atrolactic acid 526-99-8, Galactaric acid 527-00-4, Allaric acid 551-92-8, Dimetridazole 552-63-6, Tropic acid 554-12-1 593-50-0, 1-Triacontanol 597-44-4, Citramalic acid 629-70-9, Cetyl acetate 629-96-9, Arachidyl alcohol 646-06-0, Dioxolane 661-19-8, Behenyl alcohol 666-99-9, Agaricic acid 685-73-4, Galacturonic acid 693-23-2, 1,12- 768-94-5, Amantadine 821-38-5D, 1,14-Tetradecanedioic acid, deriv. 1113-60-6, Hydroxypyruvic acid 1323-03-1, Myristyl lactate 1338-41-6, Sorbitan monostearate 1393-12-0, Rimocidin 1394-02-1D, Trichomycin, deriv. 1400-61-9, Nystatin 1403-17-4, 1403-61-8, Fradicin 1403-71-0, 1403-95-8, Mediocidin 1404-63-3, Sistomycosin 1406-16-2D, Vitamin D, deriv. 1406-18-4D, Vitamin E, deriv. 1490-04-6, Menthol 1852-04-6, Undecanedioic acid 2022-85-7, Flucytosine 2040-64-4, Dodecyl myristate 2398-96-1, Tolnaftate 3056-17-5, Stavudine 3079-30-9, Methyl dodecyl sulfoxide 3234-85-3, Myristyl myristate 3366-95-8, 3687-46-5, Decyl oleate 3689-76-7, 4353-06-4, 2-(n-Nonyl)-1,3-dioxolane 4759-48-2, Isotretinoin 5306-85-4, Dimethylisosorbide 5536-17-4, Vidarabine 5627-26-9, D-Gularic acid 5666-23-9, Altraric acid 5768-54-7, Idaric acid 6006-56-0, Triguanide 6506-37-2, Nimorazole 6543-97-1, Mannaric acid 6556-12-3, Glucuronic acid 6703-05-5, Lyxaric acid 6834-98-6, 6915-15-7, 6938-94-9, Diisopropyl adipate 7235-40-7, all-trans-β Carotene 7439-92-1, Lead, biological studies 7439-97-6, , biological studies 7440-22-4, Silver, biological studies 7440-31-5, Tin, biological studies 7440-43-9, Cadmium, biological studies 7440-47-3, Chromium, biological studies 7440-50-8, Copper, biological studies 7440-57-5, Gold, biological studies 7440-66-6, Zinc, biological studies 7440-69-9, Bismuth, biological studies 7481-89-2, Zalcitabine 7553-56-2, , biological studies

Page 80 of 158

Science IP Order: 3550000 Client Reference: 3456-789

7681-93-8, Natamycin 7722-84-1, , biological studies 8065-41-6, Aureofungin 9002-92-0, Laureth 4 9004-32-4, Sodium carboxymethyl cellulose 9004-64-2, Klucel EF 9004-65-3, Hydroxy propyl methyl cellulose 9004-67-5, Methyl cellulose 9004-95-9, Polyethylene glycol cetyl ether 9004-99-3, PEG-40 stearate 9005-00-9, Steareth 21 9005-65-6, Polysorbate 80 9005-67-8, Polysorbate 60 10158-64-2D, Xylaric acid, deriv. 10401-55-5, Cetyl ricinoleate 11006-22-7, Flavofungin 11014-70-3, Levorin 11016-07-2, Perimycin 11078-21-0, Filipin 11096-49-4, Partricin 11099-07-3, Glyceryl stearate 11103-57-4D, Vitamin A, deriv. 11121-32-7, 11138-66-2, Xanthan gum 12001-76-2D, Vitamin B, deriv. 12001-79-5D, Vitamin K, deriv. 12633-72-6, Amphotericin 12633-72-6D, Amphotericin, Me derivs. 12650-69-0, Mupirocin 12676-71-0, Niphimycin 12689-28-0, Proticin 13058-67-8, Lucensomycin 13182-89-3, Metronidazole benzoate 13312-52-2 13392-28-4, Rimantadine 13444-71-8, Periodic acid (HIO4) 14333-13-2, Permanganate 14380-61-1, Hypochlorite 14797-73-0, Perchlorate 15387-18-5, Fezatione 15454-31-6, Iodate 16260-26-7, Octyl myristate 16773-42-5, 16958-85-3, Octyl palmitate 17812-24-7, Ribonic acid 17941-34-3, Aleuritic acid 18323-44-9, Clindamycin 19045-66-0, Carbamothioic acid 19387-91-8, 20246-53-1, Gulonic acid 22832-87-7, Miconazole nitrate 22916-47-8, Miconazole 23593-75-1, Clotrimazole 25231-21-4, PPG 15 stearyl ether 25322-68-3, Polyethylene glycol 25322-68-3D, alkylyl ether 25496-72-4, Glyceryl oleate 25525-21-7, Glucaric acid 27220-47-9, Econazole 27523-40-6, Isoconazole 29342-05-0, Ciclopirox 30516-87-1, Zidovudine 31566-31-1, Glyceryl monostearate 33012-62-3, Ribaric acid 34513-50-3, Octyldodecanol 35274-05-6, Cetyl lactate 35554-44-0, Enilconazole 36574-66-0D, N-coco acyl derivs 36653-82-4, Cetyl alcohol 36791-04-5, Ribavirin 37217-63-3 37217-65-5, Candimycin 37306-44-8, 38083-17-9, 41621-49-2, Ciclopiroxolamine RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (anti-infection augmentation foamable compns. and kit and uses thereof)

Page 81 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 16 OF 199 HCAPLUS COPYRIGHT 2013 ACS on STN ACCESSION NUMBER: 2007:993533 HCAPLUS Full-text DOCUMENT NUMBER: 147:284514 TITLE: Tea tree oil and benzoyl peroxide for treatment of acne INVENTOR(S): Liegeois, Nanette PATENT ASSIGNEE(S): USA SOURCE: U.S. Pat. Appl. Publ., 9 pp. LANGUAGE: English PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE ------US 20070207115 A1 20070906 US 2006-307969 20060301 PRIORITY APPLN. INFO.: US 2006-307969 20060301 AB This invention relates to compn. consisting of tea tree oil used alone or in combination with conventional over-the-counter strength anti-acne agents. A system is created whereby Tea tree oil is used in combination with other anti- acne therapies, particularly benzoyl peroxide. Subsequent steps utilize conventional anti-acne treatments. INCL 424074000; 424769000; 514568000 IPCI A61K0008-97 [I,A]; A61K0031-192 [I,A]; A61K0036-61 [I,A] IPCR A61K0008-97 [I,A]; A61K0031-192 [I,A]; A61K0036-61 [I,A] NCL 424/074.000; 424/769.000; 514/568.000 CC 62-4 (Essential Oils and Cosmetics) Section cross-reference(s): 63 ST tea tree oil benzoyl peroxide acne IT Essential oils RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Melaleuca; tea tree oil and benzoyl peroxide for treatment of acne) IT Acne Cosmetics and Personal care products (tea tree oil and benzoyl peroxide for treatment of acne) IT 69-72-7, Salicylic acid, biological studies 94-36-0, Benzoyl peroxide, biological studies 302-79-4, Tretinoin RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (tea tree oil and benzoyl peroxide for treatment of acne)

Page 82 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 17 OF 199 HCAPLUS COPYRIGHT 2013 ACS on STN ACCESSION NUMBER: 2006:759629 HCAPLUS Full-text DOCUMENT NUMBER: 145:195180 TITLE: Cosmetic composition comprising hydrophobic and hydrophilic silica particles INVENTOR(S): Ingman, Dov PATENT ASSIGNEE(S): Or-Le-Or Ltd., Israel SOURCE: Eur. Pat. Appl., 30 pp. LANGUAGE: English PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE ------EP 1685824 A1 20060802 EP 2006-100458 20060117 CA 2534306 A1 20060730 CA 2006-2534306 20060130 US 20060257437 A1 20061116 US 2006-341872 20060130 PRIORITY APPLN. INFO.: IL 2005-166646 A 20050130 AB The present invention relates to a new topical cosmetic compn. formulated for concealing wrinkles and for eliminating or reducing damages to the skin appearance resulted from a wide variety of disorders, such as for example, acne. The compn. comprises water, optionally contg. 25 to 400 ppm of Ag, hydrophobic particles, preferably hydrophobic silica, having a diam., ranged from about 5 to about 150 nm, and/or hydrophilic particles, preferably hydrophilic silica, having a diam., ranged from about 5 to about 150 nm and a sol. electrolyte, capable of releasing free in an aq. environment. Thus, a hypotonic compn. for treating acne comprised Dead Sea salt 0.2, zinc sulfate 1, hydrophobic silica 5, hydrophilic silica 5, tea tree oil 2, sea buckthorn oil 3, vitamin A 0.1, vitamin C 1.5, vitamin E acetate 0.1, methylparaben 0.1, propylene glycol 2, and water 80%, resp. A compn. comprising water, optionally contg. Ag 25 to 400 ppm, 10 wt.% Aerosil 380, 2.5 wt.% Aerosil R812, 1 to 20 wt.% Dead Sea salt, and optionally one or more conventional skincare and/or anti-acne agent, selected from evening primrose oil, sweet almond oil, sea buckthorn oil, tea tree oil, Finsolv TN, (C12-15 alkyl benzoate), octyl hydroxystearate, salicylic acid, vitamin C, citric acid, azelaic acid, benzoyl peroxide, zinc acetate and sulfur. The compn. was highly effective in treating acne. The concn. of the salt in such compn. was detd. according to the treated skin type (dried, oily, etc.) and the particular acne type, grade and state of the treated individual. Compns. contg. higher concns. of salt (10 to 20 wt.%) are preferred for treating an oily skin and an intensive acne state. IPCI A61K0008-25 [I,A]; A61K0008-19 [I,A]; A61Q0019-06 [I,A]; A61Q0019-08 [I,A] IPCR A61K0008-25 [I,A]; A61K0008-19 [I,A]; A61Q0019-06 [I,A]; A61Q0019-08 [I,A] CC 62-4 (Essential Oils and Cosmetics) Section cross-reference(s): 63 IT Essential oils RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses) (Melaleuca; cosmetic compn. contg. silica particles, electrolytes and optionally silver for concealing wrinkles and treating and/or improving skin disorders and hair loss) IT Acne Alopecia Cosmetics Eczema Electrolytes, biological Encapsulation Mycosis Particle size Particles Psoriasis Seborrhea Skin preparations (pharmaceutical)

Page 83 of 158

Science IP Order: 3550000 Client Reference: 3456-789

Wart (cosmetic compn. contg. silica particles, electrolytes and optionally silver for concealing wrinkles and treating and/or improving skin disorders and hair loss) IT 50-81-7, Ascorbic acid, biological studies 58-95-7, Vitamin E acetate 65-85-0D, Benzoic acid, C12-15 alkyl esters 69-72-7, Salicylic acid, biological studies 69-93-2, Uric acid, biological studies 77-92-9, Citric acid, biological studies 79-81-2, Retinyl palmitate 94-36-0, Benzoyl peroxide, biological studies 123-99-9, Azelaic acid, biological studies 471-34-1, Calcium carbonate, biological studies 501-30-4, Kojic acid 557-34-6, Zinc acetate 1309-37-1, Ferric oxide, biological studies 1344-28-1, Alumina, biological studies 1344-43-0, Manganous oxide, biological studies 7440-22-4, Silver, biological studies 7704-34-9, Sulfur, biological studies 7705-08-0, Ferric chloride, biological studies 7733-02-0, Zinc sulfate 7758-98-7, Copper sulfate, biological studies 7778-18-9, Calcium sulfate 13463-67-7, Titania, biological studies 38304-91-5, Minoxidil 39236-46-9, Imidazolidinyl urea 74565-11-0, Finsolv TN 112153-71-6, Aerosil R 812 148718-35-8, Octyl hydroxystearate 200135-89-3, Dead Sea salt RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses) (cosmetic compn. contg. silica particles, electrolytes and optionally silver for concealing wrinkles and treating and/or improving skin disorders and hair loss)

Page 84 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 18 OF 199 HCAPLUS COPYRIGHT 2013 ACS on STN ACCESSION NUMBER: 2004:999524 HCAPLUS Full-text DOCUMENT NUMBER: 141:416040 TITLE: Topical treatment of skin conditions INVENTOR(S): Khaiat, Alain V.; Gomes, Anna; Bhide, Vaishali PATENT ASSIGNEE(S): Singapore SOURCE: U.S. Pat. Appl. Publ., 18 pp. LANGUAGE: English PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE ------US 20040228822 A1 20041118 US 2003-439735 20030516 US 20040228885 A1 20041118 US 2003-663238 20030916 US 20050031571 A1 20050210 US 2004-844809 20040513 AU 2004240615 A1 20041202 AU 2004-240615 20040514 CA 2524868 A1 20041202 CA 2004-2524868 20040514 WO 2004103321 A2 20041202 WO 2004-US15053 20040514 WO 2004103321 A3 20050224 WO 2004103353 A2 20041202 WO 2004-US15054 20040514 WO 2004103353 A3 20050224 EP 1626779 A2 20060222 EP 2004-752156 20040514 BR 2004010358 A 20060530 BR 2004-10358 20040514 CN 1787806 A 20060614 CN 2004-80013144 20040514 JP 2007502326 T 20070208 JP 2006-533040 20040514 MX 2005012381 A 20060525 MX 2005-12381 20051116 US 20060228321 A1 20061012 US 2006-451163 20060612 US 7252831 B2 20070807 PRIORITY APPLN. INFO.: US 2003-439735 A2 20030516 US 2003-663238 A2 20030916 US 2004-844809 A1 20040513 WO 2004-US15054 W 20040514 AB This invention relates to improved compns. and methods for treating skin conditions contg. sebum redn. agents; keratolytic agents and anti-inflammatory agents that results in unexpectedly superior control of skin conditions such as acne. INCL 424070140 IPCI A61K0007-06 [ICM,7]; A61K0007-11 [ICS,7] IPCR A61K0008-368 [I,A]; A61K0008-42 [I,A]; A61K0008-44 [I,A]; A61K0008-63 [I,A]; A61K0008-64 [I,A]; A61K0008-67 [I,A]; A61K0008-97 [I,A]; A61Q0007-00 [I,A]; A61Q0009-00 [I,A]; A61Q0019-00 [I,A] NCL 424/070.140 CC 63-6 (Pharmaceuticals) Section cross-reference(s): 1, 62 ST bacterial lipase inhibitor antiinflammatory acne sebum skin prepn IT Essential oils RL: COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Melaleuca; topical treatment of skin conditions) IT Acne Anti-inflammatory agents Antibacterial agents Sebum Skin preparations (pharmaceutical) (topical treatment of skin conditions) IT 56-40-6, Glycine, biological studies 58-95-7, Tocopheryl acetate 69-72-7, Salicylic acid, biological studies 94-36-0, Benzoyl peroxide, biological studies 97-59-6, Allantoin 108-46-3, Resorcinol, biological studies 114-07-8, Erythromycin 515-69-5, α-Bisabolol 7488-56-4,

Page 85 of 158

Science IP Order: 3550000 Client Reference: 3456-789

9081-34-9, 5-Alpha-reductase 18323-44-9, Clindamycin 68797-35-3, Dipotassium glycyrrhizinate RL: COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (topical treatment of skin conditions)

Page 86 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 19 OF 199 HCAPLUS COPYRIGHT 2013 ACS on STN ACCESSION NUMBER: 2001:525887 HCAPLUS Full-text DOCUMENT NUMBER: 135:127191 TITLE: Pharmaceutical and cosmetic carrier or composition for topical application containing a fatty acid, a fatty alcohol and an oil INVENTOR(S): Eini, Meir; Tamarkin, Dov PATENT ASSIGNEE(S): Thixo Ltd., Israel SOURCE: PCT Int. Appl., 76 pp. LANGUAGE: English PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE ------WO 2001051014 A1 20010719 WO 2001-IL25 20010110 US 6348229 B1 20020219 US 2000-526509 20000316 US 6967023 B1 20051122 US 2000-653267 20000831 CA 2397068 A1 20010719 CA 2001-2397068 20010110 AU 2001023937 A 20010724 AU 2001-23937 20010110 AU 782515 B2 20050804 EP 1250116 A1 20021023 EP 2001-900239 20010110 JP 2003528821 T 20030930 JP 2001-551438 20010110 NZ 520014 A 20050527 NZ 2001-520014 20010110 IN 2002CN01082 A 20070921 IN 2002-CN1082 20020710 IN 2002CN01062 A 20071012 IN 2002-CN1062 20020710 IN 221380 A1 20080912 US 20040253275 A1 20041216 US 2002-169897 20021231 US 6911211 B2 20050628 US 20030157138 A1 20030821 US 2003-392071 20030319 US 6994863 B2 20060207 US 20060088561 A1 20060427 US 2005-294318 20051205 US 7682623 B2 20100323 US 20100137198 A1 20100603 US 2010-705219 20100212 PRIORITY APPLN. INFO.: IL 2000-133968 A 20000110 IL 2000-133969 A 20000110 US 2000-526509 A 20000316 IL 2000-137051 A 20000627 IL 2000-137052 A 20000627 US 2000-216162P P 20000703 US 2000-653267 A 20000831 WO 2001-IL25 W 20010110 US 2003-392071 A1 20030319 US 2005-294318 A1 20051205 AB A pharmaceutical or cosmetic carrier or compn. for topical application, characterized by rheol. properties which render the carrier or compn. semi-solid at rest and a liq. upon application of shear forces, is described. The compn. or carrier are prepd. by mixing (by wt.) 1-25% of a solidifying agent, such as a long-chain fatty alc. and a fatty acid, and 75-99% of a hydrophobic solvent, such as an animal, mineral, silicone, or plant-derived oil, wherein at least one of them has therapeutic or cosmetic benefits, in the presence or absence of a biol. active substance. For example, behenic acid (10 g) was heated to 80° and mixed with light paraffin oil (90 g) preheated to the same temp. Then glycerin (10 g), tristearin (10 g), and an antioxidant mixt. (1 g) were added by agitation. Bifunazole (1.2 g) and valerate (0.12 g) were added and the mixt. was poured into containers (5 g tubes) and was allowed to cool spontaneously. While the mixt. cooled to ambient temp. it gradually turned into a semisolid, i.e., an ointment contg. the agent. IPCI A61K0007-00 [ICM,7]; A61K0009-00 [ICS,7]; A61K0009-06 [ICS,7]; A61K0009-08 [ICS,7]; A61K0009-10 [ICS,7]; A61K0009-70 [ICS,7]; A61K0047-00 [ICS,7]; A61K0047-02 [ICS,7]; A61K0047-10 [ICS,7]

Page 87 of 158

Science IP Order: 3550000 Client Reference: 3456-789

IPCR A21D0002-14 [I,A]; A21D0002-16 [I,A]; A21D0013-08 [I,A]; A23C0009-13 [I,A]; A23C0011-04 [I,A]; A23C0013-12 [I,A]; A23C0015-16 [I,A]; A23C0019-055 [I,A]; A23C0019-093 [I,A]; A23D0007-00 [I,A]; A23D0007-005 [I,A]; A23D0007-01 [I,A]; A23D0009-007 [I,A]; A23D0009-02 [I,A]; A23G0001-00 [I,A]; A23G0001-30 [I,A]; A23G0001-36 [I,A]; A23G0001-38 [I,A]; A23G0003-34 [I,A]; A23G0009-32 [I,A]; A23G0009-44 [I,A]; A23G0009-52 [I,A]; A23J0003-22 [I,A]; A23L0001-00 [I,A]; A23L0001-16 [I,A]; A23L0001-164 [I,A]; A23L0001-18 [I,A]; A23L0001-19 [I,A]; A23L0001-217 [I,A]; A23L0001-30 [I,A]; A23L0001-314 [I,A]; A23L0001-40 [I,A]; A61K [I,S]; A61K0008-00 [I,A]; A61K0008-02 [I,A]; A61K0008-06 [I,A]; A61K0008-18 [I,A]; A61K0008-34 [I,A]; A61K0008-36 [I,A]; A61K0008-365 [I,A]; A61K0008-92 [I,A]; A61K0008-97 [I,A]; A61K0008-98 [I,A]; A61K0009-00 [I,A]; A61K0009-06 [I,A]; A61K0031-07 [I,A]; A61K0031-197 [I,A]; A61K0031-225 [I,A]; A61K0031-351 [I,A]; A61K0031-355 [I,A]; A61K0031-357 [I,A]; A61K0031-4188 [I,A]; A61K0031-43 [I,A]; A61K0031-4415 [I,A]; A61K0031-455 [I,A]; A61K0031-496 [I,A]; A61K0031-51 [I,A]; A61K0031-525 [I,A]; A61K0031-545 [I,A]; A61K0031-57 [I,A]; A61K0031-59 [I,A]; A61K0031-65 [I,A]; A61K0031-714 [I,A]; A61K0033-04 [I,A]; A61K0033-06 [I,A]; A61K0033-14 [I,A]; A61K0033-18 [I,A]; A61K0033-24 [I,A]; A61K0033-26 [I,A]; A61K0033-30 [I,A]; A61K0033-32 [I,A]; A61K0033-34 [I,A]; A61K0035-60 [I,A]; A61K0036-00 [I,A]; A61K0036-738 [I,A]; A61K0036-899 [I,A]; A61K0045-00 [I,A]; A61K0045-06 [I,A]; A61K0047-06 [I,A]; A61K0047-10 [I,A]; A61K0047-12 [I,A]; A61K0047-14 [N,A]; A61K0047-44 [I,A]; A61P0001-10 [I,A]; A61P0001-14 [I,A]; A61P0003-02 [I,A]; A61P0003-06 [I,A]; A61P0003-10 [I,A]; A61P0007-02 [I,A]; A61P0007-04 [I,A]; A61P0009-10 [I,A]; A61P0009-12 [I,A]; A61P0013-12 [I,A]; A61P0017-00 [I,A]; A61P0017-02 [I,A]; A61P0017-04 [I,A]; A61P0017-06 [I,A]; A61P0017-08 [I,A]; A61P0017-10 [I,A]; A61P0029-00 [I,A]; A61P0031-04 [I,A]; A61P0035-00 [I,A]; A61P0037-02 [I,A]; A61Q0019-00 [I,A] CC 63-6 (Pharmaceuticals) Section cross-reference(s): 1, 2, 62 IT Essential oils RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Melaleuca; topical compns. contg. fatty acid, fatty alc. and oil for pharmaceutical and cosmetic uses) IT Acne Antibacterial agents Antibiotics Antihistamines Antiulcer agents Antiviral agents Autoimmune disease Cosmetics Eczema Erythema Fungicides Immunosuppressants Mucous membrane Psoriasis Seborrhea Skin preparations (pharmaceutical) Wound healing promoters (topical compns. contg. fatty acid, fatty alc. and oil for pharmaceutical and cosmetic uses) IT 50-23-7, Hydrocortisone 56-75-7, 60-54-8, Tetracycline 67-73-2, Fluocinolone acetonide 76-25-5, Triamcinolone acetonide 94-36-0, Benzoyl peroxide, biological studies 98-92-0, vitamin B3 106-14-9, 12-Hydroxystearic acid 114-07-8,

Page 88 of 158

Science IP Order: 3550000 Client Reference: 3456-789

Erythromycin 118-74-1, Hexachlorobenzene 120-51-4, Benzyl benzoate 121-75-5, Malathion 126-07-8, Griseofulvin 302-79-4, Tretinoin 483-63-6, Crotamiton 768-94-5, Amantadine 1229-29-4, Doxepine hydrochloride 1397-89-3, Amphotericin B 1406-05-9, Penicillin 2022-85-7, Flucytosine 2152-44-5, Betamethasone valerate 3056-17-5, Stavudine 3093-35-4, Halcinonide 4759-48-2, Isotretinoin 5536-17-4, Vidarabine 5593-20-4, Betamethasone dipropionate 7681-11-0, , biological studies 12650-69-0, Mupirocin 13392-28-4, Rimantadine 18323-44-9, Clindamycin 22916-47-8, Miconazole 23593-75-1, Clotrimazole 25122-46-7, Clobetasol propionate 29342-05-0, Ciclopirox 30516-87-1, Zidovudine 36791-04-5, Ribavirin 57524-89-7, Hydrocortisone valerate 59198-70-8, Diflucortolone valerate 59277-89-3, Acyclovir 60628-96-8, Bifonazole 65277-42-1, Ketoconazole 66852-54-8, Halobetasol propionate 78613-35-1, Amorolfine 79217-60-0, Cyclosporin 82410-32-0, Gancyclovir 84625-61-6, Itraconazole 86386-73-4, Fluconazole 91161-71-6, Terbinafine 106685-40-9, Adapalene 108436-80-2, Rociclovir 127779-20-8, Saquinavir 129618-40-2, 134678-17-4, Lamivudine 136817-59-9, Delavirdine 150378-17-9, 155213-67-5, 159989-64-7, Nelfinavir RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (topical compns. contg. fatty acid, fatty alc. and oil for pharmaceutical and cosmetic uses)

Page 89 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 20 OF 199 HCAPLUS COPYRIGHT 2013 ACS on STN ACCESSION NUMBER: 2000:768952 HCAPLUS Full-text DOCUMENT NUMBER: 133:339965 TITLE: Formulations and methods for reducing skin irritation INVENTOR(S): Hahn, Gary S.; Thueson, David O. PATENT ASSIGNEE(S): Cosmederm Technologies, USA SOURCE: U.S., 30 pp., Cont.-in-part of U.S. 5,716,625. LANGUAGE: English PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE ------US 6139850 A 20001031 US 1997-860993 19970623 US 5716625 A 19980210 US 1994-362100 19941221 WO 9619184 A1 19960627 WO 1995-US16985 19951221 EP 1136065 A1 20010926 EP 2001-115074 19951221 EP 1136065 B1 20041124 US 20030124202 A1 20030703 US 2002-189344 20020703 PRIORITY APPLN. INFO.: US 1994-362100 A2 19941221 WO 1995-US16985 W 19951221 EP 1995-944548 A3 19951221 US 1997-860993 A2 19970623 US 2000-685992 B1 20001010 US 2001-33194 A1 20011024 AB Compns. and methods are provided for inhibiting skin irritation attributable to chem. irritants or environmental conditions, by the application of an anti- irritant amt. of water-sol. strontium cation. The compns. can be antiperspirants, deodorants, sunscreens, insect repellents, depilatories, hair dyes, hair bleaches, , ointments, suppositories, etc. Glycolic acid (6 % in 10 % ethanol-in-water) was used as a skin irritant. Strontium nitrate was coadministered as an anti-irritant to subject panels and was shown to inhibit cumulative irritation by 64-84 % at concns. ranging from 250 nM to 500 nM. INCL 424401000 IPCI A61K0007-48 [ICM,7] IPCR A61K0047-02 [I,A]; A61K0008-00 [I,A]; A61K0008-04 [I,A]; A61K0008-19 [I,A]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-23 [I,A]; A61K0008-24 [I,A]; A61K0008-29 [I,A]; A61K0008-30 [I,A]; A61K0008-33 [I,A]; A61K0008-34 [I,A]; A61K0008-36 [I,A]; A61K0008-362 [I,A]; A61K0008-365 [I,A]; A61K0008-368 [I,A]; A61K0008-37 [I,A]; A61K0008-38 [I,A]; A61K0008-40 [I,A]; A61K0008-42 [I,A]; A61K0008-44 [I,A]; A61K0008-46 [I,A]; A61K0008-49 [I,A]; A61K0008-60 [I,A]; A61K0008-64 [I,A]; A61K0008-92 [I,A]; A61K0008-97 [I,A]; A61K0031-28 [I,A]; A61K0033-24 [I,A]; A61K0036-81 [I,A]; A61K0036-82 [I,A]; A61K0036-886 [I,A]; A61Q0001-02 [I,A]; A61Q0001-06 [I,A]; A61Q0005-00 [I,A]; A61Q0005-02 [I,A]; A61Q0005-04 [I,A]; A61Q0005-08 [I,A]; A61Q0005-10 [I,A]; A61Q0005-12 [I,A]; A61Q0007-00 [I,A]; A61Q0009-02 [I,A]; A61Q0011-00 [I,A]; A61Q0015-00 [I,A]; A61Q0017-00 [I,A]; A61Q0017-04 [I,A]; A61Q0019-00 [I,A]; A61Q0019-10 [I,A]; G02F0001-13357 [I,A] NCL 424/401.000; 424/722.000; 424/760.000; 514/847.000; 514/848.000; 514/859.000; 514/881.000; 514/887.000 CC 62-4 (Essential Oils and Cosmetics) Section cross-reference(s): 63 IT Essential oils RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Melaleuca; strontium compds. for reducing skin irritation due to ingredients in compns.) IT Acne (inhibitors; strontium compds. for reducing skin irritation due to

Page 90 of 158

Science IP Order: 3550000 Client Reference: 3456-789

ingredients in compns.) IT 50-21-5, Lactic acid, biological studies 57-13-6, Urea, biological studies 58-08-2, Caffeine, biological studies 64-19-7, Acetic acid, biological studies 68-26-8, Retinol 69-72-7, biological studies 76-03-9, Trichloroacetic acid, biological studies 76-93-7, biological studies 77-92-9, biological studies 79-14-1, biological studies 87-69-4, biological studies 90-64-2, Mandelic acid 90-80-2 94-36-0, Benzoyl peroxide, biological studies 97-59-6, Allantoin 98-79-3 108-95-2, Phenol, biological studies 116-31-4, Retinal 127-17-3, Pyruvic acid, biological studies 144-62-7, Ethanedioic acid, biological studies 302-79-4, Tretinoin 404-86-4, . 515-69-5, α-Bisabolol 526-95-4, D-Gluconic acid 617-73-2, α-Hydroxy octanoic acid 1405-86-3, Glycyrrhizic acid 5393-81-7, α-Hydroxy decanoic acid 6915-15-7 70424-62-3 126094-21-1 RL: ADV (Adverse effect, including toxicity); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses) (strontium compds. for reducing skin irritation due to ingredients in compns.)

Page 91 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 21 OF 199 HCAPLUS COPYRIGHT 2013 ACS on STN ACCESSION NUMBER: 1999:100781 HCAPLUS Full-text DOCUMENT NUMBER: 130:144205 TITLE: Skin-treatment compositions containing natural products INVENTOR(S): Oliver, Benjamin PATENT ASSIGNEE(S): USA SOURCE: U.S., 4 pp. LANGUAGE: English PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE ------US 5869062 A 19990209 US 1997-863733 19970527 PRIORITY APPLN. INFO.: US 1997-863733 19970527 AB An improved skin treatment compn. is provided. The compn. comprises calamine 8- 20%, an antioxidant 0.05-3%, an herbal antibacterial substance 0.25-4%, and a base 25-60%. These ingredients are combined with a base, preferably comprised of water and glycerin, to prep. the inventive compn. A topical compn. for the treatment of acne contained water 25.25, glycerin 20, calamine 18, ZnO 18, witch hazel 5, ascorbic acid 0.88, peroxide (3% strength) 5, golden seal 2, ethanol 5, tea tree oil 0.7, and vitamin E 0.16%. INCL 424195100 IPCI A61K0035-78 [ICM,6]; A61K0039-385 [ICS,6]; A61K0033-32 [ICS,6] IPCR A61K0033-32 [I,C*]; A61K0033-32 [I,A]; A61K0036-185 [I,C*]; A61K0036-185 [I,A]; A61K0036-28 [I,A]; A61K0036-48 [I,A]; A61K0036-61 [I,A]; A61K0036-71 [I,A]; A61K0036-80 [I,A]; A61K0036-88 [I,C*]; A61K0036-8962 [I,A]; A61K0039-385 [I,C*]; A61K0039-385 [I,A] NCL 424/726.000; 424/616.000; 424/641.000; 424/737.000; 514/458.000; 514/474.000; 514/557.000; 514/714.000; 514/725.000; 514/859.000 CC 63-6 (Pharmaceuticals) ST topical calamine antioxidant herbal antibacterial acne IT Essential oils RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Melaleuca; anti-acne compns. contg. calamine and antioxidants and antibacterials) IT Acne Aloe barbadensis Clover (Trifolium pratense) Echinacea Garlic (Allium sativum) Golden seal (Hydrastis) Tabebuia Witch hazel (anti-acne compns. contg. calamine and antioxidants and antibacterials) IT RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (anti-acne compns. contg. calamine and antioxidants and antibacterials) IT Carboxylic acids RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (hydroxy; anti-acne compns. contg. calamine and antioxidants and antibacterials) IT Drug delivery systems (topical; anti-acne compns. contg. calamine and antioxidants and antibacterials) IT 50-81-7, Ascorbic acid, biological studies 56-81-5, Glycerin, biological studies 57-55-6, Propylene glycol, biological studies 64-17-5, Ethyl alcohol, biological studies 67-63-0, Isopropyl alcohol, biological

Page 92 of 158

Science IP Order: 3550000 Client Reference: 3456-789

studies 94-17-7, p-Chlorobenzoyl peroxide 94-36-0, Benzoyl peroxide, biological studies 110-05-4, tert-Butyl peroxide 110-22-5, Acetyl peroxide 1314-13-2, Zinc oxide, biological studies 1338-23-4, Methyl ethyl peroxide. 1406-18-4, Vitamin E 7235-40-7, β-Carotene 7722-84-1, Hydrogen peroxide, biological studies 8011-96-9, Calamine RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (anti-acne compns. contg. calamine and antioxidants and antibacterials)

Page 93 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 22 OF 199 HCAPLUS COPYRIGHT 2013 ACS on STN ACCESSION NUMBER: 1997:321918 HCAPLUS Full-text DOCUMENT NUMBER: 127:23503 ORIGINAL REFERENCE NO.: 127:4501a TITLE: Cosmetic and pharmaceutical delivery vehicles comprising a volatile cyclosiloxane, a particulate carbohydrate and an oil or a glyceride ester INVENTOR(S): Berndt, Dieter PATENT ASSIGNEE(S): Safe & Dry Co., Inc., USA SOURCE: U.S., 11 pp. LANGUAGE: English PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE ------US 5626856 A 19970506 US 1995-497454 19950630 PRIORITY APPLN. INFO.: US 1995-497454 19950630 AB A novel delivery system for cosmetic and topical pharmaceutical products contains a volatile cyclosiloxane, a particulate carbohydrate and an oil or a glyceride ester. The carbohydrate and oil or glyceride ester are included in wt. ratios which will produce a translucent film after the evapn. of the volatile cyclosiloxane from the compn. In addn., a no. of other components may also be added to the delivery system including bioactive agents such as antiperspirant salts and antifungal agents, film-formers, surfactants, emollients, fragrances, coloring agents, preservatives, medicinal agents and related components depending upon the desired characteristics and the purpose for which the system and final product is designed. An antiperspirant compn. contained cyclomethicone 45, starch 10, white petrolatum 15, iso-Pr palmitate 5, zirconium aluminum chlorhydrex 25, and fragrance q.s. 100%. INCL 424401000 IPCI A61K0009-48 [ICM,6] IPCR A61K0008-31 [I,A]; A61K0008-37 [I,A]; A61K0008-58 [I,A]; A61K0008-73 [I,A]; A61K0009-70 [I,A]; A61K0047-00 [I,A]; A61K0047-06 [N,A]; A61K0047-24 [N,A]; A61K0047-36 [N,A]; A61Q0001-12 [I,A]; A61Q0015-00 [I,A]; A61Q0017-04 [I,A]; A61Q0019-00 [I,A] NCL 424/401.000; 424/059.000; 424/065.000; 424/066.000; 424/068.000; 424/069.000; 514/844.000; 514/846.000 CC 62-4 (Essential Oils and Cosmetics) Section cross-reference(s): 63 IT Essential oils RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Melaleuca; cosmetic and pharmaceutical delivery vehicles comprising volatile cyclosiloxane, particulate carbohydrate and oil or glyceride ester) IT Acne Pruritus (inhibitors; cosmetic and pharmaceutical delivery vehicles comprising volatile cyclosiloxane, particulate carbohydrate and oil or glyceride ester) IT 58-95-7, Tocopheryl acetate 60-33-3, 9,12-Octadecadienoic acid (Z,Z)-, biological studies 76-22-2, Camphor 89-78-1, Menthol 94-36-0 , Benzoyl peroxide, biological studies 112-80-1, Oleic acid, biological studies 404-86-4, Capsaicin 463-40-1 540-97-6, Dodecamethylcyclohexasiloxane 541-02-6 556-67-2 1314-13-2, Zinc oxide, biological studies 1327-41-9D, Aluminum chlorhydroxide, salts 1406-16-2, Vitamin d 1406-18-4, Vitamin e 7704-34-9, Sulfur, biological studies 9004-34-6, Cellulose, biological studies 9004-34-6D, Cellulose, ethers, biological studies 9004-53-9, Dextrin 9005-25-8, Starch, biological studies 9005-79-2, Glycogen, biological

Page 94 of 158

Science IP Order: 3550000 Client Reference: 3456-789

studies 9005-82-7, Amylose 9037-22-3, Amylopectin 11103-57-4, Vitamin a 18428-88-1, Zirconyl hydroxychloride 134910-86-4, Aluminum zirconium tetrachlorhydrex glycine RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (cosmetic and pharmaceutical delivery vehicles comprising volatile cyclosiloxane, particulate carbohydrate and oil or glyceride ester)

Page 95 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 23 OF 199 HCAPLUS COPYRIGHT 2013 ACS on STN ACCESSION NUMBER: 1996:494349 HCAPLUS Full-text DOCUMENT NUMBER: 125:150779 ORIGINAL REFERENCE NO.: 125:28063a,28066a TITLE: Anti-irritant skin formulations containing aluminum or tin cations INVENTOR(S): Hahn, Gary Scott; Thueson, David Orel PATENT ASSIGNEE(S): Cosmederm Technologies, USA SOURCE: PCT Int. Appl., 49 pp. LANGUAGE: English PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE ------WO 9619183 A1 19960627 WO 1995-US16765 19951221 CA 2208078 A1 19960627 CA 1995-2208078 19951221 CA 2208078 C 20090623 AU 9645285 A 19960710 AU 1996-45285 19951221 EP 801554 A1 19971022 EP 1995-943956 19951221 EP 801554 B1 20030416 BR 9510478 A 19981215 BR 1995-10478 19951221 JP 11502504 T 19990302 JP 1996-520010 19951221 AT 237298 T 20030515 AT 1995-943956 19951221 PT 801554 E 20030829 PT 1995-943956 19951221 ES 2192586 T3 20031016 ES 1995-943956 19951221 US 6455076 B1 20020924 US 1997-860206 19970623 JP 2005314437 A 20051110 JP 2005-217695 20050727 PRIORITY APPLN. INFO.: US 1994-362058 A 19941221 JP 1996-520010 A3 19951221 WO 1995-US16765 W 19951221 AB Cosmetic and pharmaceutical compns. for inhibiting skin irritation attributable to chem. irritants or environment conditions, contain an anti-irritant amt. of aq.-sol. trivalent aluminum cation or divalent tin cation. A soln. of 250 mM stannous chloride decreased the skin irritation caused by application of 7.5% lactic acid in 10% ethanol by 50%. IPCI A61K0007-00 [ICM,6] IPCR A61K0008-00 [I,A]; A61K0008-04 [I,A]; A61K0008-19 [I,A]; A61K0008-20 [I,A]; A61K0008-21 [I,A]; A61K0008-22 [I,A]; A61K0008-23 [I,A]; A61K0008-24 [I,A]; A61K0008-26 [I,A]; A61K0008-29 [I,A]; A61K0008-30 [I,A]; A61K0008-33 [I,A]; A61K0008-34 [I,A]; A61K0008-36 [I,A]; A61K0008-362 [I,A]; A61K0008-365 [I,A]; A61K0008-368 [I,A]; A61K0008-37 [I,A]; A61K0008-38 [I,A]; A61K0008-40 [I,A]; A61K0008-42 [I,A]; A61K0008-44 [I,A]; A61K0008-46 [I,A]; A61K0008-49 [I,A]; A61K0008-60 [I,A]; A61K0008-64 [I,A]; A61K0008-92 [I,A]; A61K0008-97 [I,A]; A61K0009-00 [I,A]; A61K0031-00 [I,A]; A61K0033-06 [I,A]; A61K0033-24 [I,A]; A61K0045-06 [I,A]; A61K0047-02 [I,A]; A61P0001-00 [I,A]; A61P0011-00 [I,A]; A61P0013-02 [I,A]; A61P0015-00 [I,A]; A61P0017-00 [I,A]; A61Q0005-00 [I,A]; A61Q0005-02 [I,A]; A61Q0005-04 [I,A]; A61Q0005-08 [I,A]; A61Q0005-10 [I,A]; A61Q0007-00 [I,A]; A61Q0009-00 [I,A]; A61Q0011-00 [I,A]; A61Q0015-00 [I,A]; A61Q0017-00 [I,A]; A61Q0017-04 [I,A]; A61Q0019-00 [I,A]; C11D0007-04 [I,A]; C11D0007-26 [I,A] CC 62-4 (Essential Oils and Cosmetics) Section cross-reference(s): 63 IT Acne (inhibitors; anti-irritant skin formulations contg. aluminum or tin cations) IT Essential oils RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Melaleuca, ext.; anti-irritant skin formulations contg.

Page 96 of 158

Science IP Order: 3550000 Client Reference: 3456-789

aluminum or tin cations) IT 50-21-5, Lactic acid, biological studies 50-21-5D, Lactic acid, salts 64-19-7, Acetic acid, biological studies 68-26-8, Retinol 69-72-7, biological studies 69-72-7D, salts 76-03-9, Trichloroacetic acid, biological studies 76-93-7, biological studies 77-92-9, biological studies 77-92-9D, salts 79-14-1, biological studies 79-14-1D, salts 87-69-4, biological studies 90-64-2, Mandelic acid 90-80-2, Gluconolactone 94-36-0, Benzoyl peroxide, biological studies 98-79-3 108-95-2, Phenol, biological studies 116-31-4, Retinal 127-17-3, Pyruvic acid, biological studies 144-62-7, Ethanedioic acid, biological studies 302-79-4, Tretinoin 404-86-4, Capsaicin 526-95-4, Gluconic acid 5393-81-7, α-Hydroxy decanoic acid 6915-15-7, Malic acid 70424-62-3 126094-21-1 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study) (anti-irritant skin formulations contg. aluminum or tin cations)

Page 97 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 24 OF 199 HCAPLUS COPYRIGHT 2013 ACS on STN ACCESSION NUMBER: 1996:494350 HCAPLUS Full-text DOCUMENT NUMBER: 125:150780 ORIGINAL REFERENCE NO.: 125:28063a,28066a TITLE: Anti-irritant skin formulations containing magnesium, manganese, or lanthanide cations INVENTOR(S): Hahn, Gary Scott; Thueson, David Orel PATENT ASSIGNEE(S): Cosmederm Technologies, USA SOURCE: PCT Int. Appl., 52 pp. LANGUAGE: English PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE ------WO 9619182 A1 19960627 WO 1995-US16763 19951221 CA 2208500 A1 19960627 CA 1995-2208500 19951221 AU 9646064 A 19960710 AU 1996-46064 19951221 EP 799018 A1 19971008 EP 1995-944200 19951221 PRIORITY APPLN. INFO.: US 1994-362097 A 19941221 WO 1995-US16763 W 19951221 AB Cosmetic and pharmaceutical compns. for inhibiting skin irritation attributable to chem. irritants or environment conditions, contain an anti-irritant amt. of aq.-sol. divalent magnesium cation or divalent manganese cation, or trivalent lanthanide cations of at. nos. 56-71. A soln. of 250 mM manganese acetate decreased the skin irritation caused by application of 7.5% lactic acid in 10% ethanol by 65%. IPCI A61K0007-00 [ICM,6] IPCR A61K0008-19 [I,A]; A61K0008-20 [I,A]; A61K0008-23 [I,A]; A61K0008-365 [I,A]; A61Q0005-00 [I,A]; A61Q0009-00 [I,A]; A61Q0015-00 [I,A]; A61Q0017-00 [I,A]; A61Q0019-00 [I,A] CC 62-4 (Essential Oils and Cosmetics) Section cross-reference(s): 63 IT Acne (inhibitors; anti-irritant skin formulations contg. magnesium, manganese, or lanthanide cations) IT Essential oils RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Melaleuca, ext.; anti-irritant skin formulations contg. magnesium, manganese, or lanthanide cations) IT 50-21-5, Lactic acid, biological studies 64-19-7, Acetic acid, biological studies 68-26-8, Retinol 69-72-7, biological studies 69-72-7D, salts 76-03-9, Trichloroacetic acid, biological studies 76-93-7, biological studies 77-92-9, biological studies 79-14-1, biological studies 79-14-1D, magnesium and manganese and lanthanide salts 87-69-4, biological studies 90-64-2, Mandelic acid 90-80-2, Gluconolactone 94-36-0, Benzoyl peroxide, biological studies 98-79-3 108-95-2, Phenol, biological studies 116-31-4, Retinal 127-17-3, Pyruvic acid, biological studies 144-62-7, Ethanedioic acid, biological studies 302-79-4, Tretinoin 404-86-4, Capsaicin 526-95-4, Gluconic acid 5393-81-7, α-Hydroxy decanoic acid 6915-15-7, Malic acid 10024-66-5, Manganese citrate 70424-62-3 126094-21-1 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study) (anti-irritant skin formulations contg. magnesium, manganese, or lanthanide cations)

Page 98 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 25 OF 199 HCAPLUS COPYRIGHT 2013 ACS on STN ACCESSION NUMBER: 1996:494351 HCAPLUS Full-text DOCUMENT NUMBER: 125:150781 ORIGINAL REFERENCE NO.: 125:28063a,28066a TITLE: Anti-irritant skin formulations containing potassium or lithium cations INVENTOR(S): Hahn, Gary Scott; Thueson, David Orel PATENT ASSIGNEE(S): Cosmederm Technologies, USA SOURCE: PCT Int. Appl., 53 pp. LANGUAGE: English PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE ------WO 9619181 A1 19960627 WO 1995-US16751 19951221 US 5756107 A 19980526 US 1994-362055 19941221 CA 2208079 A1 19960627 CA 1995-2208079 19951221 AU 9646060 A 19960710 AU 1996-46060 19951221 EP 796078 A1 19970924 EP 1995-944196 19951221 PRIORITY APPLN. INFO.: US 1994-362055 A 19941221 WO 1995-US16751 W 19951221 AB Cosmetic and pharmaceutical compns. for inhibiting skin irritation attributable to chem. irritants or environment conditions, contain an anti-irritant amt. of aq.-sol. potassium or lithium cation. A soln. of 250 mM lithium acetate decreased the skin irritation caused by application of 7.5% lactic acid in 10% ethanol by 70%. IPCI A61K0007-00 [ICM,6] IPCR A61K0008-19 [I,A]; A61K0008-20 [I,A]; A61K0008-23 [I,A]; A61K0008-365 [I,A]; A61K0036-82 [I,A]; A61Q0005-00 [I,A]; A61Q0009-00 [I,A]; A61Q0015-00 [I,A]; A61Q0017-00 [I,A]; A61Q0019-00 [I,A] CC 62-4 (Essential Oils and Cosmetics) Section cross-reference(s): 63 IT Acne (inhibitors; anti-irritant skin formulations contg. potassium or lithium cations) IT Essential oils RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Melaleuca, ext.; anti-irritant skin formulations contg. potassium or lithium cations) IT 50-21-5, Lactic acid, biological studies 50-21-5D, Lactic acid, salts 64-19-7, Acetic acid, biological studies 68-26-8, Retinol 69-72-7, biological studies 69-72-7D, salts 76-03-9, Trichloroacetic acid, biological studies 76-93-7, biological studies 77-92-9, biological studies 77-92-9D, salts 79-14-1, biological studies 79-14-1D, salts 87-69-4, biological studies 90-64-2, Mandelic acid 90-80-2, Gluconolactone 94-36-0, Benzoyl peroxide, biological studies 98-79-3 108-95-2, Phenol, biological studies 116-31-4, Retinal 127-17-3, Pyruvic acid, biological studies 144-62-7, Ethanedioic acid, biological studies 302-79-4, Tretinoin 404-86-4, Capsaicin 526-95-4, Gluconic acid 5393-81-7, α-Hydroxy decanoic acid 6915-15-7, Malic acid 70424-62-3 126094-21-1 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study) (anti-irritant skin formulations contg. potassium or lithium cations)

Page 99 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 26 OF 199 HCAPLUS COPYRIGHT 2013 ACS on STN ACCESSION NUMBER: 2000:636374 HCAPLUS Full-text DOCUMENT NUMBER: 133:194977 TITLE: Make-up soap compositions containing tea tree oil and benzoyl peroxide INVENTOR(S): Lee, Yu-soon PATENT ASSIGNEE(S): Lg Chemical Co., Ltd., S. Korea SOURCE: Repub. Korea, No pp. given LANGUAGE: Korean PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE ------KR 9607395 B1 19960531 KR 1993-25419 19931126 PRIORITY APPLN. INFO.: KR 1993-25419 19931126 AB The cosmetic soap is composed of 0.01-5% tea tree oil, 1-10% benzoyl peroxide and the rest of cosmetic soap base without over-fat. The used tea tree oil comprises 2-6% 1,8-cineole and more than 30% -4-ol. The proper contents of the components reduce pimple by sterilizing pimple and removing sebum, and give good workability during soap making process. IPCI C11D0009-50 [ICM,6] IPCR C11D0009-50 [I,A] CC 46-2 (Surface Active Agents and Detergents) Section cross-reference(s): 62 ST tea tree oil benzoyl peroxide soap IT Essential oils RL: BUU (Biological use, unclassified); TEM (Technical or engineered material use); BIOL (Biological study); USES (Uses) (Melaleuca; make-up soap compns. contg. tea tree oil and benzoyl peroxide) IT Soaps RL: BUU (Biological use, unclassified); TEM (Technical or engineered material use); BIOL (Biological study); USES (Uses) (make-up soap compns. contg. tea tree oil and benzoyl peroxide) IT 94-36-0, Benzoyl peroxide, uses RL: BUU (Biological use, unclassified); TEM (Technical or engineered material use); BIOL (Biological study); USES (Uses) (make-up soap compns. contg. tea tree oil and benzoyl peroxide)

Page 100 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 39 OF 199 USPATFULL on STN ACCESSION NUMBER: 2012:368486 USPATFULL Full-text TITLE: NANOPARTICLE COMPOSITIONS INVENTOR(S): EDELSON, Jonathan, Scarsdale, NY, UNITED STATES KOTYLA, Timothy, Lowell, MA, UNITED STATES THEOBALD, Klaus, Paoli, PA, UNITED STATES PATENT ASSIGNEE(S): ANTERIOS, INC., New York, NY, UNITED STATES (U.S. corporation)

NUMBER KIND DATE ------PATENT INFORMATION: US 20120328702 A1 20121227 [Family] APPLICATION INFO.: US 2012-356621 A1 20120123 (13)

NUMBER DATE ------PRIORITY INFORMATION: US 2011-435780P 20110124 (61) AB The present invention describes novel nanoparticle compositions, and systems and methods utilizing them for treating disorders and/or conditions associated with the epidermal and/or dermal level of the skin. Such disorders include acne, hyperhidrosis, bromhidrosis, chromhidrosis, rosacea, hair loss, dermal infection, actinic keratosis, facial wrinkles, muscle contracture, and headache. Methods generally involve administering nanoparticle compositions to the skin. AB . . . utilizing them for treating disorders and/or conditions associated with the epidermal and/or dermal level of the skin. Such disorders include acne, hyperhidrosis, bromhidrosis, chromhidrosis, rosacea, hair loss, dermal infection, actinic keratosis, facial wrinkles, muscle contracture, and headache. Methods generally involve administering. . . SUMM . . . from them, and current treatments are not very successful and often have undesirable side effects. For example, according to studies, acne often leads to reduced self esteem, and sometimes even to depression or suicide (see, e.g., Goodman, 2006, Aust. Fam. Physician. . . DETD . . . known to have a particular biological effect on sebaceous glands include botulinum toxin, cleansers or soaps, a topical bactericidal (e.g., benzoyl peroxide, triclosan, and/or chlorhexidine gluconate), topical antibiotics (e.g., externally-applied erythromycin, clindamycin, tetracycline, etc.), oral antibiotics (e.g., erythromycin, tetracycline, , doxycycline, minocycline,. . . treatments (e.g., estrogen/progestogen oral contraceptives, low dose spironolactone, cortisone, etc.), a keratolytic (i.e., a substance that dissolves keratin plugging pores), benzoyl peroxide, a topical (e.g., tretinoin [RETIN-A®], adapalene [DIFFERIN®], and tazarotene [TAZORAC®], retinol, isotretinoin, etc.), oral retinoids (e.g., isotretinoin [ACCUTANE®, AMNESTEEM.TM., SOTRET.TM., CLARAVIS.TM.]), retinoic acids, a natural product with anti-acne activity (e.g., aloe vera, aruna, haldi [i.e., turmeric], papaya, etc.), azelaic acid (brand names AZELEX.TM., FINACEA®, FINEVIN®, SKINOREN, etc.), anti-inflammatory agents (e.g., naproxen, , rofecoxib, etc.), nicotinamide (i.e., vitamin B3), tea tree oil (melaleuca oil), aminolevulinic acid, azithromycin, methylaminolevuninate, nadifloxacine, PRK124, talarozole, zileuton, rofecoxib, zinc, an agent described in Krowchuk (2000, Pediatric. . . DETD . . . disorders, or conditions include, but are not limited to, a condition associated with sweat glands or sebaceous glands, such as acne; hyperhidrosis; unwanted sweating; bromhidrosis; ; chromhidrosis; hair loss; psoriasis; actinic keratosis; dermal infection; eczematous dermatitis (e.g., atopic dermatitis, etc.);. . . DETD . . . form of reducing the frequency of that symptom. To give but a

Page 101 of 158

Science IP Order: 3550000 Client Reference: 3456-789

few examples, where the condition in question is acne, symptoms of that condition are reduced when the (e.g., diameter, volume, etc.) and/or severity (e.g., redness, inflammatory response, etc.) of. . . DETD In some embodiments, the present invention provides methods and compositions for the treatment and/or prevention of one or more of acne, unwanted sweating, body odor, hyperhidrosis, bromhidrosis, chromhidrosis, rosacea, hair loss, psoriasis, actinic keratosis, eczematous dermatitis (e.g., atopic dermatitis, etc.), excess. . . DETD . . . some permanent redness with papules and/or pustules, which typically last 1 to 4 days. This subtype is commonly confused with acne. "Phymatous rosacea" is most commonly associated with , an enlargement of the nose. Symptoms include thickening skin, irregular surface nodularities,. . . DETD Acne DETD In some embodiments, provided compositions are useful for treating and/or preventing acne vulgaris (commonly referred to as "acne"), a skin disease caused by changes in the pilosebaceous units (i.e., skin structures comprising a hair follicle and its associated sebaceous gland). In some embodiments, acne is inflammatory. In some embodiments, acne is noninflammatory. While not life-threatening, acne vulgaris can cause significant problems for affected individuals. Depending on its severity and other factors, recalcitrant acne can be psychologically debilitating, and can impose significant financial and emotional costs on those whom it afflicts. Despite some recent successes in acne therapy, treatment failures are still common, especially in adult women. While many adults "outgrow" this disease, there are some who continue to be afflicted during much of adulthood, despite continued medical advances. Unfortunately, the most potent acne in current use is administered systemically via a treatment that is teratogenic, an important issue for many women. There is an unfilled need for a more localized and effective treatment for acne, one with minimal side effects. DETD In general, acne develops as a result of blockages in follicles. The pathology centers on the pilosebaceous units, comprising a sebaceous gland, a follicle (i.e., pore), and a vellus hair. Among the first events leading to acne are hyperkeratinization and formation of a plug of keratin and sebum (a "microcomedo"), obstructing the upper region of a follicle.. . . an increase in sebum production occur with increased androgen production at adrenarche. A microcomedo may enlarge to form an open comedo (a "blackhead") or closed comedo (a "whitehead"). In these conditions the naturally occurring largely commensual bacteria Propionibacterium acnes can cause inflammation, leading to inflammatory lesions (papules, infected pustules, or nodules) in the dermis around the microcomedo or comedo, which results in redness and may result in scarring or hyperpigmentation. DETD . . . sulfate (DHEAS). Increased androgen levels are thought to cause sebaceous glands to enlarge and to increase sebum production. While most acne patients have normal hormone levels, there are reasons to conclude that increased sebum production plays a role in acne. For example, there may be a correlation between the rate of sebum production and the severity of acne. In addition, acne patients typically produce sebum that is deficient in linoleic acid, which is a potential cause of abnormal keratinization and follicular. . . DETD . . . acnes, a relatively slow growing, typically aerotolerant anaerobic gram positive, diphtheroid bacterium, often colonizes the sebaceous follicles. P. acnes exacerbates acne by acting as a chemo-attractant for neutrophils. Neutrophils ingest P. acnes, and in doing so release various hydrolytic that. . . DETD Follicles are lined with squamous epithelium, a layer of cells that is contiguous with the skin surface. In an acne-prone individual, the

Page 102 of 158

Science IP Order: 3550000 Client Reference: 3456-789

shedding of cells from this lining is often impeded, perhaps due to an increased level of intercellular adhesion that promotes the retention of cells. Retained cells can obstruct follicles, resulting in comedones. Such inhibited shedding may be related to abnormalities in epidermal differentiation and/or to abnormal sebum composition (e.g., a deficiency in. . . can irritate keratinocytes, causing the release of interleukin-1, which in turn can cause follicular hyperkeratinization. In general, each of these acne-causing routes, which are not mutually exclusive, is associated with follicular obstruction. DETD Several factors are known to be linked to acne, including, but not limited to, family and/or genetic history (see, e.g., Ballanger et al., 2006, Dermatology, 212:145-149; incorporated herein by. . . DETD In some embodiments, acne treatments work via one or more of the following mechanisms: (1) normalizing shedding into the pore to prevent blockage; (2). . . DETD The present invention provides methods of treating and/or preventing acne comprising administration of a provided composition to a subject suffering from, susceptible to, and/or displaying symptoms of acne. In some embodiments, such a provided composition is administered locally to an affected site (e.g., face, neck, back, arms, chest,. . . DETD In some embodiments, provided compositions for treatment of acne are formulated into a cream, liniment, lotion, gel, sunscreen, etc. DETD Exemplary current treatments for acne include, but are not limited to, botulinum toxin, cleansers or soaps; topical bactericidals (e.g., benzoyl peroxide, triclosan, chlorhexidine gluconate, etc.); topical antibiotics (e.g., externally-applied erythromycin, clindamycin, tetracycline, etc.); oral antibiotics (e.g., erythromycin, tetracycline, oxytetracycline, doxycycline, minocycline,. . . ibuprofen, rofecoxib [Tehrani and Dharmalingam, 2004, Indian J. Dermatol. Venereol. Leprol., 70:345-348; incorporated herein by reference], etc.); nicotinamide [vitamin B3]; tea tree oil [melaleuca oil]; rofecoxib; zinc (Dreno et al., 1989, Acta Derm. Venereol., 69:541-3; and Dreno et al., 2001, Dermatology, 203:135-40;. . . DETD Alternative or additional current therapies for the treatment and/or prevention of acne include, but are not limited to, phototherapy (e.g., alternating blue and red light); photodynamic therapy (e.g., intense blue/violet light); laser. . . DETD It is known in the art that short-term improvement of acne can be achieved with sunlight, but studies have shown that sunlight worsens acne long-term. More recently, visible light has been successfully employed to treat acne (i.e., "phototherapy")--in particular, intense violet light (405 nm-420 nm) generated by purpose-built fluorescent lighting, dichroic bulbs, LEDs, and/or lasers. Used twice weekly, this has been shown to reduce the number of acne lesions by about 64% (Kawada et al., 2002, J. Dermatol. Sci., 30:129-35; incorporated herein by reference) and is even more. . . DETD . . . some evidence that photodynamic therapy (e.g., therapy with intense blue/violet light (405 nm-425 nm)) can decrease the number of inflammatory acne lesion by 60%-70% in 4 weeks of therapy, particularly when P. acnes is pretreated with delta-aminolevulinic acid (ALA), which increases. . . DETD Laser surgery has been in use for some time to reduce the scars left behind by acne, but research has been done on lasers for prevention of acne formation itself In general, laser is used to burn away the follicle sac from which the hair grows, to burn. . . DETD Local heating therapies are sometimes used, for example, to kill bacteria in a developing pimple, thereby expediting healing. DETD In some embodiments, provided compositions for treatment and/or prevention of acne are formulated into a cream, liniment, lotion, gel, sunscreen, etc.

Page 103 of 158

Science IP Order: 3550000 Client Reference: 3456-789

DETD In some embodiments, provided compositions for treatment and/or prevention of acne are administered locally to an affected site (e.g., axillae, hands, feet, face, neck, back, arms, chest, etc.). DETD . . . the skin. Hyperpigmentation is often due to skin damage due to sun exposure, , and/or inflammation (including inflammation due to acne vulgaris). Melasma is a condition of dark, irregular patches of skin found most usually on the upper cheek, nose, lips,. . . DETD . . . In certain embodiments, the pharmaceutical pack or kit includes an additional approved therapeutic agent (e.g., benzoyl peroxide for treatment of acne; aluminum compounds for treatment of hyperhidrosis; etc.) for use in combination therapies. Optionally associated with such container(s) can be a. . . CLM What is claimed is: . . . composition, lotion, or pharmaceutical composition is administered for treatment of a condition or disorder selected from the group consisting of acne, hyperhidrosis, unwanted sweating, bromhidrosis, body odor, chromhidrosis, excess sebum-producing disorders, seborrhea, seborrheic dermatitis, rosacea, hair loss, psoriasis, dermal infections, viral. . . CLM What is claimed is: . . . wherein the nanoparticle composition, lotion, or pharmaceutical composition is administered for treatment of hyperhidrosis, unwanted sweating, bromhidrosis, body odor, chromhidrosis, acne, wrinkles, headache, or any combination thereof.

Page 104 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 40 OF 199 USPATFULL on STN ACCESSION NUMBER: 2012:368485 USPATFULL Full-text TITLE: NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR INVENTOR(S): EDELSON, Jonathan, Scarsdale, NY, UNITED STATES KOTYLA, Timothy, Lowell, MA, UNITED STATES THEOBALD, Klaus, Paoli, PA, UNITED STATES PATENT ASSIGNEE(S): ANTERIOS, INC., New York, NY, UNITED STATES (U.S. corporation)

NUMBER KIND DATE ------PATENT INFORMATION: US 20120328701 A1 20121227 [Family] APPLICATION INFO.: US 2012-356617 A1 20120123 (13)

NUMBER DATE ------PRIORITY INFORMATION: US 2011-435778P 20110124 (61) AB The present invention describes novel nanoparticle compositions, and systems and methods utilizing them for treating disorders and/or conditions. Methods generally involve administering nanoparticle compositions (e.g., nanoparticle compositions comprising at least one known therapeutic agent and/or independently active biologically active agent; and/or empty nanoparticle compositions) to a subject in need thereof. SUMM . . . known to have a particular biological effect on sebaceous glands include botulinum toxin, cleansers or soaps, a topical bactericidal (e.g., benzoyl peroxide, triclosan, and/or chlorhexidine gluconate), topical antibiotics (e.g., externally-applied erythromycin, clindamycin, tetracycline, etc.), oral antibiotics (e.g., erythromycin, tetracycline, oxytetracycline, doxycycline, minocycline,. . . treatments (e.g., estrogen/progesterone oral contraceptives, low dose spironolactone, cortisone, etc.), a keratolytic (i.e., a substance that dissolves keratin plugging pores), benzoyl peroxide, a topical retinoid (e.g., tretinoin [RETIN-A®], adapalene [DIFFERIN®], and tazarotene [TAZORAC®], retinol, isotretinoin, etc.), oral retinoids (e.g., isotretinoin [ACCUTANE®, AMNESTEEM.TM., SOTRET.TM., CLARAVIS.TM.]), retinoic acids, a natural product with anti-acne activity (e.g., aloe vera, aruna, haldi [i.e., turmeric], papaya, etc.), azelaic acid (brand names AZELEX.TM., FINACEA®, FINEVIN®, SKINOREN, etc.), anti-inflammatory agents (e.g., naproxen, ibuprofen, rofecoxib, etc.), nicotinamide (i.e., vitamin B3), tea tree oil (melaleuca oil), aminolevulinic acid, azithromycin, methylaminolevuninate, nadifloxacine, PRK124, talarozole, zileuton, rofecoxib, zinc, an agent described in Krowchuk (2000, Pediatric. . . SUMM . . . disorders, or conditions include, but are not limited to, a condition associated with sweat glands or sebaceous glands, such as acne; hyperhidrosis; unwanted sweating; bromhidrosis; body odor; chromhidrosis; hair loss; psoriasis; actinic keratosis; dermal infection; eczematous dermatitis (e.g., atopic dermatitis, etc.);. . . SUMM . . . form of reducing the frequency of that symptom. To give but a few examples, where the condition in question is acne, symptoms of that condition are reduced when the (e.g., diameter, volume, etc.) and/or severity (e.g., redness, inflammatory response, etc.) of. . . DETD In some embodiments, the present invention provides methods and compositions for the treatment and/or prevention of one or more of acne, unwanted sweating, body odor, hyperhidrosis, bromhidrosis, chromhidrosis, rosacea, hair loss, psoriasis, actinic keratosis, eczematous dermatitis (e.g., atopic dermatitis, etc.), excess. . . DETD . . . some permanent redness with papules and/or pustules, which typically last 1 to 4 days. This subtype is commonly confused with

Page 105 of 158

Science IP Order: 3550000 Client Reference: 3456-789

acne. "Phymatous rosacea" is most commonly associated with rhinophyma, an enlargement of the nose. Symptoms include thickening skin, irregular surface nodularities,. . . DETD Acne DETD In some embodiments, provided compositions are useful for treating and/or preventing acne vulgaris (commonly referred to as "acne"), a skin disease caused by changes in the pilosebaceous units (i.e., skin structures comprising a hair follicle and its associated sebaceous gland). In some embodiments, acne is inflammatory. In some embodiments, acne is noninflammatory. While not life-threatening, acne vulgaris can cause significant problems for affected individuals. Depending on its severity and other factors, recalcitrant acne can be psychologically debilitating, and can impose significant financial and emotional costs on those whom it afflicts. Despite some recent successes in acne therapy, treatment failures are still common, especially in adult women. While many adults "outgrow" this disease, there are some who continue to be afflicted during much of adulthood, despite continued medical advances. Unfortunately, the most potent acne medication in current use is administered systemically via a treatment that is teratogenic, an important issue for many women. There is an unfilled need for a more localized and effective treatment for acne, one with minimal side effects. DETD In general, acne develops as a result of blockages in follicles. The pathology centers on the pilosebaceous units, comprising a sebaceous gland, a follicle (i.e., pore), and a vellus hair. Among the first events leading to acne are hyperkeratinization and formation of a plug of keratin and sebum (a "microcomedo"), obstructing the upper region of a follicle.. . . an increase in sebum production occur with increased androgen production at adrenarche. A microcomedo may enlarge to form an open comedo (a "blackhead") or closed comedo (a "whitehead"). In these conditions the naturally occurring largely commensual bacteria Propionibacterium acnes can cause inflammation, leading to inflammatory lesions (papules, infected pustules, or nodules) in the dermis around the microcomedo or comedo, which results in redness and may result in scarring or hyperpigmentation. DETD . . . sulfate (DHEAS). Increased androgen levels are thought to cause sebaceous glands to enlarge and to increase sebum production. While most acne patients have normal hormone levels, there are reasons to conclude that increased sebum production plays a role in acne. For example, there may be a correlation between the rate of sebum production and the severity of acne. In addition, acne patients typically produce sebum that is deficient in linoleic acid, which is a potential cause of abnormal keratinization and follicular. . . DETD . . . acnes, a relatively slow growing, typically aerotolerant anaerobic gram positive, diphtheroid bacterium, often colonizes the sebaceous follicles. P. acnes exacerbates acne by acting as a chemo-attractant for neutrophils. Neutrophils ingest P. acnes, and in doing so release various hydrolytic enzymes that. . . DETD Follicles are lined with squamous epithelium, a layer of cells that is contiguous with the skin surface. In an acne-prone individual, the shedding of cells from this lining is often impeded, perhaps due to an increased level of intercellular adhesion that promotes the retention of cells. Retained cells can obstruct follicles, resulting in comedones. Such inhibited shedding may be related to abnormalities in epidermal differentiation and/or to abnormal sebum composition (e.g., a deficiency in. . . can irritate keratinocytes, causing the release of interleukin-1, which in turn can cause follicular hyperkeratinization. In general, each of these acne-causing routes, which are not mutually exclusive, is associated with follicular obstruction. DETD Several factors are known to be linked to acne, including, but not

Page 106 of 158

Science IP Order: 3550000 Client Reference: 3456-789

limited to, family and/or genetic history (see, e.g., Ballanger et al., 2006, Dermatology, 212:145-149; incorporated herein by. . . DETD In some embodiments, acne treatments work via one or more of the following mechanisms: (1) normalizing shedding into the pore to prevent blockage; (2). . . DETD The present invention provides methods of treating and/or preventing acne comprising administration of a provided composition to a subject suffering from, susceptible to, and/or displaying symptoms of acne. In some embodiments, such a provided composition is administered locally to an affected site (e.g., face, neck, back, arms, chest,. . . DETD In some embodiments, provided compositions for treatment of acne are formulated into a cream, liniment, lotion, gel, sunscreen, etc. DETD Exemplary current treatments for acne include, but are not limited to, botulinum toxin; cleansers or soaps; topical bactericidals (e.g., benzoyl peroxide, triclosan, chlorhexidine gluconate, etc.); topical antibiotics (e.g., externally-applied erythromycin, clindamycin, tetracycline, etc.); oral antibiotics (e.g., erythromycin, tetracycline, oxytetracycline, doxycycline, minocycline,. . . ibuprofen, rofecoxib [Tehrani and Dharmalingam, 2004, Indian J. Dermatol. Venereol. Leprol., 70:345-348; incorporated herein by reference], etc.); nicotinamide [vitamin B3]; tea tree oil [melaleuca oil]; rofecoxib; zinc (Dreno et al., 1989, Acta Derm. Venereol., 69:541-3; and Dreno et al., 2001, Dermatology, 203:135-40;. . . DETD Alternative or additional current therapies for the treatment and/or prevention of acne include, but are not limited to, phototherapy (e.g., alternating blue and red light); photodynamic therapy (e.g., intense blue/violet light); laser. . . DETD It is known in the art that short-term improvement of acne can be achieved with sunlight, but studies have shown that sunlight worsens acne long-term. More recently, visible light has been successfully employed to treat acne (i.e., "phototherapy")--in particular, intense violet light (405 nm-420 nm) generated by purpose-built fluorescent lighting, dichroic bulbs, LEDs, and/or lasers. Used twice weekly, this has been shown to reduce the number of acne lesions by about 64% (Kawada et al., 2002, J. Dermatol. Sci., 30:129-35; incorporated herein by reference) and is even more. . . DETD . . . some evidence that photodynamic therapy (e.g., therapy with intense blue/violet light (405 nm-425 nm)) can decrease the number of inflammatory acne lesion by 60%-70% in 4 weeks of therapy, particularly when P. acnes is pretreated with delta-aminolevulinic acid (ALA), which increases. . . DETD Laser surgery has been in use for some time to reduce the scars left behind by acne, but research has been done on lasers for prevention of acne formation itself. In general, laser is used to burn away the follicle sac from which the hair grows, to burn. . . DETD Local heating therapies are sometimes used, for example, to kill bacteria in a developing pimple, thereby expediting healing. DETD In some embodiments, provided compositions for treatment and/or prevention of acne are formulated into a cream, liniment, lotion, gel, sunscreen, etc. DETD In some embodiments, provided compositions for treatment and/or prevention of acne are administered locally to an affected site (e.g., axillae, hands, feet, face, neck, back, arms, chest, etc.). DETD . . . the skin. Hyperpigmentation is often due to skin damage due to sun exposure, medications, and/or inflammation (including inflammation due to acne vulgaris). Melasma is a condition of dark, irregular patches of skin found most usually on the upper cheek, nose, lips,. . . DETD . . . In certain embodiments, the pharmaceutical pack or kit includes an additional approved therapeutic agent (e.g., benzoyl peroxide for

Page 107 of 158

Science IP Order: 3550000 Client Reference: 3456-789

treatment of acne; aluminum compounds for treatment of hyperhidrosis; etc.) for use in combination therapies. Optionally associated with such container(s) can be a. . . CLM What is claimed is: . . . composition, lotion, or pharmaceutical composition is administered for treatment of a condition or disorder selected from the group consisting of acne, hyperhidrosis, unwanted sweating, bromhidrosis, body odor, chromhidrosis, excess sebum-producing disorders, seborrhea, seborrheic dermatitis, rosacea, hair loss, psoriasis, dermal infections, viral. . . CLM What is claimed is: . . . 36, wherein the nanoparticle composition, lotion, or pharmaceutical composition is administered for treatment of unwanted sweating, bromhidrosis, body odor, chromhidrosis, acne, wrinkles, headache, or any combination thereof.

Page 108 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 41 OF 199 USPATFULL on STN ACCESSION NUMBER: 2012:368310 USPATFULL Full-text TITLE: NANOPARTICLE COMPOSITIONS AND COMPONENTS THEREOF INVENTOR(S): EDELSON, Jonathan, Scarsdale, NY, UNITED STATES KOTYLA, Timothy, Lowell, MA, UNITED STATES THEOBALD, Klaus, Paoli, PA, UNITED STATES PATENT ASSIGNEE(S): ANTERIOS, INC., New York, NY, UNITED STATES (U.S. corporation)

NUMBER KIND DATE ------PATENT INFORMATION: US 20120328525 A1 20121227 [Family] APPLICATION INFO.: US 2012-356623 A1 20120123 (13)

NUMBER DATE ------PRIORITY INFORMATION: US 2011-435749P 20110124 (61) AB The present invention describes systems and methods for treating disorders and/or conditions associated with the dermal level of the skin. Such disorders include acne, hyperhidrosis, bromhidrosis, chromhidrosis, rosacea, hair loss, dermal infection, and/or actinic keratosis, among others. Methods generally involve administering provided compositions to the skin. AB . . . describes systems and methods for treating disorders and/or conditions associated with the dermal level of the skin. Such disorders include acne, hyperhidrosis, bromhidrosis, chromhidrosis, rosacea, hair loss, dermal infection, and/or actinic keratosis, among others. Methods generally involve administering provided compositions to. . . SUMM . . . suffer from them. Current treatments are not very successful and often have undesirable side effects. For example, according to studies, acne often leads to reduced self esteem, and sometimes even to depression or suicide (see, e.g., Goodman, 2006, Aust. Fam. Physician. . . SUMM . . . glands, sebaceous glands, hair follicles, etc.). Exemplary conditions or disorders associated with dermal structures include, but are not limited to, acne, hyperhidrosis, unwanted sweating, bromhidrosis, body odor, chromhidrosis, rosacea, hair loss, psoriasis, dermal infection (e.g., herpes simplex virus infection, human papillomavirus. . . SUMM . . . invention, provided compositions are useful in various cosmetic and medical applications. In some embodiments, provided compositions are utilized to treat acne. In some embodiments, provided compositions are utilized to treat hyperhidrosis. In some embodiments, provided compositions are utilized to treat acne. In some embodiments, provided compositions are utilized to treat unwanted sweating. In some embodiments, provided compositions are utilized to treat bromhidrosis. In some embodiments, provided compositions are utilized to treat acne. In some embodiments, provided compositions are utilized to treat body odor. In some embodiments, provided compositions are utilized to treat. . . SUMM . . . known to have a particular biological effect on sebaceous glands include botulinum toxin, cleansers or soaps, a topical bactericidal (e.g., benzoyl peroxide, triclosan, and/or chlorhexidine gluconate), topical antibiotics (e.g., externally-applied erythromycin, clindamycin, tetracycline, etc.), oral antibiotics (e.g., erythromycin, tetracycline, oxytetracycline, doxycycline, minocycline,. . . treatments (e.g., estrogen/progesterone oral contraceptives, low dose spironolactone, cortisone, etc.), a keratolytic (i.e., a substance that dissolves keratin plugging pores), benzoyl peroxide, a topical retinoid (e.g., tretinoin [RETIN-A®], adapalene [DIFFERIN®], and tazarotene [TAZORAC®], retinol, isotretinoin, etc.), oral retinoids

Page 109 of 158

Science IP Order: 3550000 Client Reference: 3456-789

(e.g., isotretinoin [ACCUTANE®, AMNESTEEM.TM., SOTRET.TM., CLARAVIS.TM.]), retinoic acids, a natural product with anti-acne activity (e.g., aloe vera, aruna, haldi [i.e., turmeric], papaya, etc.), azelaic acid (brand names AZELEX.TM., FINACEA®, FINEVIN®, SKINOREN, etc.), anti-inflammatory agents (e.g., naproxen, ibuprofen, rofecoxib, etc.), nicotinamide (i.e., vitamin B3), tea tree oil (melaleuca oil), aminolevulinic acid, azithromycin, methylaminolevuninate, nadifloxacine, PRK124, talarozole, zileuton, rofecoxib, zinc, an agent described in Krowchuk (2000, Pediatric. . . SUMM . . . disorders, or conditions include, but are not limited to, a condition associated with sweat glands or sebaceous glands, such as acne; hyperhidrosis; unwanted sweating; bromhidrosis; body odor; chromhidrosis; hair loss; psoriasis; actinic keratosis; dermal infection; eczematous dermatitis (e.g., atopic dermatitis, etc.);. . . SUMM . . . form of reducing the frequency of that symptom. To give but a few examples, where the condition in question is acne, symptoms of that condition are reduced when the size (e.g., diameter, volume, etc.) and/or severity (e.g., redness, inflammatory response, etc.). . . DETD . . . odor. In some embodiments, the present invention provides treatments for rosacea. In some embodiments, the present invention provides treatments for acne. In some embodiments, the present invention provides treatments for hair loss. In some embodiments, the present invention provides treatments for. . . DETD In some embodiments, the present invention provides methods and compositions for the treatment and/or prevention of one or more of acne, unwanted sweating, body odor, hyperhidrosis, bromhidrosis, chromhidrosis, rosacea, hair loss, psoriasis, actinic keratosis, eczematous dermatitis (e.g., atopic dermatitis, etc.), excess. . . DETD . . . some permanent redness with papules and/or pustules, which typically last 1 to 4 days. This subtype is commonly confused with acne. "Phymatous rosacea" is most commonly associated with rhinophyma, an enlargement of the nose. Symptoms include thickening skin, irregular surface nodularities,. . . DETD Acne DETD In some embodiments, provided compositions are useful for treating and/or preventing acne vulgaris (commonly referred to as "acne"), a skin disease caused by changes in the pilosebaceous units (i.e., skin structures comprising a hair follicle and its associated sebaceous gland). In some embodiments, acne is inflammatory. In some embodiments, acne is noninflammatory. While not life-threatening, acne vulgaris can cause significant problems for affected individuals. Depending on its severity and other factors, recalcitrant acne can be psychologically debilitating, and can impose significant financial and emotional costs on those whom it afflicts. Despite some recent successes in acne therapy, treatment failures are still common, especially in adult women. While many adults "outgrow" this disease, there are some who continue to be afflicted during much of adulthood, despite continued medical advances. Unfortunately, the most potent acne medication in current use is administered systemically via a treatment that is teratogenic, an important issue for many women. There is an unfilled need for a more localized and effective treatment for acne, one with minimal side effects. DETD In general, acne develops as a result of blockages in follicles. The pathology centers on the pilosebaceous units, comprising a sebaceous gland, a follicle (i.e., pore), and a vellus hair. Among the first events leading to acne are hyperkeratinization and formation of a plug of keratin and sebum (a "microcomedo"), obstructing the upper region of a follicle.. . . an increase in sebum production occur with increased androgen production at adrenarche. A microcomedo may enlarge to form an open comedo (a "blackhead") or closed comedo (a "whitehead"). In

Page 110 of 158

Science IP Order: 3550000 Client Reference: 3456-789

these conditions the naturally occurring largely commensual bacteria Propionibacterium acnes can cause inflammation, leading to inflammatory lesions (papules, infected pustules, or nodules) in the dermis around the microcomedo or comedo, which results in redness and may result in scarring or hyperpigmentation. DETD . . . sulfate (DHEAS). Increased androgen levels are thought to cause sebaceous glands to enlarge and to increase sebum production. While most acne patients have normal hormone levels, there are reasons to conclude that increased sebum production plays a role in acne. For example, there may be a correlation between the rate of sebum production and the severity of acne. In addition, acne patients typically produce sebum that is deficient in linoleic acid, which is a potential cause of abnormal keratinization and follicular. . . DETD . . . acnes, a relatively slow growing, typically aerotolerant anaerobic gram positive, diphtheroid bacterium, often colonizes the sebaceous follicles. P. acnes exacerbates acne by acting as a chemo-attractant for neutrophils. Neutrophils ingest P. acnes, and in doing so release various hydrolytic enzymes that. . . DETD Follicles are lined with squamous epithelium, a layer of cells that is contiguous with the skin surface. In an acne-prone individual, the shedding of cells from this lining is often impeded, perhaps due to an increased level of intercellular adhesion that promotes the retention of cells. Retained cells can obstruct follicles, resulting in comedones. Such inhibited shedding may be related to abnormalities in epidermal differentiation and/or to abnormal sebum composition (e.g., a deficiency in. . . can irritate keratinocytes, causing the release of interleukin-1, which in turn can cause follicular hyperkeratinization. In general, each of these acne-causing routes, which are not mutually exclusive, is associated with follicular obstruction. DETD Several factors are known to be linked to acne, including, but not limited to, family and/or genetic history (see, e.g., Ballanger et al., 2006, Dermatology, 212:145-149; incorporated herein by. . . DETD In some embodiments, acne treatments work via one or more of the following mechanisms: (1) normalizing shedding into the pore to prevent blockage; (2). . . DETD The present invention provides methods of treating and/or preventing acne comprising administration of a provided composition to a subject suffering from, susceptible to, and/or displaying symptoms of acne. In some embodiments, such a provided composition is administered locally to an affected site (e.g., face, neck, back, arms, chest,. . . DETD In some embodiments, provided compositions for treatment of acne are formulated into a cream, liniment, lotion, gel, sunscreen, etc. DETD Exemplary current treatments for acne include, but are not limited to, botulinum toxin, cleansers or soaps; topical bactericidals (e.g., benzoyl peroxide, triclosan, chlorhexidine gluconate, etc.); topical antibiotics (e.g., externally-applied erythromycin, clindamycin, tetracycline, etc.); oral antibiotics (e.g., erythromycin, tetracycline, oxytetracycline, doxycycline, minocycline,. . . ibuprofen, rofecoxib [Tehrani and Dharmalingam, 2004, Indian J. Dermatol. Venereol. Leprol., 70:345-348; incorporated herein by reference], etc.); nicotinamide [vitamin B3]; tea tree oil [melaleuca oil]; rofecoxib; zinc (Dreno et al., 1989, Acta Derm. Venereol., 69:541-3; and Dreno et al., 2001, Dermatology, 203:135-40;. . . DETD Alternative or additional current therapies for the treatment and/or prevention of acne include, but are not limited to, phototherapy (e.g., alternating blue and red light); photodynamic therapy (e.g., intense blue/violet light); laser. . . DETD It is known in the art that short-term improvement of acne can be achieved with sunlight, but studies have shown that sunlight worsens acne long-term. More recently, visible light has been successfully

Page 111 of 158

Science IP Order: 3550000 Client Reference: 3456-789

employed to treat acne (i.e., "phototherapy")--in particular, intense violet light (405 nm-420 nm) generated by purpose-built fluorescent lighting, dichroic bulbs, LEDs, and/or lasers. Used twice weekly, this has been shown to reduce the number of acne lesions by about 64% (Kawada et al., 2002, J. Dermatol. Sci., 30:129-35; incorporated herein by reference) and is even more. . . DETD . . . some evidence that photodynamic therapy (e.g., therapy with intense blue/violet light (405 nm-425 nm)) can decrease the number of inflammatory acne lesion by 60%-70% in 4 weeks of therapy, particularly when P. acnes is pretreated with delta-aminolevulinic acid (ALA), which increases. . . DETD Laser surgery has been in use for some time to reduce the scars left behind by acne, but research has been done on lasers for prevention of acne formation itself. In general, laser is used to burn away the follicle sac from which the hair grows, to burn. . . DETD Local heating therapies are sometimes used, for example, to kill bacteria in a developing pimple, thereby expediting healing. DETD In some embodiments, provided compositions for treatment and/or prevention of acne are formulated into a cream, liniment, lotion, gel, sunscreen, etc. DETD In some embodiments, provided compositions for treatment and/or prevention of acne are administered locally to an affected site (e.g., axillae, hands, feet, face, neck, back, arms, chest, etc.). DETD . . . the skin. Hyperpigmentation is often due to skin damage due to sun exposure, medications, and/or inflammation (including inflammation due to acne vulgaris). Melasma is a condition of dark, irregular patches of skin found most usually on the upper cheek, nose, lips,. . . DETD . . . therapies employed may achieve a desired effect for the same disorder (for example, an empty nanoparticle composition useful for treating acne may be administered concurrently with a therapeutic agent and/or independently active biologically active agent that is also useful for treating acne), or they may achieve different effects (for example, an empty nanoparticle composition that is useful for treating acne may be administered concurrently with a therapeutic agent and/or independently active biologically active agent that is useful for alleviating adverse. . . DETD . . . In some embodiments, the pharmaceutical pack or kit includes an additional approved therapeutic agent (e.g., benzoyl peroxide for treatment of acne; aluminum compounds for treatment of hyperhidrosis; etc.) for use in combination therapies, as described herein. Optionally associated with such container(s). . . DETD . . . or at risk for conditions or disorders associated with the dermal level of the skin, including, but not limited to, acne, hyperhidrosis, unwanted sweating, bromhidrosis, body odor, chromhidrosis, rosacea, hair loss, actinic keratosis, psoriasis, eczematous dermatitis (e.g., atopic dermatitis, etc.), excess. . . DETD Exemplary Provided Compositions for Treatment of Acne DETD Inclusion criteria include a diagnosis of acne. DETD The clinical investigator wipes a region affected by acne with an alcohol wipe and then wipe dry with cotton gauze. Using a latex-gloved finger, the investigator massages the topical. . . DETD . . . these results, the investigator concludes that topical treatment using empty nanoemulsions in accordance with the invention is effective in treating acne. CLM What is claimed is: 9. The method of claim 8, wherein the condition or disorder of the sebaceous glands is acne.

CLM What is claimed is:

Page 112 of 158

Science IP Order: 3550000 Client Reference: 3456-789

10. The method of claim 9, wherein the step of administering comprises administering the empty nanoparticle composition so that acne is reduced or onset is delayed.

CLM What is claimed is: . . . of claim 1, wherein the condition or disorder associated with a dermal structure is selected from the group consisting of acne, hyperhidrosis, unwanted sweating, bromhidrosis, body odor, chromhidrosis, excess sebum-producing disorders, seborrhea, seborrheic dermatitis, rosacea, hair loss, psoriasis, dermal infections, viral. . . CLM What is claimed is: . . . of claim 1, wherein the condition or disorder associated with a dermal structure is selected from the group consisting of acne, hyperhidrosis, unwanted sweating, bromhidrosis, body odor, chromhidrosis, excess sebum-producing disorders, seborrhea, seborrheic dermatitis, rosacea, hair loss, psoriasis, dermal infections, viral. . . CLM What is claimed is: 77. The method of claim 75, wherein the condition or disorder is acne, hyperhidrosis, bromhidrosis, unwanted sweating, body odor, hair loss, or any combination thereof.

CLM What is claimed is: . . . wherein the step of administering comprises administering the at least one isolated component of an empty nanoparticle composition so that acne one or more symptoms is reduced or onset is delayed.

Page 113 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 42 OF 199 USPATFULL on STN ACCESSION NUMBER: 2012:360563 USPATFULL Full-text TITLE: SURFACTANT COMPOSITIONS INVENTOR(S): EDELSON, Jonathan, Scarsdale, NY, UNITED STATES KOTYLA, Timothy, Lowell, MA, UNITED STATES THEOBALD, Klaus, Paoli, PA, UNITED STATES PATENT ASSIGNEE(S): ANTERIOS, INC., New York, NY, UNITED STATES (U.S. corporation)

NUMBER KIND DATE ------PATENT INFORMATION: US 20120321579 A1 20121220 [Family] APPLICATION INFO.: US 2012-356629 A1 20120123 (13)

NUMBER DATE ------PRIORITY INFORMATION: US 2011-435756P 20110124 (61) AB The present invention provides surfactant compositions and associated methods and reagents, particularly useful for the treatment of dermatologic conditions. In some embodiments, provided compositions are formulated for and achieve transdermal delivery, for example by topical administration. SUMM . . . surprising discovery, the present invention provides a teaching that certain surfactant agents are useful in the treatment and/or prevention of acne. In a still further surprising discovery, the present invention provides a teaching that certain surfactant agents are useful in the. . . SUMM . . . disorders, or conditions include, but are not limited to, a condition associated with sweat glands or sebaceous glands, such as acne; hyperhidrosis; unwanted sweating; bromhidrosis; body odor; chromhidrosis; hair loss; psoriasis; actinic keratosis; dermal infection; eczematous dermatitis (e.g., atopic dermatitis, etc.);. . . SUMM . . . form of reducing the frequency of that symptom. To give but a few examples, where the condition in question is acne, symptoms of that condition are reduced when the (e.g., diameter, volume, etc.) and/or severity (e.g., redness, inflammatory response, etc.) of. . . DETD In some embodiments, the present invention provides methods and compositions for the treatment and/or prevention of one or more of acne, unwanted sweating, body odor, hyperhidrosis, bromhidrosis, chromhidrosis, rosacea, hair loss, psoriasis, actinic keratosis, eczematous dermatitis (e.g., atopic dermatitis, etc.), excess. . . DETD . . . some permanent redness with papules and/or pustules, which typically last 1 to 4 days. This subtype is commonly confused with acne. "Phymatous rosacea" is most commonly associated with rhinophyma, an enlargement of the nose. Symptoms include thickening skin, irregular surface nodularities,. . . DETD Acne DETD In some embodiments, provided compositions are useful for treating and/or preventing acne vulgaris (commonly referred to as "acne"), a skin disease caused by changes in the pilosebaceous units (i.e., skin structures comprising a hair follicle and its associated sebaceous gland). In some embodiments, acne is inflammatory. In some embodiments, acne is noninflammatory. While not life-threatening, acne vulgaris can cause significant problems for affected individuals. Depending on its severity and other factors, recalcitrant acne can be psychologically debilitating, and can impose significant financial and emotional costs on those whom it afflicts. Despite some recent successes in acne therapy, treatment failures are still common, especially in adult women. While many adults "outgrow" this disease, there are some who continue to be afflicted during much of adulthood, despite continued medical advances. Unfortunately, the most potent acne medication in

Page 114 of 158

Science IP Order: 3550000 Client Reference: 3456-789

current use is administered systemically via a treatment that is teratogenic, an important issue for many women. There is an unfilled need for a more localized and effective treatment for acne, one with minimal side effects. DETD In general, acne develops as a result of blockages in follicles. The pathology centers on the pilosebaceous units, comprising a sebaceous gland, a follicle (i.e., pore), and a vellus hair. Among the first events leading to acne are hyperkeratinization and formation of a plug of keratin and sebum (a "microcomedo"), obstructing the upper region of a follicle.. . . an increase in sebum production occur with increased androgen production at adrenarche. A microcomedo may enlarge to form an open comedo (a "blackhead") or closed comedo (a "whitehead"). In these conditions the naturally occurring largely commensual bacteria Propionibacterium acnes can cause inflammation, leading to inflammatory lesions (papules, infected pustules, or nodules) in the dermis around the microcomedo or comedo, which results in redness and may result in scarring or hyperpigmentation. DETD . . . sulfate (DHEAS). Increased androgen levels are thought to cause sebaceous glands to enlarge and to increase sebum production. While most acne patients have normal hormone levels, there are reasons to conclude that increased sebum production plays a role in acne. For example, there may be a correlation between the rate of sebum production and the severity of acne. In addition, acne patients typically produce sebum that is deficient in linoleic acid, which is a potential cause of abnormal keratinization and follicular. . . DETD . . . acnes, a relatively slow growing, typically aerotolerant anaerobic gram positive, diphtheroid bacterium, often colonizes the sebaceous follicles. P. acnes exacerbates acne by acting as a chemo-attractant for neutrophils. Neutrophils ingest P. acnes, and in doing so release various hydrolytic enzymes that. . . DETD Follicles are lined with squamous epithelium, a layer of cells that is contiguous with the skin surface. In an acne-prone individual, the shedding of cells from this lining is often impeded, perhaps due to an increased level of intercellular adhesion that promotes the retention of cells. Retained cells can obstruct follicles, resulting in comedones. Such inhibited shedding may be related to abnormalities in epidermal differentiation and/or to abnormal sebum composition (e.g., a deficiency in. . . can irritate keratinocytes, causing the release of interleukin-1, which in turn can cause follicular hyperkeratinization. In general, each of these acne-causing routes, which are not mutually exclusive, is associated with follicular obstruction. DETD Several factors are known to be linked to acne, including, but not limited to, family and/or genetic history (see, e.g., Ballanger et al., 2006, Dermatology, 212:145-149; incorporated herein by. . . DETD In some embodiments, acne treatments work via one or more of the following mechanisms: (1) normalizing shedding into the pore to prevent blockage; (2). . . DETD The present invention provides methods of treating and/or preventing acne comprising administration of a provided composition to a subject suffering from, susceptible to, and/or displaying symptoms of acne. In some embodiments, such a provided composition is administered locally to an affected site (e.g., face, neck, back, arms, chest,. . . DETD In some embodiments, provided compositions for treatment of acne are formulated into a cream, liniment, lotion, gel, sunscreen, etc. DETD Exemplary current treatments for acne include, but are not limited to, botulinum toxin, cleansers or soaps; topical bactericidals (e.g., benzoyl peroxide, triclosan, chlorhexidine gluconate, etc.); topical antibiotics (e.g., externally-applied erythromycin, clindamycin, tetracycline, etc.); oral antibiotics (e.g., erythromycin, tetracycline, oxytetracycline, doxycycline, minocycline,. . . ibuprofen, rofecoxib

Page 115 of 158

Science IP Order: 3550000 Client Reference: 3456-789

[Tehrani and Dharmalingam, 2004, Indian J. Dermatol. Venereol. Leprol., 70:345-348; incorporated herein by reference], etc.); nicotinamide [vitamin B3]; tea tree oil [melaleuca oil]; rofecoxib; zinc (Dreno et al., 1989, Acta Derm. Venereol., 69:541-3; and Dreno et al., 2001, Dermatology, 203:135-40;. . . DETD Alternative or additional current therapies for the treatment and/or prevention of acne include, but are not limited to, phototherapy (e.g., alternating blue and red light); photodynamic therapy (e.g., intense blue/violet light); laser. . . DETD It is known in the art that short-term improvement of acne can be achieved with sunlight, but studies have shown that sunlight worsens acne long-term. More recently, visible light has been successfully employed to treat acne (i.e., "phototherapy")--in particular, intense violet light (405 nm-420 nm) generated by purpose-built fluorescent lighting, dichroic bulbs, LEDs, and/or lasers. Used twice weekly, this has been shown to reduce the number of acne lesions by about 64% (Kawada et al., 2002, J. Dermatol. Sci., 30:129-35; incorporated herein by reference) and is even more. . . DETD . . . some evidence that photodynamic therapy (e.g., therapy with intense blue/violet light (405 nm-425 nm)) can decrease the number of inflammatory acne lesion by 60%-70% in 4 weeks of therapy, particularly when P. acnes is pretreated with delta-aminolevulinic acid (ALA), which increases. . . DETD Laser surgery has been in use for some time to reduce the scars left behind by acne, but research has been done on lasers for prevention of acne formation itself. In general, laser is used to burn away the follicle sac from which the hair grows, to burn. . . DETD Local heating therapies are sometimes used, for example, to kill bacteria in a developing pimple, thereby expediting healing. DETD In some embodiments, provided compositions for treatment and/or prevention of acne are formulated into a cream, liniment, lotion, gel, sunscreen, etc. DETD In some embodiments, provided compositions for treatment and/or prevention of acne are administered locally to an affected site (e.g., axillae, hands, feet, face, neck, back, arms, chest, etc.). DETD . . . the skin. Hyperpigmentation is often due to skin damage due to sun exposure, medications, and/or inflammation (including inflammation due to acne vulgaris). Melasma is a condition of dark, irregular patches of skin found most usually on the upper cheek, nose, lips,. . . CLM What is claimed is: . . . susceptible to hyperhidrosis; suffering from or susceptible to chromhidrosis; suffering from or susceptible to bromhidrosis; suffering from or susceptible to acne; suffering from or susceptible to seborrhea; suffering from or susceptible to psoriasis; suffering from or susceptible to body odor; or. . . CLM What is claimed is: . . . The method of claim 14, wherein the active component further includes one or more additional active agents for treatment of acne, unwanted sweating, hyperhidrosis, body odor, bromhidrosis, chromhidrosis, rosacea, hair loss, psoriasis, actinic keratosis, eczematous dermatitis, excess sebum-producing disorders, burns, Raynaud's. . . CLM What is claimed is: 30. The method of claim 14, wherein the active component further includes an anti-acne agent selected from the group consisting of a topical bactericidal, a topical antibiotic, a topical retinoid, and combinations thereof.

Page 116 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 43 OF 199 USPATFULL on STN ACCESSION NUMBER: 2012:360555 USPATFULL Full-text TITLE: PARABEN COMPOSITIONS INVENTOR(S): EDELSON, Jonathan, Scarsdale, NY, UNITED STATES KOTYLA, Timothy, Lowell, MA, UNITED STATES THEOBALD, Klaus, Paoli, PA, UNITED STATES PATENT ASSIGNEE(S): ANTERIOS, INC., New York, NY, UNITED STATES (U.S. corporation)

NUMBER KIND DATE ------PATENT INFORMATION: US 20120321571 A1 20121220 [Family] APPLICATION INFO.: US 2012-356627 A1 20120123 (13)

NUMBER DATE ------PRIORITY INFORMATION: US 2011-435760P 20110124 (61) AB The present invention provides paraben compositions and associated methods and reagents, particularly useful for the treatment of dermatologic conditions. In some embodiments, provided compositions are formulated for and achieve transdermal delivery, for example by topical administration. SUMM . . . surprising discovery, the present invention provides a teaching that certain paraben agents are useful in the treatment and/or prevention of acne. In a still further surprising discovery, the present invention provides a teaching that certain paraben agents are useful in the. . . SUMM . . . disorders, or conditions include, but are not limited to, a condition associated with sweat glands or sebaceous glands, such as acne; hyperhidrosis; unwanted sweating; bromhidrosis; body odor; chromhidrosis; hair loss; psoriasis; actinic keratosis; dermal infection; eczematous dermatitis (e.g., atopic dermatitis, etc.);. . . SUMM . . . form of reducing the frequency of that symptom. To give but a few examples, where the condition in question is acne, symptoms of that condition are reduced when the (e.g., diameter, volume, etc.) and/or severity (e.g., redness, inflammatory response, etc.) of. . . DETD In some embodiments, the present invention provides methods and compositions for the treatment and/or prevention of one or more of acne, unwanted sweating, body odor, hyperhidrosis, bromhidrosis, chromhidrosis, rosacea, hair loss, psoriasis, actinic keratosis, eczematous dermatitis (e.g., atopic dermatitis, etc.), excess. . . DETD . . . some permanent redness with papules and/or pustules, which typically last 1 to 4 days. This subtype is commonly confused with acne. "Phymatous rosacea" is most commonly associated with rhinophyma, an enlargement of the nose. Symptoms include thickening skin, irregular surface nodularities,. . . DETD Acne DETD In some embodiments, provided compositions are useful for treating and/or preventing acne vulgaris (commonly referred to as "acne"), a skin disease caused by changes in the pilosebaceous units (i.e., skin structures comprising a hair follicle and its associated sebaceous gland). In some embodiments, acne is inflammatory. In some embodiments, acne is noninflammatory. While not life-threatening, acne vulgaris can cause significant problems for affected individuals. Depending on its severity and other factors, recalcitrant acne can be psychologically debilitating, and can impose significant financial and emotional costs on those whom it afflicts. Despite some recent successes in acne therapy, treatment failures are still common, especially in adult women. While many adults "outgrow" this disease, there are some who continue to be afflicted during much of adulthood, despite continued medical advances. Unfortunately, the most potent acne medication in

Page 117 of 158

Science IP Order: 3550000 Client Reference: 3456-789

current use is administered systemically via a treatment that is teratogenic, an important issue for many women. There is an unfilled need for a more localized and effective treatment for acne, one with minimal side effects. DETD In general, acne develops as a result of blockages in follicles. The pathology centers on the pilosebaceous units, comprising a sebaceous gland, a follicle (i.e., pore), and a vellus hair. Among the first events leading to acne are hyperkeratinization and formation of a plug of keratin and sebum (a "microcomedo"), obstructing the upper region of a follicle.. . . an increase in sebum production occur with increased androgen production at adrenarche. A microcomedo may enlarge to form an open comedo (a "blackhead") or closed comedo (a "whitehead"). In these conditions the naturally occurring largely commensual bacteria Propionibacterium acnes can cause inflammation, leading to inflammatory lesions (papules, infected pustules, or nodules) in the dermis around the microcomedo or comedo, which results in redness and may result in scarring or hyperpigmentation. DETD . . . sulfate (DHEAS). Increased androgen levels are thought to cause sebaceous glands to enlarge and to increase sebum production. While most acne patients have normal hormone levels, there are reasons to conclude that increased sebum production plays a role in acne. For example, there may be a correlation between the rate of sebum production and the severity of acne. In addition, acne patients typically produce sebum that is deficient in linoleic acid, which is a potential cause of abnormal keratinization and follicular. . . DETD . . . acnes, a relatively slow growing, typically aerotolerant anaerobic gram positive, diphtheroid bacterium, often colonizes the sebaceous follicles. P. acnes exacerbates acne by acting as a chemo-attractant for neutrophils. Neutrophils ingest P. acnes, and in doing so release various hydrolytic enzymes that. . . DETD Follicles are lined with squamous epithelium, a layer of cells that is contiguous with the skin surface. In an acne-prone individual, the shedding of cells from this lining is often impeded, perhaps due to an increased level of intercellular adhesion that promotes the retention of cells. Retained cells can obstruct follicles, resulting in comedones. Such inhibited shedding may be related to abnormalities in epidermal differentiation and/or to abnormal sebum composition (e.g., a deficiency in. . . can irritate keratinocytes, causing the release of interleukin-1, which in turn can cause follicular hyperkeratinization. In general, each of these acne-causing routes, which are not mutually exclusive, is associated with follicular obstruction. DETD Several factors are known to be linked to acne, including, but not limited to, family and/or genetic history (see, e.g., Ballanger et al., 2006, Dermatology, 212:145-149; incorporated herein by. . . DETD In some embodiments, acne treatments work via one or more of the following mechanisms: (1) normalizing shedding into the pore to prevent blockage; (2). . . DETD The present invention provides methods of treating and/or preventing acne comprising administration of a provided composition to a subject suffering from, susceptible to, and/or displaying symptoms of acne. In some embodiments, such a provided composition is administered locally to an affected site (e.g., face, neck, back, arms, chest,. . . DETD In some embodiments, provided compositions for treatment of acne are formulated into a cream, liniment, lotion, gel, sunscreen, etc. DETD Exemplary current treatments for acne include, but are not limited to, botulinum toxin, cleansers or soaps; topical bactericidals (e.g., benzoyl peroxide, triclosan, chlorhexidine gluconate, etc.); topical antibiotics (e.g., externally-applied erythromycin, clindamycin, tetracycline, etc.); oral antibiotics (e.g., erythromycin, tetracycline, oxytetracycline, doxycycline, minocycline,. . . ibuprofen, rofecoxib

Page 118 of 158

Science IP Order: 3550000 Client Reference: 3456-789

[Tehrani and Dharmalingam, 2004, Indian J. Dermatol. Venereol. Leprol., 70:345-348; incorporated herein by reference], etc.); nicotinamide [vitamin B3]; tea tree oil [melaleuca oil]; rofecoxib; zinc (Dreno et al., 1989, Acta Derm. Venereol., 69:541-3; and Dreno et al., 2001, Dermatology, 203:135-40;. . . DETD Alternative or additional current therapies for the treatment and/or prevention of acne include, but are not limited to, phototherapy (e.g., alternating blue and red light); photodynamic therapy (e.g., intense blue/violet light); laser. . . DETD It is known in the art that short-term improvement of acne can be achieved with sunlight, but studies have shown that sunlight worsens acne long-term. More recently, visible light has been successfully employed to treat acne (i.e., "phototherapy")--in particular, intense violet light (405 nm-420 nm) generated by purpose-built fluorescent lighting, dichroic bulbs, LEDs, and/or lasers. Used twice weekly, this has been shown to reduce the number of acne lesions by about 64% (Kawada et al., 2002, J. Dermatol. Sci., 30:129-35; incorporated herein by reference) and is even more. . . DETD . . . some evidence that photodynamic therapy (e.g., therapy with intense blue/violet light (405 nm-425 nm)) can decrease the number of inflammatory acne lesion by 60%-70% in 4 weeks of therapy, particularly when P. acnes is pretreated with delta-aminolevulinic acid (ALA), which increases. . . DETD Laser surgery has been in use for some time to reduce the scars left behind by acne, but research has been done on lasers for prevention of acne formation itself In general, laser is used to burn away the follicle sac from which the hair grows, to burn. . . DETD Local heating therapies are sometimes used, for example, to kill bacteria in a developing pimple, thereby expediting healing. DETD In some embodiments, provided compositions for treatment and/or prevention of acne are formulated into a cream, liniment, lotion, gel, sunscreen, etc. DETD In some embodiments, provided compositions for treatment and/or prevention of acne are administered locally to an affected site (e.g., axillae, hands, feet, face, neck, back, arms, chest, etc.). DETD . . . the skin. Hyperpigmentation is often due to skin damage due to sun exposure, medications, and/or inflammation (including inflammation due to acne vulgaris). Melasma is a condition of dark, irregular patches of skin found most usually on the upper cheek, nose, lips,. . . CLM What is claimed is: . . . susceptible to hyperhidrosis; suffering from or susceptible to chromhidrosis; suffering from or susceptible to bromhidrosis; suffering from or susceptible to acne; suffering from or susceptible to seborrhea; suffering from or susceptible to psoriasis; suffering from or susceptible to body odor; or. . . CLM What is claimed is: . . . The method of claim 14, wherein the active component further includes one or more additional active agents for treatment of acne, unwanted sweating, hyperhidrosis, body odor, bromhidrosis, chromhidrosis, rosacea, hair loss, psoriasis, actinic keratosis, eczematous dermatitis, excess sebum-producing disorders, burns, Raynaud's. . . CLM What is claimed is: 30. The method of claim 14, wherein the active component further includes an anti-acne agent selected from the group consisting of a topical bactericidal, a topical antibiotic, a topical retinoid, and combinations thereof.

Page 119 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 44 OF 199 USPATFULL on STN ACCESSION NUMBER: 2012:273993 USPATFULL Full-text TITLE: REVERSELY THERMO-REVERSIBLE HYDROGEL COMPOSITIONS INVENTOR(S): Lu, Shao Xiang, Shanghai, CHINA Lu, Jeffrey, Shanghai, CHINA Liu, Letian, Shanghai, CHINA PATENT ASSIGNEE(S): Broda Technologies Co., Ltd., Shanghai, CHINA (non-U.S. corporation)

NUMBER KIND DATE ------PATENT INFORMATION: US 20120244097 A1 20120927 [Family] APPLICATION INFO.: US 2012-425923 A1 20120321 (13) RELATED APPLN. INFO.: Continuation of Ser. No. WO 2011-CN462, filed on 21 Mar 2011, PENDING AB A reversely thermo-reversible hydrogel composition comprising a water soluble block copolymer comprising at least two blocks of polyethylene oxide and at least one block of polypropylene oxide, and at least one associative gelling adjuvant having water less than 0.5 g/100 ml, preferably less than 0.3 g/100 ml at 20° C., and being capable of forming water soluble inter- molecular complexes with the water soluble block copolymer in water. The hydrogel composition exhibits improved gelling efficiency, enhanced solubility and/or stability for water sparely soluble and insoluble pharmaceutical agents. The hydrogel compositions are useful in a variety of pharmaceutical and cosmetic products and applications, such as esophageal, otic, vaginal, rectal, ophthalmic, treatments of disorders and imperfections of the skin, and treating and/or preventing alopecia and restoring and/or promoting hair growth. SUMM . . . active ingredients in such aqueous liquid solutions. For example, the use of Salicylic acid or its derivatives for treating , acne, skin wrinkling, skin pigmentation, warts, freckles, or skin-related problems is well known in the preparation of dermatologic and cosmetic formulations.. . . DETD . . . stabilize sparely soluble or insoluble active ingredients. For example, the use of Salicylic acid or its derivatives for treating dandruff, acne, skin wrinkling, skin pigmentation, warts, freckles, or skin-related problems is well known in the preparation of dermatologic and cosmetic formulations.. . . DETD . . . Botulinum toxin, interferon, substance P enkephalins, epidermal growth factor, eyederived growth factor, fibronectin, insulin-like growth factor and mesodermal growth factor; (17) Acne treatment agents, such as salicylic acid and its derivatives, sulfur, lactic acid, glycolic, pyruvic acid, azelaic acid, benzoyl peroxide, urea,. . . DETD . . . composition of cosmetic active ingredients. The cosmetic may be skincare products such as facial hydrogel, hands and foot care hydrogels; acne treatment hydrogel, shaving hydrogel, cleansing hydrogel; antiperspirant; hair remover hydrogel, tooth whitening hydrogel, color makeup products such as makeup base,. . . DETD . . . compositions of the present invention can be essential oils, moisture retention agents, skin-beautifying agents, sun screen, antiperspirants, vitamins, amino acids, anti-acne agents, or antibacterial agents, zinc salts, tooth whitening agents, depilatory agents, fragrance oils, insect repellants, antioxidants, chelating agents, refrigerants,. . . or the nucleic acids include deoxyribonucleic acid; and examples of the hormones include estradiol and ethenyl estradiol, and the like; (8) Anti-acne agents, such as salicylic acid and its derivatives, sulfur, lactic acid, glycolic, pyruvic acid, azelaic acid, benzoyl peroxide, urea, tea tree oil, resorcinol and N-acetylcysteine, and retinoids,

Page 120 of 158

Science IP Order: 3550000 Client Reference: 3456-789

such as retinoic acid, and its derivatives, and the like; (9) Antiseptics or antibacterial agents. . . DETD The following ACNE treatment hydrogel compositions are prepared: CLM What is claimed is: . . . agents, amoebacidal compounds, trichomonacidal agents, analgesics, anti-arthritics, anti-asthmatics, anti-coagulants, anti-convulsants, anti-depressants, anti-diabetics, anti-neoplastics, anti-psychotics, anti-hypertensive agents, muscle relaxants, proteins, peptides, acne treatment agents, lubricating agents, and mixtures thereof.

CLM What is claimed is: 29. The composition of claim 20, comprising an acne treatment pharmaceutical hydrogel composition.

CLM What is claimed is: 30. The composition of claim 29, wherein the acne treatment pharmaceutical hydrogel composition comprising at least one acne treatment agent is selected from the group consisting of salicylic acid or its derivatives, sulfur, lactic acid, glycolic acid, pyruvic acid, azelaic acid, benzoyl peroxide, urea, resorcinol, N-acetylcysteine, retinoids and their derivatives, and mixtures thereof.

CLM What is claimed is: 31. The composition of claim 30, wherein the acne treatment agent is salicylic acid, or its derivatives.

CLM What is claimed is: 32. The composition of claim 29, wherein the acne treatment pharmaceutical hydrogel comprising an alcohol-free composition.

CLM What is claimed is: . . . is selected from the group consisting of essential oils, moisture retention agents, skin-beautifying agents, sun screens, antiperspirants, vitamins, amino acids, anti-acne agents, antiseptics, antibacterial agents, zinc salts, tooth whitening agents, depilatory agents, fragrance oils, insect repellants, antioxidants, chelating agents, refrigerants, anti-inflammatory. . . CLM What is claimed is: . . . tooth whitening, and antibacterial, depilatory, antiperspirant or deodorant, insect repellant, perfume, sunscreen, baby diaper rash, shaving, hair coloring, and anti-acne cosmetic hydrogel compositions.

CLM What is claimed is: 59. The composition of claim 53, wherein the at least one cosmetic active ingredient is an anti-acne agent selected from the group consisting of salicylic acid and its derivatives, sulfur, lactic acid, glycolic acid, pyruvic acid, azelaic acid, benzoyl peroxide, urea, tea tree oil, resorcinol and N-acetylcysteine, retinoids and their derivatives, and mixtures thereof.

CLM What is claimed is: 60. The composition of claim 59, wherein the anti-acne agent (s) is salicylic acid or its derivatives.

Page 121 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 45 OF 199 USPATFULL on STN ACCESSION NUMBER: 2012:205728 USPATFULL Full-text TITLE: HIGH LOAD DISPERSIONS INVENTOR(S): Supamahitorn, Jai, Buffalo, NY, UNITED STATES McMillan, Lauren, Hamburg, NY, UNITED STATES PATENT ASSIGNEE(S): AUSTIN RESEARCH LABS CORP., Buffalo, NY, UNITED STATES (U.S. corporation)

NUMBER KIND DATE ------PATENT INFORMATION: US 20120183588 A1 20120719 [Family] APPLICATION INFO.: US 2012-350532 A1 20120113 (13)

NUMBER DATE ------PRIORITY INFORMATION: US 2011-432381P 20110113 (61) AB The present invention relates to the field of carrier and delivery systems for active molecular compounds. In particular, the present invention provides aqueous dispersions for delivery of active molecular compounds. SUMM . . . the present invention in the preparation of a medicament for treating one or more conditions including, but not limited to: acne, infection, wound infection, etc. DETD Embodiments of the present invention provide ointments, creams, lotions, gels, and or liquids for the topical treatment of acne in a subject. Such compositions find use in treatment of acne in infants, children, adolescents, teenagers, and/or adults would suffer from various forms of acne. In some embodiments, acne-treatment compositions find use in treating and/or killing Propionibacterium acnes, Staphylococcus aureus, etc. In some embodiments, the active agent in acne treatment compositions include, but are not limited to: , hydrophobically modified salicylate, salicylic acid, benzoyl peroxide, acetone, tea tree oil, isotretinoin (for rosasea, cystic acne), allantoin. DETD . . . anti-itch treatment. Active agents in anti-itch treatment compositions include, but are not limited to: benzethonium chloride, isotretinoin (for rosasea, cystic acne), clotrimazole, steroids (), hydrocortisone, allantoin, econasole nitrate, etc.

Page 122 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 132 OF 199 PCTFULL COPYRIGHT 2013 LNU on STN ACCESSION NUMBER: 2012177986 PCTFULL Full-text ENTRY DATE: 20121231 TITLE (ENGLISH): CONJUGATE-BASED ANTIFUNGAL AND ANTIBACTERIAL PRODRUGS TITLE (FRENCH): PROMEDICAMENTS ANTIFONGIQUES ET ANTIBACTERIENS A BASE D'UN CONJUGUE INVENTOR(S): BAPAT, Abhijit S., C-5/128, Milan Vihar, 72 I.P. Extension, Patparganj, Delhi 110092, IN, [NAT: IN, RES: IN], for US only MAHESH, Gauthami, 5-C, Sanchar Lok, Near Max Hospital, Patparganj, East Delhi 110092, IN, [NAT: IN, RES: IN], for US only GOKHALE, Rajesh S., Director's Bunglow, Type VI-I, CRRI Colony, C.V. Raman Marg, Maharani Bagh, New Delhi 110065, IN, [NAT: IN, RES: IN], for US only SHAH, Sayali S., 5-C, Sanchar Lok, Near Max Hospital, Patparganj, East Delhi 110092, IN, [NAT: IN, RES: IN], for US only SENGUPTA, Shiladitya, 606 South Street, Apt. #C, Waltham, Massachusetts 02453, US, [NAT: IN, RES: US], for US only PRASAD, Sudhanand, A/204, Eldeco Appartments, Sector 4, Vaishali, Ghaziabad, Uttar Pradesh 201010, IN, [NAT: IN, RES: IN], for US only GHOSH, Sumana, Ashoka Enclave, Dwarka Sector-11, Plot No-8A, Flat No. 2703, New Delhi 110065, IN, [NAT: IN, RES: IN], for US only CHAWRAI, Suresh R., 66, Vidhi Appartments, Plot No. 116, I.P. Extension, Patparganj, Delhi 110092, IN, [NAT: IN, RES: IN], for US only ARORA, Nidhi, G-1, Mansarover Garden (Ground Floor), New Delhi 110015, IN, [NAT: CA, RES: IN], for US only REDDY, D. Sreedhar, Ramachandrapuram, Nelakondapally (MD), Khammam (Dt), Andhra Pradesh 507160, IN, [NAT: IN, RES: IN], for US only MISHRA, Mallika, SF 66, Vardan Apartment, Abhaykhand 3, Module 19 & 20, Indirapuram, Ghaziabad 201014, IN, [NAT: IN, RES: IN], for US only BAJAJ, Kirti, H. No. 1135, Ward No. 9, Mandi Dabwali, Sirsa, Haryana 125104, IN, [NAT: IN, RES: IN], for US only PATENT APPLICANT(S): VYOME BIOSCIENCES, Plot No. 459 F.I.E., 1st Floor, Patparganj Industrial Area, Delhi 110092, IN, [NAT: IN, RES: IN], for all designated states except US BAPAT, Abhijit S., C-5/128, Milan Vihar, 72 I.P. Extension, Patparganj, Delhi 110092, IN, [NAT: IN, RES: IN], for US only MAHESH, Gauthami, 5-C, Sanchar Lok, Near Max Hospital, Patparganj, East Delhi 110092, IN, [NAT: IN, RES: IN], for US only GOKHALE, Rajesh S., Director's Bunglow, Type VI-I, CRRI Colony, C.V. Raman Marg, Maharani Bagh, New Delhi 110065, IN, [NAT: IN, RES: IN], for US only SHAH, Sayali S., 5-C, Sanchar Lok, Near Max Hospital, Patparganj, East Delhi 110092, IN, [NAT: IN, RES: IN], for US only SENGUPTA, Shiladitya, 606 South Street, Apt. #C, Waltham, Massachusetts 02453, US, [NAT: IN, RES: US], for US only PRASAD, Sudhanand, A/204, Eldeco Appartments, Sector 4,

Page 123 of 158

Science IP Order: 3550000 Client Reference: 3456-789

Vaishali, Ghaziabad, Uttar Pradesh 201010, IN, [NAT: IN, RES: IN], for US only GHOSH, Sumana, Ashoka Enclave, Dwarka Sector-11, Plot No-8A, Flat No. 2703, New Delhi 110065, IN, [NAT: IN, RES: IN], for US only CHAWRAI, Suresh R., 66, Vidhi Appartments, Plot No. 116, I.P. Extension, Patparganj, Delhi 110092, IN, [NAT: IN, RES: IN], for US only ARORA, Nidhi, G-1, Mansarover Garden (Ground Floor), New Delhi 110015, IN, [NAT: CA, RES: IN], for US only REDDY, D. Sreedhar, Ramachandrapuram, Nelakondapally (MD), Khammam (Dt), Andhra Pradesh 507160, IN, [NAT: IN, RES: IN], for US only MISHRA, Mallika, SF 66, Vardan Apartment, Abhaykhand 3, Module 19 & 20, Indirapuram, Ghaziabad 201014, IN, [NAT: IN, RES: IN], for US only BAJAJ, Kirti, H. No. 1135, Ward No. 9, Mandi Dabwali, Sirsa, Haryana 125104, IN, [NAT: IN, RES: IN], for US only PATENT INFORMATION: WO 2012177986 A2 20121227 APPLICATION INFO.: WO 2012-US43717 20120622 PRIORITY INFO.: IN 2011-DE1770 20110622 US 2011-61514305 20110802

ABEN The invention provides conjugate-based antifungal or antibacterial prodrugs formed by coupling at least one antifungal agent or antibacterial agent with at least one linker and/or carrier. The prodrugs are of formula: (i) (AFA)m-X-(L)n; (ii) [(AFA)m'-X]p-L; (iii) AFA-[X-(L)n']q; or (iv) (AFA)m"-X, wherein: AFA is an antifungal agent or an antibacterial agent; L is a carrier; X is a linker; m ranges from 1 to 10; n ranges from 2 to 10; m' is 1 to 10; p is 1 to 10; n' is 1 to 10; and q is 1 to 10, provided that q' and n are not both 1; and m" is 1 to 10. The invention also provides nonaprticels comprising the conjugate-based prodrugs. Additonoally, the invention also provides non-conjugated antifungal and antibacterial agents in the form of nanoparticles.

ABFR La presente invention concerne des promedicaments antifongiques ou antibacteriens a base d'un conjugue obtenus par couplage d'au moins un agent antifongique ou antibacterien avec au moins une sequence de liaison et/ou un support. Lesdits promedicaments sont de formule (i) (AFA)m-X-(L)n ; (ii) [(AFA)m'-X]p-L ; (iii) AFA-[X-(L)n']q ; ou (iv) (AFA)m »-X. Dans lesdites formules, AFA represente un agent antifongique ou antibacterien ; L represente un support ; X represente une sequence de liaison ; m varie de 1 a 10 ; n varie de 2 a 10 ; m' est egal a 1 a 10 ; p est egal a 1 a 10 ; n' est egal a 1 a 10 ; et q est egal a 1 a 10, sous reserve que q' et n ne soient pas tous deux egaux a 1 ; et m » est egal a 1 a 10. La presente invention concerne egalement des nanoparticules contenant lesdits promedicaments a base d'un conjugue. En outre, l'invention concerne egalement des agents antifongiques et antibacteriens non-conjugues se presentant sous la forme de nanoparticules.

DETDEN [0016] In yet another aspect, the invention provides a method for treating or preventing acne comprising applying a personal care compositions described herein to the skin of a subject in need thereof.

DETDEN . . . to treat or prevent dandruff. Compositions described herein can also be used in skin care compositions to treat or prevent acne. In some embodiments,

Page 124 of 158

Science IP Order: 3550000 Client Reference: 3456-789

the composition described herein can be used to treat a fugal or bacterial infection. For example, the. . .

DETDEN [0074] In some embodiments, the antibacterial agent is an antiacne agent. As used herein, the term "antiacne agent" refers to any chemical that is effective in the treatment of acne and/or the symptoms associated therewith. Antiacne agents are well known in the art such as U.S. Pat. App. Pub. No. 2006/ 0008538 and U.S. Pat. No. 5,607,980, content of both of which is incorporated herein by reference. Examples of useful antiacne agents include, but are not limited to keratolyses, such as salicylic acid, derivatives of salicylic acid, and resorcinol; retinoids, such. . . tretinoin, adapalene, tazarotene; sulfur-containing D- and L-amino acids and their derivatives and salts; lipoic acid; antibiotics and , such as benzoyl peroxide, triclosan, chlorhexidine gluconate, octopirox, tetracycline, 2,4,4'-trichloro-2'-hydroxy diphenyl ether, 3,4,4'-trichlorobanilide, nicotinamide, tea tree oil, rofecoxib, azelaic acid and its derivatives, phenoxyethanol,

DETDEN [0075] Additionally, the antiacne agent may be an antimicrobial peptide having activity against P. acnes. Antimicrobial peptides are ubiquitous in nature and play an. . .

DETDEN [00122] Beta hydroxyl acid (BHA) is oil-soluble. Accordingly, BHA works very well in clearing up whiteheads and blackheads by penetrating inside pores that are clogged with sebum and a buildup of dead cells. BHA is a powerful exfoliant. . .

DETDEN . . . new ones. It keeps the pores of the skin clear, hence minimizes clogging and actively breaks down all forms of acne. Salicylic acid loosens dry and damaged skin patches by softening epidermal protein- keratin. It remains on the skin surface long. . .

DETDEN . . . peel and shed, revealing new and smoother skin underneath. It is effective in clearing skin problems such as eczema, psoriasis, acne, and age spots; and helps stimulate collagen growth in the cells. One major side effect of AHA is increase in. . .

DETDEN . . . be incorporated into the compositions include those that improve or eradicate age spots, keratoses and wrinkles; local analgesics and anesthetics; antiacne agents; antibacterials; antiyeast agents; antifungal agents; antiviral agents; antidandruff agents; antidermatitis agents; antihistamine agents; antipruritic agents; antiemetics;

DETDEN . . . or salicylic acid. Triclosan can act as a protective agent that increases the longetivity and effectiveness of other treatments of acne.

DETDEN . . . peel and shed, revealing new and smoother skin underneath. It is effective in clearing skin problems such as eczema, psoriasis, acne, and age spots; and helps stimulate collagen growth in the cells. One major side effect of AHA is increase in. . .

DETDEN

Page 125 of 158

Science IP Order: 3550000 Client Reference: 3456-789

[00148] Beta hydroxyl acid (BHA) is oil-soluble. Accordingly, BHA works very well in clearing up whiteheads and blackheads by penetrating inside pores that are clogged with sebum and a buildup of dead cells. BHA is a powerful exfoliant. . .

DETDEN . . . new ones. It keeps the pores of the skin clear, hence minimizes clogging and actively breaks down all forms of acne. Salicylic acid loosens dry and damaged skin patches by softening epidermal protein- keratin. It remains on the skin surface long. . .

DETDEN . . . It has both exfoliating and anti-inflammatory effects. It is possibly more effective than tretinoin 0.025% gel in the treatment of acne.

DETDEN . . . embodiments, the personal care composition is a skin care composition. A skin care composition can be used to or prevent acne. Skin care compositions are herein defined as compositions for the treatment of skin including, but not limited to, skin conditioners,. . .

DETDEN . . . as alpha-hydroxy acids and beta-hydroxy acids), and sunless tanning agents. Examples of common raw materials and suitable adjuvants for an acne treatment composition are described by Beumer et al. supra and Robinson et al., supra.

DETDEN [00228] In another aspect, a method is provided for treating or preventing acne, the method comprising applying a skin care composition described herein to the skin of subject in need thereof. After application,. . .

DETDEN [00234] In some embodiments, the subject needs treatment for dandruff and/or acne.

DETDEN [00236] A subject can be one who is currently being treated for dandruff , acne, oral or vaginal candidiasis, ringworm (tinea infections of the body, scalp, beard, jock itch, athlete's foot), nail infection, or ear. . .

DETDEN [00238] In some embodiments of the aspects described herein, the method further comprising diagnosing a subject for dandruff, acne, oral or vaginal candidiasis, ringworm (tinea infections of the body, scalp, beard, jock itch, athlete's foot), nail infection, or ear. . .

DETDEN The conjugate-based prodrug of any of paragraphs 1-17, wherein the antibacterial agent is effective against P. acne.

DETDEN . . . selected from the group consisting of those that improve or eradicate age spots, keratoses and wrinkles; local analgesics and anesthetics; antiacne agents; antibacterials; antiyeast agents; antifungal agents; antiviral agents; antidandruff agents; antidermatitis agents; antihistamine agents; antipruritic agents; antiemetics; antimotionsickness agents; antiinflammatory. . .

DETDEN

Page 126 of 158

Science IP Order: 3550000 Client Reference: 3456-789

49. A method for treating or preventing acne in a subject, the method comprising the step of applying a composition of any of paragraph 41-46 or 48 to. . .

DETDEN [00386] Minimum Inhibitory Concentration (MIC): MIC is an index which measures the anti-acne efficacy. Generally, lower the MIC values of the composition higher its antibacterial efficacy, because of its inherent ability to inhibit. . .

CLMEN The conjugate-based prodrug of any of claims 1 -17, wherein the antibacterial agent is effective against P. acne.

CLMEN. . . selected from the group consisting of those that improve or eradicate age spots, keratoses and wrinkles; local analgesics and anesthetics; antiacne agents; antibacterials; antiyeast agents; antifungal agents; antiviral agents; antidandruff agents; antidermatitis agents; antihistamine agents; antipruritic agents; antiemetics; antimotionsickness agents; antiinflammatory. . .

CLMEN 49. A method for treating or preventing acne in a subject, the method comprising the step of applying a composition of any of claim 41-46 or 48 to. . .

Page 127 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 133 OF 199 PCTFULL COPYRIGHT 2013 LNU on STN ACCESSION NUMBER: 2012177433 PCTFULL Full-text ENTRY DATE: 20121231 TITLE (ENGLISH): TOPICAL COMPOSITIONS FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS TITLE (FRENCH): COMPOSITIONS TOPIQUES DESTINEES AU TRAITEMENT DE TROUBLES DERMATOLOGIQUES INVENTOR(S): WEINBERGER, Gary, I., 1975 Dodge Road, East Amherst, NY 14051, US, [NAT: US, RES: US], for US only NAGEL, H., Robert, 21 Park Avenue, Newton, MA 02458, US, [NAT: US, RES: US], for US only BROWN, Richard, A., 2547 Lower Lando Lane, Park City, UT 84098, US, [NAT: US, RES: US], for US only PATENT APPLICANT(S): EVOLOGIE LLC, 21 Park Avenue, Newton, MA 02458, US, [NAT: US, RES: US], for all designated states except US WEINBERGER, Gary, I., 1975 Dodge Road, East Amherst, NY 14051, US, [NAT: US, RES: US], for US only NAGEL, H., Robert, 21 Park Avenue, Newton, MA 02458, US, [NAT: US, RES: US], for US only BROWN, Richard, A., 2547 Lower Lando Lane, Park City, UT 84098, US, [NAT: US, RES: US], for US only PATENT INFORMATION: WO 2012177433 A1 20121227 APPLICATION INFO.: WO 2012-US41895 20120611 PRIORITY INFO.: US 2011-61499523 20110621

ABEN The present invention relates to pharmaceutical compositions and methods useful for the treatment of dermatological disorders, and in particular acne vulgaris and skin pigmentation disorders. Pharmaceutical compositions comprising one or more arginine, salicylic acid and/or azelaic acid that are useful for the treatment of dermatological diseases and the symptoms and underlying causes of such dermatological diseases are also disclosed.

ABFR La presente invention concerne des compositions pharmaceutiques et des procedes utiles dans le traitement de troubles dermatologiques, et en particulier de l'acne simple et des troubles de pigmentation de la peau. La presente invention concerne des compositions pharmaceutiques comprenant de l'arginine et/ou de l'acide salicylique et/ou de l'acide azelaique, utiles dans le traitement de maladies dermatologiques et des symptomes et causes sous-jacentes de ces maladies dermatologiques.

ABEN The present invention relates to pharmaceutical compositions and methods useful for the treatment of dermatological disorders, and in particular acne vulgaris and skin pigmentation disorders. Pharmaceutical compositions comprising one or more arginine, salicylic acid and/or azelaic acid that are useful. . .

ABFR. . . presente invention concerne des compositions pharmaceutiques et des procedes utiles dans le traitement de troubles dermatologiques, et en particulier de l'acne simple et des troubles de pigmentation de la peau. La presente invention concerne des compositions pharmaceutiques comprenant de l'arginine et/ou. . .

DETDEN . . . or more of arginine, salicylic acid and/or azelaic acid and are useful for the treatment of dermatological disorders, such as acne vulgaris and skin pigmentation disorders.

Page 128 of 158

Science IP Order: 3550000 Client Reference: 3456-789

DETDEN . . . dermatological disorders often associated with the production or over production of sebum are well known. One such dermatological disorder includes acne vulgaris (acne), which is the most common dermatological disorder treated by physicians. It is estimated that as many as 32 million Americans exhibit some form of unwanted acne. Acne affects more than eighty-five percent of teenagers, and although acne most commonly occurs during adolescence, the condition may commonly continue into adulthood. (William, J., N Engl J Med, (2005) 352:. . .

DETDEN Acne is an inflammatory dermatological disorder affecting the pilosebaceous units of affected subjects. Acne is cause by bacteria that infects the hair follicles, which in turn leads to the formation of comedones composed of sebum, keratin and further proliferation of microorganisms, which include for example, Propionibacierium acnes (P. acnes or P. acneis).. . . is further believed that P, acnes plays a role in the digestion of the sebum and keratin present in the comedones into inflammatory by-products which are responsible for further irritating the affected hair follicle, thereby resulting in further inflammation, the formation. . .

DETDEN In many affected subjects, acne scarring and/or post-inflammatory hyperpigmentation (PIH) occurs as a result of inflammation of the pilo-sebaceous unit (PSU), and in some cases. . . by PIH generally present with irregular, darkly-pigmented spots occurring after inflammation due to a skin insult such as, for example acne. In some individuals PIH may resolve slowly but may persist for months. (Kenney, J., et al, Clinics in Dermatology (1989). . .

DETDEN The complications of acne are not limited to the skin of affected subjects. The physical symptoms of acne may contribute to the development of emotional and psychological distress, depression, anxiety and increased risks of suicide. {See, e.g., Kilkenny. . . Paediat Child Health, (2006) 42:793-796.) The emotional distress which is caused by, or is otherwise aggravated by, the symptoms of acne may be particularly troublesome for adolescent subjects.

DETDEN Various topical agents are utilized in the treatment of acne and these include sulfur, resorcinol, salicylic acid, benzoyl peroxide, retinoids and topical antibiotics. For example, commercially available topical treatments include. . .

DETDEN Systemically available treatments have also been used to treat acne, including, for example such as minocycline. Generally, subjects are prescribed an extended course of antibiotic therapy and despite. . .

DETDEN Oral retinoids, such as isotretinoin, may also be effective; however their use is generally reserved for severe cases of acne due to the association of serious side effects, which may include teratogenicity, depression and suicidal ideation. Many of the available acne treatments are expensive and may cause considerable adverse effects. Furthermore, some medications may require continuous therapy and/or subjects may not. . .

DETDEN

Page 129 of 158

Science IP Order: 3550000 Client Reference: 3456-789

Novel and effective therapies are needed for the treatment of acne, and in particular novel topical therapies that improve symptoms in a safe, rapid and effective manner are needed. There is. . .

DETDEN . . . compositions, as well as methods for treating subjects afflicted with or otherwise affected by one or more dermatological disorders (e.g., acne vulgaris and/or post-inflammatory hyperpigmentation (Ρ1E)). The pharmaceutical compositions disclosed herein may be topically administered to a subject and are generally. . .

DETDEN . . . more dermatological disorders. Dermatological disorders for which the pharmaceutical compositions disclosed herein may be used to treat include, for example, acne, PIH, rosacea, dyspigmentation, uneven skin tones and melasma. The pharmaceutical composition may be administered to the subject at least once. . .

DETDEN . . . upon application to a subject the pharmaceutical compositions disclosed herein are preferably capable of improving the signs and symptoms of acne (e.g., reduce excessive sebum production and/or reduce hyperpigmentation caused by acne scarring). Accordingly, one aspect of the present inventions relates to methods of treating one or more dermatological disorders, including, but not limited to acne and PIH. For example, in one embodiment the present invention relates to a method of treating a subject with a. . . of azelaic acid, salicylic acid and arginine to a subject. The dermatological disorders to be treated may include, for example, acne and/or PIH. In one embodiment of the present invention, the treated subject is an adolescent or an adult. In one. . .

DETDEN . . . one embodiment of the present invention the signs and symptoms of the dermatological disorders (e.g., sebum production, the presence of acne lesions, inflammation, and/or scarring) improve or are otherwise resolved following the administration of the pharmaceutical compositions of the present invention. . .

DETDEN . . . relates to novel pharmaceutical compositions and related methods of use for the treatment of dermatological disorders, which include, for example, acne vulgaris, acne rosacea and dermatological pigmentation disorders such as post-inflammatory hyperpigmentation (P1H) and melasma. Such pharmaceutical compositions are generally stable and comprise. . .

DETDEN . . . other components of the pharmaceutical composition (e.g., therapeutically-active agents) into the skin of an affected subject (e.g., a subject with acne). In some embodiments, the inclusion of one or more arginine compounds in the pharmaceutical compositions of the present invention may. . .

DETDEN . . . in the amount of one or more therapeutically-active agents necessary to achieve one or more clinical endpoints (e.g., resolution of acne symptoms or reduced pigmentation). In one embodiment, the synergy demonstrated by the pharmaceutical compositions of the present invention enable a. . .

DETDEN . . . relates to the ability of one or more therapeutic compounds or agents to

Page 130 of 158

Science IP Order: 3550000 Client Reference: 3456-789

improve the objective signs and symptoms of acne (e.g., a statistically significant reduction in mean inflammatory lesion count, erythema severity, pigmentation, acne scarring and/or sebum production). In other embodiments of the present invention, therapeutic activity relates to a subject's subjective perception regarding. . .

DETDEN . . . acids. Azelaic acid is known for its anti-bacterial and comedolytic properties and has been used clinically for the treatment of acne and hyperpigmentation disorders. (Fitton, A., et al, Drugs (1991 ) 41 (5): 180-798.) Generally, azelaic acid is an effective and well-tolerated monotherapy in mild and moderate forms of acne and is comparable in its efficacy to other topical acne treatments, such as benzoyl peroxide. (Liu, R., et al, Arch. Dermatol. (2006) 142(8): 1047-1052.) Azelaic acid also inhibits the growth. . .

DETDEN . . . disorder" refers to any disease or condition of the skin, dermis, or any substructure therein. Dermatological disorders include, for example, acne vulgaris, pigmentation disorders such as post-inflammatory hyperpigmentation, dyspigmentation, melasma, uneven skin tone, or hyperpigmentation or dark spots resulting from aging or exposure to sunlight or ultraviolet radiation, acne rosacea, xeroderma, psoriasis, ectopic dermatitis, skin cancers, and any other disease or condition affecting the skin, dermis or structures therein.. . . by topically administering such compositions to a subject affected by such dermatological disorder. In certain embodiments, the dermatological disorder is acne vulgaris. Acne vulgaris is a dermatological disorder resulting from the action of hormones and other substances on a subject's sebaceous glands and hair follicles, which result in plugged pores and outbreaks of lesions commonly referred to as pimples. Acne is frequently referred to as a disease of the pilosebaceous units (PSU), which are found over most of the body.. . . each PSU consists of a sebaceous gland connected to a canal, called a follicle that contains a fine hair. Although acne is generally not viewed as a serious health threat, it can be a source of significant emotional distress and in. . .

DETDEN Subjects affected by acne frequently present with a variety of topical lesions. The basic acne lesion, called the comedone, is simply an enlarged and plugged hair follicle. If the plugged follicle, or comedone, stays beneath the skin, it is referred to as a closed comedone and produces a white bump referred to as a whitehead. A comedone that reaches the surface of the skin and opens up is referred to as an open comedone or blackhead because it looks black on the skin's surface.

DETDEN hyperpigmentation caused by acne scarring). In another embodiment, the present invention relates to the treatment of a subject with, for example, acne by topically administering on a regular basis (e.g., once daily) a topical pharmaceutical composition to the affected area of the. . .

DETDEN Preferably, a therapeutically effective amount is sufficient to significantly and positively modify the condition to be treated (e.g., acne) while minimizing or avoiding serious adverse effects.

DETDEN . . . lycopene). In some embodiments, the pharmaceutical compositions disclosed herein may also comprise one or more antibacterial agents (e.g., azelaic acid, benzoyl peroxide and/or tea tree oil).

Page 131 of 158

Science IP Order: 3550000 Client Reference: 3456-789

DETDEN . . . of a pharmaceutical composition in the form of a serum and that is useful for the treatment of, for example, acne.

DETDEN Approximately l OOg of acne serum was produced comprising a tripartite complex of azelaic acid, salicylic acid and arginine. Following exposure to freeze/thaw cycling at. . .

DETDEN A total of 60 subjects with acne vulgaris participated in a clinical trial designed to demonstrate the safety and efficacy of the pharmaceutical compositions of the present. . .

DETDEN In addition to a reduction in the presence of acne lesions, hyperpigmentation and acne scarring was also observed. No serious adverse reactions were observed or otherwise reported to the investigators during the investigation. The foregoing therefore provides that the compositions of the present invention provide an effective therapy for the treatment of acne and PIH, and in particular novel topical therapies that improve symptoms in a safe, rapid and effective manner.

CLMEN 43. The method of claim 42, wherein the dermatological disorder is acne vulgaris.

CLMEN 86. The method of claim 85, wherein the dermatological disorder is acne vulgaris.

CLMEN 91 . The method of claim 90, wherein the dermatological disorder is selected from the group consisting of acne vulgaris and post-inflammatory hyperpigmentation (PIH).

CLMEN. . . 125. The method of claims 90-124, wherein the symptoms of the dermatological disorder comprise one or more of sebum overproduction, comedones and acne scarring.

Page 132 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 134 OF 199 PCTFULL COPYRIGHT 2013 LNU on STN ACCESSION NUMBER: 2012174096 PCTFULL Full-text ENTRY DATE: 20121224 TITLE (ENGLISH): PERSONAL CARE COMPOSITIONS COMPRISING A DI-AMIDO GELLANT AND METHODS OF USING TITLE (FRENCH): COMPOSITIONS DE SOINS PERSONNELS COMPRENANT UN AGENT GELIFIANT DI-AMIDO ET PROCEDES D'UTILISATION INVENTOR(S): FERNANDEZ PRIETO, Susana, C/Hernan Cortes 45, 3-H, E-12578 Benicarlo-castellon, ES, [NAT: ES, RES: ES], for US only SMETS, Johan, Bollenberg 79, B-3210 Lubbeek, BE, [NAT: BE, RES: BE], for US only ESCUDER GIL, Beatriu, Monges, 26, E-12170 Sant Mateu-Castello, ES, [NAT: ES, RES: ES], for US only MIRAVET CELADES, Juan, Felipe, C/ Rio Cenia 8, 1-D, E-12005 Castellon, ES, [NAT: ES, RES: ES], for US only NEBOT CARDA, Vicent, Josep, C/ Pere Gil N2, 1-D, E-12540 Vila-real-Castellon, ES, [NAT: ES, RES: ES], for US only TANNER, Paul, Robert, 3325 Golden Fox Trail, Lebanon, OH 45036, US, [NAT: US, RES: US], for US only PATENT APPLICANT(S): THE PROCTER & GAMBLE COMPANY, One Procter & Gamble Plaza, Cincinnati, OH 45202, US, [NAT: US, RES: US], for all designated states except US FERNANDEZ PRIETO, Susana, C/Hernan Cortes 45, 3-H, E-12578 Benicarlo-castellon, ES, [NAT: ES, RES: ES], for US only SMETS, Johan, Bollenberg 79, B-3210 Lubbeek, BE, [NAT: BE, RES: BE], for US only ESCUDER GIL, Beatriu, Monges, 26, E-12170 Sant Mateu-Castello, ES, [NAT: ES, RES: ES], for US only MIRAVET CELADES, Juan, Felipe, C/ Rio Cenia 8, 1-D, E-12005 Castellon, ES, [NAT: ES, RES: ES], for US only NEBOT CARDA, Vicent, Josep, C/ Pere Gil N2, 1-D, E-12540 Vila-real-Castellon, ES, [NAT: ES, RES: ES], for US only TANNER, Paul, Robert, 3325 Golden Fox Trail, Lebanon, OH 45036, US, [NAT: US, RES: US], for US only PATENT INFORMATION: WO 2012174096 A2 20121220 APPLICATION INFO.: WO 2012-US42228 20120613 PRIORITY INFO.: US 2011-61496303 20110613 201161496303 61/496,303 US201161496303P

ABEN A personal care composition is disclosed comprising a di-amido gellant, wherein the di- amido gellant has a formula (I) wherein R1 and R2 are aminofunctional end-groups which may be the same or different, and L is a linking moiety of molecular weight from 14 to 500 g/mol. The personal care composition may take a variety of forms such as a leave-on composition or an emulsion and/or may comprise one or more actives or agents.

ABFR L'invention concerne une composition de soins personnels comprenant un agent gelifiant di-amido, dans lequel l'agent gelifiant di-amido a une formule (I) dans laquelle R1 et R2 sont des groupes terminaux aminofonctionnels qui peuvent etre identiques ou differents, et L est une fraction de liaison de masse moleculaire de 14 a 500 g/mole. La composition de soins personnels peut revetir une diversite de formes, telles qu'une composition a application sans

Page 133 of 158

Science IP Order: 3550000 Client Reference: 3456-789

rincage ou une emulsion et/ou peut comprendre un ou plusieurs actifs ou agents.

DETDEN . . . anti-wrinkle actives, anti-atrophy actives, , N-acyl amino acid compounds, retinoids, peptides, particulate materials, UV actives, photostabilizers, anti-cellulite agents, desquamation actives, anti-acne actives, antioxidants, radical scavengers, conditioning agents, anti-inflammatory agents, tanning actives, skin lightening agents, botanical extracts, antimicrobial actives, antifungal actives, antibacterial. . .

DETDEN . . . anti-wrinkle actives, anti-atrophy actives, flavonoids, N-acyl amino acid compounds, retinoids, peptides, particulate materials, UV actives, photostabilizers, anti-cellulite agents, desquamation actives, anti-acne actives, antioxidants, radical scavengers, conditioning agents, anti-inflammatory agents, tanning actives, skin lightening agents, botanical extracts, antimicrobial actives, antifungal actives, antibacterial. . .

DETDEN 17. Anti-Acne Actives

DETDEN The compositions of the present invention can comprise one or more anti-acne actives.

DETDEN Suitable anti-acne actives include, but are not limited to, resorcinol, sulfur, salicylic acid, retinoids such as retinoic acid and its derivatives, sulfur-containing amino acids and their derivatives and salts (e.g. , N-acetyl derivatives such as N-acetyl-L-cysteinc), and lipoic acid. Other suitable anti-acne actives may be chosen from (i) antibiotics and antimicrobials such as benzoyl peroxide, octopirox, tetracycline, 2,4,4'trichloro-2'-hydiOxy diphenyl ether, 3,4,4'- trichlorobanilide,. . . as flavonoids; and (iii) bile salts such as scymnol sulfate and its derivatives, deoxycholate, and cholate. Further examples of suitable anti-acne actives are described in U. S. Patent No. 5,607,980.

DETDEN . . . % to about 30%, 25%, 20%, 10%, 7%, 5%, or 3%, by weight of the composition, of one or more anti-acne compounds.

DETDEN Suitable actives useful herein include those selected from the group consisting of benzoyl peroxide, 3-hydroxy benzoic acid, glycolic acid, lactic acid, 4-hydroxy benzoic acid, 2- hydroxybutanoic acid, 2-hydroxypentanoic acid, 2-hydroxyhexanoic acid, phytic acid, lipoic. . . bitter orange, urea preparations, griseofulvin, 8- Hydroxyquinoline ciloquinol, thiobendazole, thiocarbamates, haloprogin, polyenes, hydroxypyridone, mo holine, , (such as terbinafine), tea tree oil, clove leaf oil, coriander, palmarosa, berberine, thyme red, cinnamon oil, cinnamic aldehyde, citronellic acid, hinokitol, ichthyol pale, ethylhexylglycerin, hexamidine. . .

DETDEN . . . be added to the composition herein. Examples of these functional classes include, but are not limited to: abrasives, absorbents, fragrances, anti-acne agents, anti- caking agents, antifoaming agents, antimicrobial agents (e.g. , iodopropyl butylcarbamate), antifungal agents, antioxidants, binders, buffering agents, bulking agents,. . .

Page 134 of 158

Science IP Order: 3550000 Client Reference: 3456-789

DETDEN . . . vessels and/or red blotchiness on mammalian skin, fine lines and wrinkles, dryness (e.g. , roughness, scaling, flak ing), cellulite, and acne.

CLMEN. . . anti-wrinkle actives, anti-atrophy actives, flavonoids, N-acyl amino acid compounds, retinoids, peptides, particulate materials, UV actives, photostabilizers, anti-cellulite agents, desquamation actives, anti-acne actives, anti-oxidants, radical scavengers, conditioning agents, anti-inflammatory agents, tanning actives, skin lightening agents, botanical extracts, antimicrobial actives, antifungal actives, antibacterial. . .

Page 135 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 135 OF 199 PCTFULL COPYRIGHT 2013 LNU on STN ACCESSION NUMBER: 2012092320 PCTFULL Full-text ENTRY DATE: 20120709 TITLE (ENGLISH): EYE TREATMENT TITLE (FRENCH): TRAITEMENT OCULAIRE INVENTOR(S): NICHAMIN, Louis, D., 103 Jefferson Street, Brookville, PA 15825, US, [NAT: US, RES: US], for all designated states PATENT APPLICANT(S): NICHAMIN, Louis, D., 103 Jefferson Street, Brookville, PA 15825, US, [NAT: US, RES: US], for all designated states PATENT INFORMATION: WO 2012092320 A2 20120705 APPLICATION INFO.: WO 2011-US67479 20111228 PRIORITY INFO.: US 2010-428043P 20101229

ABEN Methods and kits for treating or preventing an eye condition or for cleaning an eye area tissue are provided. A method of the invention includes administering an isoprenoidal essential oil to eye area tissue, chafing eye area tissue with an abrasive, and removing the abrasive. A kit according to the invention includes an isoprenoidal essential oil, an abrasive for chafing eye area tissue, and in instruction for use for treating an eye condition or cleansing an eye area tissue. The invention also includes a composition of matter comprising an isoprenoidal essential oil and a plurality of abrasive particles in ophthamologically acceptable base.

ABFR Cette invention concerne des methodes et des trousses pour traiter ou prevenir une affection oculaire ou pour nettoyer un tissu de la zone oculaire. La methode selon l'invention comprend l'administration d'une huile essentielle derivee d'isoprenoides au tissu de la zone oculaire, le frictionnement du tissu de la zone oculaire avec un abrasif, et l'elimination de l'abrasif. Une trousse selon l'invention comprend une huile essentielle derivee d'isoprenoides, un abrasif pour frictionner le tissu de la zone oculaire, et des instructions d'utilisation pour traiter une affection oculaire ou nettoyer un tissu de la zone oculaire. Cette invention concerne egalement une composition de matiere comprenant une huile essentielle derivee d'isoprenoides et une pluralite de particules abrasives dans une base acceptable sur le plan ophtalmologique.

DETDEN [00011] Although sometimes referred to as "acne rosacea" and confused with acne vulgaris (referred to commonly as "acne") because both cause irritation to the face, facial rosacea and acne are different, and therefore the treatments recommended to manage them are also different. [00012] Acne is the most common skin condition in the United States. While it can occur at any age, it most commonly affects teenagers and young adults. Facial rosacea is distinguished from acne vulgaris by the presence of non-inflammatory comedones (follicles filled with sebum and sloughed off cells; commonly referred to as "whiteheads" and "blackheads") with acne and their absence in facial rosacea.

DETDEN [00013] Although acne and rosacea sometimes co-exist in skin, they often occur do not overlap and dermatologists recommend different protocols for treatment of rosacea and acne. The goals with acne treatments are to reduce oil production, speed up skin turnover, control bacterial infection and reduce inflammation. In addition to cleansing the skin, acne may be treated with application of acetone, alcohol, antibiotics, astringents, benzoyl peroxide, retinoids and salicylic acid, and/or ingestion of oral. .

Page 136 of 158

Science IP Order: 3550000 Client Reference: 3456-789

.

DETDEN [00014] The effects of acne may be reduced but not eliminated by applying a sufficient amount of tea tree oil. Enshaieh et al. (Indian J.. . .

DETDEN 73(1 ):22-25) describe the difficulties of obtaining an acne treatment medicine that has an effect and is tolerated by patients. Enshaieh et al. report use of 5% tea tree oil to treat mild to moderate acne vulgaris and found that 5% tea tree oil was 3.55 times more effective in improving total acne lesions and 5.75 times more effective in reducing acne severity as measured by the Acne Severity Index (ASI). Bassett et al. (MedJAus), 1990, Oct. 15, 153(8):455-8 examined the effectiveness of 5% tea tree oil in reducing the number of inflamed and non-inflamed lesions in patients with acne. Application of 5% tea tree oil for twenty minutes two times a day for 45 minutes to patients suffering from acne reduced the number of lesions. The tea tree oil acted more slowly than the acne treatment (benzoyl peroxide) to which it was compared. Of note, even using frequent (e.g. twice daily) and relatively long application times over the course of many weeks, 5% tea tree oil treatment was of limited efficacy in treating acne.

DETDEN [00015] U.S. Patent Application Publication 2005/0037034 to Rhoades describes a composition for treating comedonal acne associated with acne vulgaris and inflammatory acne. The composition contains an acne treatment agent together with abrasive particles in a base. A method of using the agent is described. The face is buffed or otherwise treated with the agent using, for example, a hand-held vibratory device. The acne treatment agent can be, for example, benzoyl peroxide, salicylic acid, retinol, hydroxyl acid, or tea tree oil.

DETDEN [00016] Increasingly aggressive acne treatment modalities may be used, as shown by the use of oral medications such as isotretinoin, which has significant side effects on the entire body for individuals whose acne cannot be managed by other methods. Simple, effective and safe acne treatments are still lacking.

DETDEN [00017] These acne treatments tend to be harsh, and harsh treatments have traditionally been thought to worsen the symptoms of rosacea. In particular,. . .

DETDEN . . . the deeper layers of the skin. Epithelialization and collagen production are stimulated. It is used to counteract the effects of acne and photoaging and reduces acne scars, age spots, enlarged pores, fine lines, and the appearance of blemishes, other scars, stretch marks, undesired skin pigmentation, and. . .

DETDEN [00064] Other constituents may be added, either singularly or in combination, including but not limited to acne treatment agent, alcohol, animal extract, anti-oxidant agent, anti-parasitic agent, antiseptic agent, anti-bacterial agent, ash, astringent, balm, binder, bleaching agents, collagen. . .

Page 137 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L56 ANSWER 199 OF 199 IFIPAT COPYRIGHT 2013 IFI on STN AN 03035874 IFIPAT;IFIUDB;IFICDB Full-text TITLE: TOPICAL PRODUCT FORMULATIONS CONTAINING STRONTIUM FOR REDUCING SKIN IRRITATION; SIDE EFFECT REDUCTION INVENTOR(S): Hahn, Gary S., Cardiff by the Sea, CA Quick, Timothy W., San Diego, CA Thueson, David O., Poway, CA PATENT ASSIGNEE(S): Cosmederm Technologies, La Jolla, CA

NUMBER PK DATE ------PATENT INFORMATION: US 5804203 A 19980908 (CITED IN 057 LATER PATENTS) APPLICATION INFORMATION: US 1996-666978 19960620 (8) EXPIRATION DATE: 21 Dec 2014

GRANTED PATENT NO. APPLN. NUMBER DATE OR STATUS ------CONTINUATION-IN-PART OF: US 1994-362100 19941221 5716625 FAMILY INFORMATION: US 5804203 19980908 US 5716625 Reassigned OTHER SOURCE: CA 129:221022 ENTRY DATE: Entered STN: 15 Oct 1998

MICROFILM REEL NO: 008187 FRAME NO: 0186 008729 0641 009075 0431 010299 0036 010499 0614 011064 0991 013699 0103 013699 0115 013705 0735 AB Topical formulations comprising an anti-irritant amount of aqueous-soluble strontium (Sr2+) cation, and method for using the same to inhibit skin irritation are disclosed. ACLM . . . therapeutically active ingredient is selected from the group consisting of anti-inflammatory, antibiotic, local anesthetic, sunscreen, retinoid, antiperspirant, antihistamine, analgesic, contraceptive, anti-acne and anti-dandruff ingredients. . . . therapeutically active ingredient is selected from the group consisting of anti-inflammatory, antibiotic, local anesthetic, sunscreen, retinoid, antiperspirant, antihistamine, analgesic, contraceptive, anti-acne and anti-dandruff ingredients. . . . therapeutically active ingredient is selected from the group consisting of anti-inflammatory, antibiotic, local anesthetic, sunscreen, retinoid, antiperspirant, antihistamine, analgesic, contraceptive, anti-acne and anti-dandruff ingredients. . . . the group consisting of steroidal or non-steroidal anti-inflammatory agents, aloe vera, chamomile, Alpha -bisabolol, Cola nitida extract, green tea extract, tea tree oil, licorice extract, allantoin, urea, caffeine or other xanthines and glycyrrhizic acid. . . . the group consisting of steroidal or non-steroidal anti-inflammatory agents, aloe vera, chamomile, Alpha -bisabolol, Cola nitida extract, green tea extract, tea tree oil, licorice extract, allantoin, urea, caffeine or other xanthines and glycyrrhizic acid. Return to Table of Contents

Page 138 of 158

Science IP Order: 3550000 Client Reference: 3456-789

Non-Patent References For this sample report, only the 2 references from HCAPLUS, the reference from Medline, the first 2 references from Embase are displayed below. L53 ANSWER 1 OF 42 HCAPLUS COPYRIGHT 2013 ACS on STN DUPLICATE 1 ACCESSION NUMBER: 2008:1292473 HCAPLUS Full-text DOCUMENT NUMBER: 149:439244 TITLE: Effective over-the-counter acne treatments AUTHOR(S): Bowe, Whitney P.; Shalita, Alan R. CORPORATE SOURCE: Department of Dermatology, SUNY Downstate Medical Center, Brooklyn, NY, USA SOURCE: Seminars in Cutaneous Medicine and Surgery (2008), 27(3), 170-176 PUBLISHER: Elsevier Inc. DOCUMENT TYPE: Journal; General Review LANGUAGE: English AB A review. Acne is the most common disease of the skin, yet only a fraction of acne sufferers are treated with prescription products by physicians. There is, however, a large and expanding market for over-the-counter (OTC) medications, many of which are not only effective but also well tolerated and cosmetically elegant. Given the presence of OTC acne medications on the television, the Internet, and store shelves, patients will be acutely aware of these OTC remedies and will have questions. Patients will expect dermatologists to advise them regarding products to use either as a sole therapy or in combination with prescription drugs. Recently, combinations of OTC acne medications in treatment regimens or "kits" have gained popularity and appear to have increased patient compliance. Quality-of-life outcomes from OTC medication use, in at least one study, have demonstrated good benefit. The most common OTC ingredients include benzoyl peroxide, a potent antibacterial agent, and salicylic acid, a mild comedolytic and antiinflammatory medication. Other, less-common OTC ingredients include sulfur, sodium sulfacetamide, and alpha hydroxy acids. Zinc, vitamin A, tea tree oil, and ayurvedic therapies also are available OTC for acne. Addnl. and better studies are needed to clarify the benefit of these latter medications. CC 1-0 (Pharmacology) Section cross-reference(s): 62 ST review acne antibacterial antiinflammatory cosmetic IT Essential oils RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Melaleuca alternifolia; effective over-the-counter acne treatments) IT Acne (comedo; effective over-the-counter acne treatments) IT Acne Anti-inflammatory agents Antibacterial agents Cosmetics and Personal care products Human Natural products, pharmaceutical (effective over-the-counter acne treatments) IT Carboxylic acids RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (hydroxy, α; effective over-the-counter acne treatments) IT 69-72-7, Salicylic acid, biological studies 94-36-0, Benzoyl peroxide, biological studies 127-56-0, Sodium

Page 139 of 158

Science IP Order: 3550000 Client Reference: 3456-789

sulfacetamide 7440-66-6, Zinc, biological studies 7704-34-9, Sulfur, biological studies 11103-57-4, Vitamin A RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (effective over-the-counter acne treatments)

Page 140 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L53 ANSWER 2 OF 42 HCAPLUS COPYRIGHT 2013 ACS on STN ACCESSION NUMBER: 2011:1431427 HCAPLUS Full-text TITLE: Anti-acne actives AUTHOR(S): Abrutyn, Eric S. CORPORATE SOURCE: TPC2 Advisors Ltd., Inc., USA SOURCE: Cosmetics & Toiletries (2011), 126(10), 684, 686-690 PUBLISHER: Allured Business Media DOCUMENT TYPE: Journal LANGUAGE: English AB Acne vulgaris (acne) is a skin disease that can be caused by multiple chronic issues including: hyperkeratinization, sebaceous gland hyperplasia with seborrhea, Propionibacterium acnes proliferation and inflammation. The management of acne can be complex, often requiring aggressive combination therapy and a long-term therapeutic strategy. Tea tree oil is sometimes considered a good substitute for benzoyl peroxide in fighting acne. Isotretinoin (13-cis retinoic acid) is also incorporated as a potent pharmacol. inhibitor of sebum secretion. The key components of anti-acne actives, their formulations and recent patents, including nano-sized silver and modulating the CIDEA protein, are discussed. CC 62 (Essential Oils and Cosmetics) ST Propionibacterium acne sebaceous gland IT INDEXING IN PROGRESS IT Propionibacterium acnes (Propionibacterium acnes caused development of acne in human) IT Dermatological agents (anti-acne agents; benzoyl peroxide, salicylic acid and tea tree oil showed effective antiacne activities in human) IT Acne Antibiotics Human Sebaceous gland (benzoyl peroxide, salicylic acid and tea tree oil showed effective antiacne activities in human)

Page 141 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L53 ANSWER 3 OF 42 MEDLINE ® on STN ACCESSION NUMBER: 1991014851 MEDLINE Full-text DOCUMENT NUMBER: PubMed ID: 2145499 TITLE: A comparative study of tea-tree oil versus Benzoylperoxide in the treatment of acne. AUTHOR: Bassett I B; Pannowitz D L; Barnetson R S CORPORATE SOURCE: Department of Dermatology, Royal Prince Alfred Hospital, Camperdown, NSW. SOURCE: The Medical journal of Australia, (1990 Oct 15) Vol. 153, No. 8, pp. 455-8. Journal code: 0400714. ISSN: 0025-729X. L-ISSN: 0025-729X. PUB. COUNTRY: Australia DOCUMENT TYPE: (CLINICAL TRIAL) (COMPARATIVE STUDY) Journal; Article; (JOURNAL ARTICLE) (RANDOMIZED CONTROLLED TRIAL) LANGUAGE: English ENTRY MONTH: 199011 ENTRY DATE: Entered STN: 17 Jan 1991 Entered Medline: 16 Nov 1990 ABSTRACT: Tea-tree oil (an essential oil of the Australian native tree Melaleuca alternifolia) has long been regarded as a useful topical antiseptic agent in Australia and has been shown to have a variety of antimicrobial activities; however, only anecdotal evidence exists for its efficacy in the treatment of various skin conditions. We have performed a single-blind, randomised clinical trial on 124 patients to evaluate the efficacy and skin tolerance of 5% tea-tree oil gel in the treatment of mild to moderate acne when compared with 5% benzoyl peroxide lotion. The results of this study showed that both 5% tea-tree oil and 5% benzoyl peroxide had a significant effect in ameliorating the patients' acne by reducing the number of inflamed and non-inflamed lesions (open and closed comedones), although the onset of action in the case of tea-tree oil was slower. Encouragingly, fewer side effects were experienced by patients treated with tea-tree oil. CONTROLLED TERM: Check Tags: Female; Male *Acne Vulgaris: DT, drug therapy Acne Vulgaris: PA, pathology Adolescent Adult Benzoyl Peroxide: AD, administration & dosage Benzoyl Peroxide: AE, adverse effects *Benzoyl Peroxide: TU, therapeutic use Child Gels Humans Oils, Volatile: AD, administration & dosage Oils, Volatile: AE, adverse effects *Oils, Volatile: TU, therapeutic use Plant Oils: AD, administration & dosage Plant Oils: AE, adverse effects *Plant Oils: TU, therapeutic use Prospective Studies Single-Blind Method Skin: PA, pathology Time Factors *Trees CAS REGISTRY NO.: 94-36-0 (Benzoyl Peroxide) CHEMICAL NAME: Gels; Oils, Volatile; Plant Oils

Page 142 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L53 ANSWER 9 OF 42 EMBASE COPYRIGHT (c) 2013 Elsevier B.V. All rights reserved on STN ACCESSION NUMBER: 2012618102 EMBASE Full-text TITLE: A review on anti-acne potential of medicinal plant extracts against propionibacterium acnes. AUTHOR: Amrita, G.; Greeshma, N.; Deepa, M.; Poornima, E.H. (correspondence) CORPORATE SOURCE: Department of Botany, Mount Carmel College (Autonomous), Bangalore, India. SOURCE: International Journal of Pharma and Bio Sciences, (July/September 2012) Vol. 3, No. 3, pp. B987-B997. Refs: 56 E-ISSN: 0975-6299 PUBLISHER: International Journal of Pharma and Bio Sciences, 103, Bhagwan Towers, 7th Line, Muthyal Reddy Nagar,, Amaravathi Road, Guntur,, 522002, India. COUNTRY: India DOCUMENT TYPE: Journal; General Review; (Review) LANGUAGE: English ENTRY DATE: Entered STN: 7 Nov 2012 ABSTRACT: Acne vulgaris (Acne) is the most common skin disorder characterized by noninflammatory comedones or inflammatory papules, pustules and nodules. Although acne does not pose serious threat to general health, it is one of the most socially distressing conditions especially for adolescents. The acne inflammation is triggered by pus forming bacteria recognized as Propionibacterium acnes and Staphylococcus epidermidis. Acne therapy includes prolonged use of comedolytic agents, antibiotics and anti-inflammatory agents that are known to cause many side effects. Moreover, the widespread and long-term use of antibiotics over the years has unfortunately led to emergence of resistant strains. To avoid side effects, traditional or herbal formulations are preferred. Herbs are safe, efficacious and multifunctional. Medicinal plant extracts are known to have enormous therapeutic potential. Plant-based preparations with little or no side effects are cyclically returning to complement dermatological therapy. They serve as safer choice or in some cases is the only effective treatment.

CONTROLLED TERM: Medical Descriptors: *acne: DT, drug therapy *acne: ET, etiology *acne: SI, side effect Amphiroa antibacterial activity antifungal activity antimicrobial activity autoimmune hepatitis: SI, side effect Ayurveda dizziness: SI, side effect DRESS syndrome: SI, side effect *drug identification dry skin: SI, side effect erythema: SI, side effect Halimeda macroloba human injection site stinging: SI, side effect liver toxicity: SI, side effect lung toxicity: SI, side effect *medicinal plant nephrotoxicity: SI, side effect nonhuman *Propionibacterium acnes

Page 143 of 158

Science IP Order: 3550000 Client Reference: 3456-789

pruritus: SI, side effect review Sargassum Sargassum binderi skin burning sensation: SI, side effect skin infection: DT, drug therapy systemic lupus erythematosus: SI, side effect Turbinaria conoides unspecified side effect: SI, side effect CONTROLLED TERM: Drug Descriptors: acetylsalicylic acid: CM, drug comparison algal extract: AN, drug analysis Aloe vera extract: DT, drug therapy Aloe vera extract: PD, pharmacology Amphiroa extract: AN, drug analysis antibiotic agent: AE, adverse drug reaction antibiotic agent: CB, drug combination antibiotic agent: DT, drug therapy antibiotic agent: PO, oral drug administration antibiotic agent: TP, topical drug administration Azadirachta indica extract: DT, drug therapy Azadirachta indica extract: PD, pharmacology benzoyl peroxide: AE, adverse drug reaction benzoyl peroxide: CB, drug combination benzoyl peroxide: DT, drug therapy benzoyl peroxide: TP, topical drug administration Calendula extract: DT, drug therapy Calendula extract: PD, pharmacology clindamycin: DT, drug therapy clindamycin: PO, oral drug administration clindamycin: TP, topical drug administration Cymbopogon citratus extract: AN, drug analysis erythromycin: DT, drug therapy erythromycin: PO, oral drug administration erythromycin: TP, topical drug administration guava extract: AN, drug analysis Halimeda macroloba extract: AN, drug analysis lupeol: AN, drug analysis metronidazole: AE, adverse drug reaction metronidazole: PO, oral drug administration metronidazole: TP, topical drug administration minocycline: AE, adverse drug reaction minocycline: CM, drug comparison minocycline: DT, drug therapy minocycline: PO, oral drug administration minocycline: TP, topical drug administration Momordica charantia extract: DT, drug therapy Momordica charantia extract: PD, pharmacology : CM, drug comparison : AN, drug analysis red clover extract: DT, drug therapy red clover extract: PD, pharmacology retinoid derivative: AE, adverse drug reaction retinoid derivative: CB, drug combination retinoid derivative: DT, drug therapy retinoid derivative: TP, topical drug administration salicylic acid: DT, drug therapy Sargassum binderi extract: AN, drug analysis tea tree oil: DT, drug therapy tea tree oil: PD, pharmacology

Page 144 of 158

Science IP Order: 3550000 Client Reference: 3456-789

tetracycline: DT, drug therapy tetracycline: PO, oral drug administration tetracycline: TP, topical drug administration tetracycline derivative: AE, adverse drug reaction tetracycline derivative: CM, drug comparison tetracycline derivative: PO, oral drug administration tetracycline derivative: TP, topical drug administration triclosan: DT, drug therapy triclosan: PO, oral drug administration triclosan: TP, topical drug administration Turbinaria conoides extract: AN, drug analysis Turbinaria conoides extract: CM, drug comparison turpentine: AN, drug analysis unclassified drug unindexed drug SUPPLEMENTARY TERM: Acne vulgaris; Comedones; Propionibacterium acnes and staphylococcus epidermidis CAS REGISTRY NO.: (acetylsalicylic acid) 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; (benzoyl peroxide) 94-36-0; (clindamycin) 18323-44-9; (erythromycin) 114-07-8, 70536-18-4; (lupeol) 545-47-1; (metronidazole) 39322-38-8, 443-48-1; (minocycline) 10118-90-8, 11006-27-2, 13614-98-7; (phenylbutazone) 129-18-0, 50-33-9, 8054-70-4; (pinene) 80-56-8; (salicylic acid) 63-36-5, 69-72-7; (tetracycline) 23843-90-5, 60-54-8, 64-75-5, 8021-86-1; (triclosan) 3380-34-5; (turpentine) 9005-90-7

Page 145 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L53 ANSWER 10 OF 42 EMBASE COPYRIGHT (c) 2013 Elsevier B.V. All rights reserved on STN ACCESSION NUMBER: 2012601594 EMBASE Full-text TITLE: Harnessing the power of crowds: Crowdsourcing as a novel research method for evaluation of acne treatments. AUTHOR: Armstrong, April W., Dr. Prof. (correspondence); Wu, Julie; Harskamp, Caitlin T.; Schupp, Clayton W. CORPORATE SOURCE: Department of Dermatology, University of California Davis Health System, 3301 C Street, Sacramento, CA 95816, United States. [email protected] AUTHOR: Cheeney, Safia CORPORATE SOURCE: University of Arizona, Tucson, AZ, United States. SOURCE: American Journal of Clinical Dermatology, (2012) Vol. 13, No. 6, pp. 405-416. Refs: 50 PUBLISHER: Adis International Ltd, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, 1311, New Zealand. COUNTRY: New Zealand DOCUMENT TYPE: Journal; Article LANGUAGE: English ENTRY DATE: Entered STN: 23 Oct 2012 ABSTRACT: Background: Crowdsourcing is a novel process of data collection that can provide insight into the effectiveness of acne treatments in real-world settings. Little is known regarding the feasibility of crowdsourcing as a means of collecting dermatology research data, the quality of collected data, and how the data compare to the published literature. Objective: The objective of this analysis is to compare acne data collected from a medical crowdsourcing site with high-quality controlled studies from peer-reviewed medical literature. Methods: Crowdsourced data was collected from 662 online acne patients. Online patients reported data in a Likert-type format to characterize their symptom severity (740 total responses) and their treatment outcomes (958 total responses). The crowdsourced data were compared with meta-analyses and reviews on acne treatment from August 20, 2010 to August 20, 2011. Results: We compared topical, oral systemic, alternative, phototherapy, and physical acne treatments of crowdsourced data to published literature. We focused on topical tretinoin due to the large number of online patient responses. While approximately 80% of tretinoin users observed clinical improvement after a 12-week treatment period in clinical trials, 46%of online users reported improvement in an unspecified time period. For most topical treatments, medication with high efficacy in clinical trials did not produce high effectiveness ratings based on the crowdsourced online data. Conclusion: While limitations exist with the current methods of crowdsourced data collection, with standardization of data collection and use of validated instruments, crowdsourcing will provide an important and valuable platform for collecting high-volume patient data in real-world settings. Adis .COPYRGT. 2012 Springer International Publishing AG. All rights reserved.

CONTROLLED TERM: Medical Descriptors: *acne: DT, drug therapy *acne: TH, therapy alternative medicine article comparative study crowding *data collection method drug efficacy drug response human information processing Internet

Page 146 of 158

Science IP Order: 3550000 Client Reference: 3456-789

major clinical study online analysis *online system phototherapy priority journal quality control standardization treatment outcome treatment response CONTROLLED TERM: Drug Descriptors: benzoyl peroxide: DT, drug therapy benzoyl peroxide: TP, topical drug administration benzoyl peroxide plus clindamycin: DT, drug therapy benzoyl peroxide plus clindamycin: TP, topical drug administration clindamycin: TP, topical drug administration cosmetic cotrimoxazole: DT, drug therapy cotrimoxazole: PO, oral drug administration doxycycline: DT, drug therapy doxycycline: PO, oral drug administration isotretinoin: DT, drug therapy isotretinoin: PO, oral drug administration oral contraceptive agent: PO, oral drug administration retinoic acid: DT, drug therapy retinoic acid: TP, topical drug administration salicylic acid: TP, topical drug administration tea tree oil tetracycline: DT, drug therapy tetracycline: PO, oral drug administration SUPPLEMENTARY TERM: Acne; Data collection CAS REGISTRY NO.: (benzoyl peroxide) 94-36-0; (clindamycin) 18323-44-9; (cotrimoxazole) 8064-90-2; (doxycycline) 10592-13-9, 17086-28-1, 564-25-0; (isotretinoin) 4759-48-2; (retinoic acid) 302-79-4; (salicylic acid) 63-36-5, 69-72-7; (tetracycline) 23843-90-5, 60-54-8, 64-75-5, 8021-86-1 CHEMICAL NAME: acnetrex; bactrim; benzaclin; doryx; retin a; roaccutane; stieva a

Page 147 of 158

Science IP Order: 3550000 Client Reference: 3456-789

L53 ANSWER 34 OF 42 IPA COPYRIGHT (c) 2013 The Thomson Corporation on STN

ACCESSION NUMBER: 2004:10666 IPA Full-text DOCUMENT NUMBER: 41-10667 TITLE: ACNE - diet doesn't count AUTHOR: Anonymous SOURCE: Pharmacy Today (New Zealand), (2004) p. 18. DOCUMENT TYPE: Journal LANGUAGE: English ABSTRACT: A review of pharmaceutical therapies available for the treatment of acne, including manifestations of disease, OTC drugs, role of keratolytic, antiseptic, antibiotic agents and available formulations in controling the disease. Hormonal products are also discussed. SECTION: 11 Pharmacology; 6 Drug Evaluations CLASSIFICATION: 84:28 Keratolytic agents; 28:08.04 Anti inflammatory agents; 84:28 Keratolytic agents; 84:00 Skin and mucous membrane preparations; 68:00 Hormones; 8:12 Antibiotics INDEX TERM: Benzoyl peroxide; Acne vulgaris INDEX TERM: Tea tree oil; Acne vulgaris INDEX TERM: Isotretinoin; Acne vulgaris INDEX TERM: Azelaic acid; Acne vulgaris INDEX TERM: Acne vulgaris; benzoyl peroxide INDEX TERM: Keratolytic agents; benzoyl peroxide INDEX TERM: Acne vulgaris; tea tree oil INDEX TERM: Anti inflammatory agents; tea tree oil INDEX TERM: Acne vulgaris; isotretinoin INDEX TERM: Keratolytic agents; isotretinoin INDEX TERM: Acne vulgaris; azelaic acid INDEX TERM: Skin and mucous membrane preparations; azelaic acid INDEX TERM: Drugs, over the counter; Acne vulgaris INDEX TERM: Hormones; Acne vulgaris INDEX TERM: Nutrition; diet INDEX TERM: Antibiotics; Acne vulgaris INDEX TERM: Plants; medicinal CAS REGISTRY NO.: 94-36-0 (Benzoyl peroxide) CAS REGISTRY NO.: 68647-73-4 (Tea tree oil) CAS REGISTRY NO.: 4759-48-2 (Isotretinoin) CAS REGISTRY NO.: 123-99-9 (Azelaic acid) CHEMICAL NAME: Benzoyl peroxide (Benzac W 5); Isotretinoin (Roaccutane)

Return to Table of Contents

Page 148 of 158

Science IP Order: 3550000 Client Reference: 3456-789

Science IP Search Documentation

Search Strategy

FILE 'REGISTRY' ENTERED AT 08:55:25 ON 09 JAN 2013 L1 2 SEA ABB=ON "TEA TREE OIL"/CN

FILE 'HCAPLUS' ENTERED AT 08:55:34 ON 09 JAN 2013 L2 0 SEA ABB=ON L1 L3 1676 SEA ABB=ON "ESSENTIAL OILS (L) MELALEUCA"/CT L4 866 SEA ABB=ON TEA TREE OIL# L5 1096 SEA ABB=ON TEA TREE(S)OIL# L6 1951 SEA ABB=ON L3 OR L4 OR L5

FILE 'REGISTRY' ENTERED AT 08:59:24 ON 09 JAN 2013 E BENZOYL PEROXIDE/CN L7 1 SEA ABB=ON "BENZOYL PEROXIDE"/CN

FILE 'STNGUIDE' ENTERED AT 08:59:35 ON 09 JAN 2013 L8 QUE ABB=ON ACNE OR ANTIACNE# OR PIMPLE# OR BLACKHEAD# OR BLACK HEAD# OR WHITEHEAD# OR WHITE HEAD# OR COMEDONE# OR COMEDO OR COMEDOS OR ZIT OR ZITS L9 QUE ABB=ON TEATREE OR TEA TREE L10 QUE ABB=ON MELAELUCA L11 QUE ABB=ON BENZOYL PEROXIDE#

FILE 'REGISTRY' ENTERED AT 09:25:00 ON 09 JAN 2013 SEL L7 1- NAME

FILE 'STNGUIDE' ENTERED AT 09:26:00 ON 09 JAN 2013 D SEL L12 QUE ABB=ON "BENZOYL PEROXIDE"/BI OR "BENZOYL SUPEROXIDE"/BI OR BENOXYL/BI OR BENZAGEL/BI OR LUCIDOL/BI OR BREVOXYL/BI OR "DIBENZOYL PEROXIDE"/BI OR "DIPHENYLGLYOXAL PEROXIDE"/BI OR PEROXYDERM/BI OR SOLUGEL/BI OR PANOXYL/BI OR LOROXIDE/BI OR BENZASHAVE/BI OR BENZOPEROXIDE/BI OR ACETOXYL/BI OR ACNEZOYL/BI

EDIT QUE L12 L13 QUE ABB=ON "BENZOYL PEROXIDE" OR "BENZOYL SUPEROXIDE" OR BENOXYL OR BENZAGEL OR LUCIDOL OR BREVOXYL OR "DIBENZOYL PEROXIDE" OR "DIPHENYLGLYOXAL PEROXIDE" OR PEROXYDERM OR SOLUGEL OR PANOXYL OR LOROXIDE OR BENZASHAVE OR BENZOPEROXI DE OR ACETOXYL OR ACNEZOYL

FILE 'HCAPLUS' ENTERED AT 09:28:41 ON 09 JAN 2013 L14 28 SEA ABB=ON (L13 OR L7 OR L11) AND (L9 OR L10 OR L6) AND L8

FILE 'WPINDEX' ENTERED AT 09:30:07 ON 09 JAN 2013 L15 1 SEA ABB=ON "BENZOYL PEROXIDE"/CN L16 12616 SEA ABB=ON L15/DCR L17 17006 SEA ABB=ON L16 OR L13 L18 1 SEA ABB=ON "TEA TREE OIL"/CN L19 606 SEA ABB=ON L18/DCR L20 1635 SEA ABB=ON L19 OR L9 OR L10 L21 33 SEA ABB=ON (L17 OR L11) AND L20 AND L8

Page 149 of 158

Science IP Order: 3550000 Client Reference: 3456-789

FILE 'FRANCEPAT, JAPIO, KOREAPAT, RUSSIAPAT' ENTERED AT 09:31:38 ON 09 JAN 2013 L22 1 SEA ABB=ON (L9 OR L10) AND (L13 OR L11) AND L8

INDEX '2MOBILITY, ADISCTI, AGRICOLA, ANABSTR, APOLLIT, BIBLIODATA, BIOSIS, BIOTECHABS, BIOTECHDS, CABA, CEABA-VTB, CHEMINFORMRX, CHEMSAFE, COMPENDEX, COMPUSCIENCE, CROPB, CSNB, DDFB, DDFU, DETHERM, DKF, DRUGB, DRUGU, EMBAL, EMBASE, ENCOMPLIT, ENCOMPLIT2, ...' ENTERED AT 09:32:18 ON 09 JAN 2013 SEA L22 ------1 FILE ADISCTI 2 FILE BIOSIS 1 FILE CABA 4 FILE DDFU 30 FILE EMBASE 1 FILE IPA 6 FILE KOSMET 2 FILE MEDLINE 6 FILE SCISEARCH L23 QUE ABB=ON L22 ------

FILE 'MEDLINE, ADISCTI, BIOSIS, DDFU, EMBASE, IPA, KOSMET, SCISEARCH, CABA' ENTERED AT 09:34:40 ON 09 JAN 2013 L24 53 SEA ABB=ON L23 L25 41 DUPLICATE REMOV L24 (12 DUPLICATES REMOVED) ANSWERS '1-2' FROM FILE MEDLINE ANSWER '3' FROM FILE ADISCTI ANSWER '4' FROM FILE BIOSIS ANSWERS '5-7' FROM FILE DDFU ANSWERS '8-32' FROM FILE EMBASE ANSWER '33' FROM FILE IPA ANSWERS '34-39' FROM FILE KOSMET ANSWER '40' FROM FILE SCISEARCH ANSWER '41' FROM FILE CABA

FILE 'USPATFULL, USPAT2' ENTERED AT 09:35:39 ON 09 JAN 2013 L26 70 SEA ABB=ON (L13 OR L11)(250A)(L9 OR L10)(250A) L8 L27 101 SEA ABB=ON (L13 OR L11)(250A)(L9 OR L10) AND L8 L28 41 SEA ABB=ON (L13/TI,AB,CLM OR L11/TI,AB,CLM) AND (L9/TI,AB,CLM OR L10/TI,AB,CLM) AND L8/TI,AB,CLM L29 121 SEA ABB=ON L26 OR L27 OR L28

FILE 'EPFULL, FRFULL, GBFULL, PATDPAFULL, PCTFULL, AUPATFULL, CANPATFULL, CNFULL, JPFULL' ENTERED AT 09:37:32 ON 09 JAN 2013 L30 85 SEA ABB=ON L26 L31 146 SEA ABB=ON L27 L32 59 SEA ABB=ON L28 L33 190 SEA ABB=ON L30 OR L31 OR L32

FILE 'IFIREF' ENTERED AT 09:41:15 ON 09 JAN 2013 L34 2 SEA ABB=ON "BENZOYL PEROXIDE"/CN SEL L34 1- UN

FILE 'IFIUDB' ENTERED AT 09:41:30 ON 09 JAN 2013 L35 9780 SEA ABB=ON 50118/UN

Page 150 of 158

Science IP Order: 3550000 Client Reference: 3456-789

FILE 'IFIPAT' ENTERED AT 09:41:33 ON 09 JAN 2013 L36 9780 SEA ABB=ON L35 L37 46 SEA ABB=ON (L36 OR L13 OR L11) AND (L9 OR L10) AND L8

Removing Duplicates FILE 'HCAPLUS' ENTERED AT 09:42:30 ON 09 JAN 2013 SEL L14 1- PN L38 2 SEA ABB=ON L14 NOT P/DT L39 26 SEA ABB=ON L14 AND P/DT

FILE 'WPINDEX' ENTERED AT 09:42:58 ON 09 JAN 2013 L40 12 SEA ABB=ON L21 NOT (GB2474930/PN OR CA2776482/PN OR US20110281 827/PN OR WO2011138678/PN OR AU2006339311/PN OR CA2208078/PN OR EP1136065/PN OR EP2422768/PN OR EP801554/PN OR US20120064135 /PN OR WO2004037225/PN OR WO2004103321/PN OR WO2004103353/PN OR WO2007099396/PN OR WO2008152444/PN OR WO2010087964/PN OR WO2011039637/PN OR WO2011039638/PN OR WO2012037000/PN OR WO2012047733/PN OR AT237298/PN OR AU2001023937/PN OR AU20042406 15/PN OR AU2004313285/PN OR AU2006201878/PN OR AU2007355106/PN OR AU2009261995/PN OR AU2010302350/PN OR AU782515/PN OR AU9645285/PN OR AU9646060/PN OR AU9646064/PN OR BR2004010358/PN OR BR9510478/PN OR CA2208079/PN OR CA2208500/PN OR CA2397068/P N OR CA2524868/PN OR CA2534306/PN OR CA2611577/PN OR CA2726836/ PN OR CA2750233/PN OR CA2776366/PN OR CA2776471/PN OR CA2776474 /PN OR CA2776692/PN OR CN102076333/PN OR CN102686205/PN OR CN1787806/PN OR EP1250116/PN OR EP1626779/PN OR EP1685824/PN OR EP1919449/PN OR EP2097065/PN OR EP2310000/PN OR EP2391342/PN OR EP2482788/PN OR EP796078/PN OR EP799018/PN OR ES2192586/PN OR IL198688/PN OR IL209697/PN OR IN2002CN01062/PN OR IN2002CN01 082/PN OR IN2007KN04925/PN OR IN2011CN00566/PN OR IN221380/PN OR JP11502504/PN OR JP2003528821/PN OR JP2005314437/PN OR JP2007502326/PN OR JP2011526302/PN OR KR2011033243/PN OR KR9607395/PN OR MX2005012381/PN OR MX2010013562/PN OR MX2012003 985/PN OR NZ520014/PN OR PT801554/PN OR US20030124202/PN OR US20030157138/PN OR US20040228822/PN OR US20040228885/PN OR US20040253275/PN OR US20050031547/PN OR US20050031571/PN OR US20050069566/PN OR US20050074414/PN OR US20050186142/PN OR US20060088561/PN OR US20060140984/PN OR US20060228321/PN OR US20060257437/PN OR US20060269485/PN OR US20070207115/PN OR US20070292355/PN OR US20090143295/PN OR US20090246156/PN OR US20100040561/PN OR US20100137198/PN OR US20100226983/PN OR US201 SEL L40 1- PN

FILE 'FRANCEPAT, JAPIO, KOREAPAT, RUSSIAPAT' ENTERED AT 09:43:30 ON 09 JAN 2013 L41 0 SEA ABB=ON L22 NOT ((GB2474930/PN OR CA2776482/PN OR US2011028 1827/PN OR WO2011138678/PN OR AU2006339311/PN OR CA2208078/PN OR EP1136065/PN OR EP2422768/PN OR EP801554/PN OR US20120064135 /PN OR WO2004037225/PN OR WO2004103321/PN OR WO2004103353/PN OR WO2007099396/PN OR WO2008152444/PN OR WO2010087964/PN OR WO2011039637/PN OR WO2011039638/PN OR WO2012037000/PN OR WO2012047733/PN OR AT237298/PN OR AU2001023937/PN OR AU20042406 15/PN OR AU2004313285/PN OR AU2006201878/PN OR AU2007355106/PN OR AU2009261995/PN OR AU2010302350/PN OR AU782515/PN OR AU9645285/PN OR AU9646060/PN OR AU9646064/PN OR BR2004010358/PN OR BR9510478/PN OR CA2208079/PN OR CA2208500/PN OR CA2397068/P N OR CA2524868/PN OR CA2534306/PN OR CA2611577/PN OR CA2726836/

Page 151 of 158

Science IP Order: 3550000 Client Reference: 3456-789

PN OR CA2750233/PN OR CA2776366/PN OR CA2776471/PN OR CA2776474 /PN OR CA2776692/PN OR CN102076333/PN OR CN102686205/PN OR CN1787806/PN OR EP1250116/PN OR EP1626779/PN OR EP1685824/PN OR EP1919449/PN OR EP2097065/PN OR EP2310000/PN OR EP2391342/PN OR EP2482788/PN OR EP796078/PN OR EP799018/PN OR ES2192586/PN OR IL198688/PN OR IL209697/PN OR IN2002CN01062/PN OR IN2002CN01 082/PN OR IN2007KN04925/PN OR IN2011CN00566/PN OR IN221380/PN OR JP11502504/PN OR JP2003528821/PN OR JP2005314437/PN OR JP2007502326/PN OR JP2011526302/PN OR KR2011033243/PN OR KR9607395/PN OR MX2005012381/PN OR MX2010013562/PN OR MX2012003 985/PN OR NZ520014/PN OR PT801554/PN OR US20030124202/PN OR US20030157138/PN OR US20040228822/PN OR US20040228885/PN OR US20040253275/PN OR US20050031547/PN OR US20050031571/PN OR US20050069566/PN OR US20050074414/PN OR US20050186142/PN OR US20060088561/PN OR US20060140984/PN OR US20060228321/PN OR US20060257437/PN OR US20060269485/PN OR US20070207115/PN OR US20070292355/PN OR US20090143295/PN OR US20090246156/PN OR US20100040561/PN OR US20100137198/PN OR US20100226983/PN OR US201

FILE 'USPATFULL, USPAT2' ENTERED AT 09:44:41 ON 09 JAN 2013 L42 87 SEA ABB=ON L29 NOT ((GB2474930/PN OR CA2776482/PN OR US2011028 1827/PN OR WO2011138678/PN OR AU2006339311/PN OR CA2208078/PN OR EP1136065/PN OR EP2422768/PN OR EP801554/PN OR US20120064135 /PN OR WO2004037225/PN OR WO2004103321/PN OR WO2004103353/PN OR WO2007099396/PN OR WO2008152444/PN OR WO2010087964/PN OR WO2011039637/PN OR WO2011039638/PN OR WO2012037000/PN OR WO2012047733/PN OR AT237298/PN OR AU2001023937/PN OR AU20042406 15/PN OR AU2004313285/PN OR AU2006201878/PN OR AU2007355106/PN OR AU2009261995/PN OR AU2010302350/PN OR AU782515/PN OR AU9645285/PN OR AU9646060/PN OR AU9646064/PN OR BR2004010358/PN OR BR9510478/PN OR CA2208079/PN OR CA2208500/PN OR CA2397068/P N OR CA2524868/PN OR CA2534306/PN OR CA2611577/PN OR CA2726836/ PN OR CA2750233/PN OR CA2776366/PN OR CA2776471/PN OR CA2776474 /PN OR CA2776692/PN OR CN102076333/PN OR CN102686205/PN OR CN1787806/PN OR EP1250116/PN OR EP1626779/PN OR EP1685824/PN OR EP1919449/PN OR EP2097065/PN OR EP2310000/PN OR EP2391342/PN OR EP2482788/PN OR EP796078/PN OR EP799018/PN OR ES2192586/PN OR IL198688/PN OR IL209697/PN OR IN2002CN01062/PN OR IN2002CN01 082/PN OR IN2007KN04925/PN OR IN2011CN00566/PN OR IN221380/PN OR JP11502504/PN OR JP2003528821/PN OR JP2005314437/PN OR JP2007502326/PN OR JP2011526302/PN OR KR2011033243/PN OR KR9607395/PN OR MX2005012381/PN OR MX2010013562/PN OR MX2012003 985/PN OR NZ520014/PN OR PT801554/PN OR US20030124202/PN OR US20030157138/PN OR US20040228822/PN OR US20040228885/PN OR US20040253275/PN OR US20050031547/PN OR US20050031571/PN OR US20050069566/PN OR US20050074414/PN OR US20050186142/PN OR US20060088561/PN OR US20060140984/PN OR US20060228321/PN OR US20060257437/PN OR US20060269485/PN OR US20070207115/PN OR US20070292355/PN OR US20090143295/PN OR US20090246156/PN OR US20100040561/PN OR US20100137198/PN OR US20100226983/PN OR US201 L43 ANALYZE L42 1- PN : 91 TERMS

FILE 'IFIPAT' ENTERED AT 09:45:48 ON 09 JAN 2013 L44 87 SEA ABB=ON L43 L45 39 SEA ABB=ON L37 NOT L44 L46 1 SEA ABB=ON L45 NOT (50118/UN OR GB2474930/PN OR CA2776482/PN OR US20110281827/PN OR WO2011138678/PN OR AU2006339311/PN OR

Page 152 of 158

Science IP Order: 3550000 Client Reference: 3456-789

CA2208078/PN OR EP1136065/PN OR EP2422768/PN OR EP801554/PN OR US20120064135/PN OR WO2004037225/PN OR WO2004103321/PN OR WO2004103353/PN OR WO2007099396/PN OR WO2008152444/PN OR WO2010087964/PN OR WO2011039637/PN OR WO2011039638/PN OR WO2012037000/PN OR WO2012047733/PN OR AT237298/PN OR AU20010239 37/PN OR AU2004240615/PN OR AU2004313285/PN OR AU2006201878/PN OR AU2007355106/PN OR AU2009261995/PN OR AU2010302350/PN OR AU782515/PN OR AU9645285/PN OR AU9646060/PN OR AU9646064/PN OR BR2004010358/PN OR BR9510478/PN OR CA2208079/PN OR CA2208500/PN OR CA2397068/PN OR CA2524868/PN OR CA2534306/PN OR CA2611577/P N OR CA2726836/PN OR CA2750233/PN OR CA2776366/PN OR CA2776471/ PN OR CA2776474/PN OR CA2776692/PN OR CN102076333/PN OR CN102686205/PN OR CN1787806/PN OR EP1250116/PN OR EP1626779/PN OR EP1685824/PN OR EP1919449/PN OR EP2097065/PN OR EP2310000/PN OR EP2391342/PN OR EP2482788/PN OR EP796078/PN OR EP799018/PN OR ES2192586/PN OR IL198688/PN OR IL209697/PN OR IN2002CN01062/ PN OR IN2002CN01082/PN OR IN2007KN04925/PN OR IN2011CN00566/PN OR IN221380/PN OR JP11502504/PN OR JP2003528821/PN OR JP2005314 437/PN OR JP2007502326/PN OR JP2011526302/PN OR KR2011033243/PN OR KR9607395/PN OR MX2005012381/PN OR MX2010013562/PN OR MX2012003985/PN OR NZ520014/PN OR PT801554/PN OR US20030124202/ PN OR US20030157138/PN OR US20040228822/PN OR US20040228885/PN OR US20040253275/PN OR US20050031547/PN OR US20050031571/PN OR US20050069566/PN OR US20050074414/PN OR US20050186142/PN OR US20060088561/PN OR US20060140984/PN OR US20060228321/PN OR US20060257437/PN OR US20060269485/PN OR US20070207115/PN OR US20070292355/PN OR US20090143295/PN OR US20090246156/PN OR US20100040561/PN OR US20100137198/PN OR US20100226983/PN OR US201 SEL L46 1- PN

FILE 'HCAPLUS' ENTERED AT 09:46:20 ON 09 JAN 2013 L47 69 SEA ABB=ON L43 L48 70 SEA ABB=ON US5804203/PN OR L47 L49 ANALYZE L48 1- PN : 361 TERMS

FILE 'EPFULL, FRFULL, GBFULL, PATDPAFULL, PCTFULL, AUPATFULL, CANPATFULL, CNFULL, JPFULL' ENTERED AT 09:46:48 ON 09 JAN 2013 L50 185 SEA ABB=ON L49 L51 9 SEA ABB=ON L43 L52 73 SEA ABB=ON L33 NOT ((50118/UN OR GB2474930/PN OR CA2776482/PN OR US20110281827/PN OR WO2011138678/PN OR AU2006339311/PN OR CA2208078/PN OR EP1136065/PN OR EP2422768/PN OR EP801554/PN OR US20120064135/PN OR WO2004037225/PN OR WO2004103321/PN OR WO2004103353/PN OR WO2007099396/PN OR WO2008152444/PN OR WO2010087964/PN OR WO2011039637/PN OR WO2011039638/PN OR WO2012037000/PN OR WO2012047733/PN OR AT237298/PN OR AU20010239 37/PN OR AU2004240615/PN OR AU2004313285/PN OR AU2006201878/PN OR AU2007355106/PN OR AU2009261995/PN OR AU2010302350/PN OR AU782515/PN OR AU9645285/PN OR AU9646060/PN OR AU9646064/PN OR BR2004010358/PN OR BR9510478/PN OR CA2208079/PN OR CA2208500/PN OR CA2397068/PN OR CA2524868/PN OR CA2534306/PN OR CA2611577/P N OR CA2726836/PN OR CA2750233/PN OR CA2776366/PN OR CA2776471/ PN OR CA2776474/PN OR CA2776692/PN OR CN102076333/PN OR CN102686205/PN OR CN1787806/PN OR EP1250116/PN OR EP1626779/PN OR EP1685824/PN OR EP1919449/PN OR EP2097065/PN OR EP2310000/PN OR EP2391342/PN OR EP2482788/PN OR EP796078/PN OR EP799018/PN OR ES2192586/PN OR IL198688/PN OR IL209697/PN OR IN2002CN01062/ PN OR IN2002CN01082/PN OR IN2007KN04925/PN OR IN2011CN00566/PN OR IN221380/PN OR JP11502504/PN OR JP2003528821/PN OR JP2005314

Page 153 of 158

Science IP Order: 3550000 Client Reference: 3456-789

437/PN OR JP2007502326/PN OR JP2011526302/PN OR KR2011033243/PN OR KR9607395/PN OR MX2005012381/PN OR MX2010013562/PN OR MX2012003985/PN OR NZ520014/PN OR PT801554/PN OR US20030124202/ PN OR US20030157138/PN OR US20040228822/PN OR US20040228885/PN OR US20040253275/PN OR US20050031547/PN OR US20050031571/PN OR US20050069566/PN OR US20050074414/PN OR US20050186142/PN OR US20060088561/PN OR US20060140984/PN OR US20060228321/PN OR US20060257437/PN OR US20060269485/PN OR US20070207115/PN OR US20070292355/PN OR US20090143295/PN OR US20090246156/PN OR US20100040561/PN OR US20100137198/PN OR US20100226983/PN OR US201

Non-Patent Literature References FILE 'HCAPLUS, MEDLINE, ADISCTI, BIOSIS, DDFU, EMBASE, IPA, KOSMET, SCISEARCH, CABA' ENTERED AT 09:50:12 ON 09 JAN 2013 L53 42 DUPLICATE REMOV L38 L25 (1 DUPLICATE REMOVED) ANSWERS '1-2' FROM FILE HCAPLUS ANSWER '3' FROM FILE MEDLINE ANSWER '4' FROM FILE ADISCTI ANSWER '5' FROM FILE BIOSIS ANSWERS '6-8' FROM FILE DDFU ANSWERS '9-33' FROM FILE EMBASE ANSWER '34' FROM FILE IPA ANSWERS '35-40' FROM FILE KOSMET ANSWER '41' FROM FILE SCISEARCH ANSWER '42' FROM FILE CABA D L53 1-2 IBIB AB HITIND D L53 3 IALL D L53 9-10 IALL D L53 34 IALL

FILE 'INPAFAMDB' ENTERED AT 09:51:05 ON 09 JAN 2013 L54 2 SEA ABB=ON (L9 OR L10) AND (L13 OR L11) AND L8 L55 0 SEA ABB=ON L54 NOT ((GB2474930/PN OR CA2776482/PN OR US2011028 1827/PN OR WO2011138678/PN OR AU2006339311/PN OR CA2208078/PN OR EP1136065/PN OR EP2422768/PN OR EP801554/PN OR US20120064135 /PN OR WO2004037225/PN OR WO2004103321/PN OR WO2004103353/PN OR WO2007099396/PN OR WO2008152444/PN OR WO2010087964/PN OR WO2011039637/PN OR WO2011039638/PN OR WO2012037000/PN OR WO2012047733/PN OR AT237298/PN OR AU2001023937/PN OR AU20042406 15/PN OR AU2004313285/PN OR AU2006201878/PN OR AU2007355106/PN OR AU2009261995/PN OR AU2010302350/PN OR AU782515/PN OR AU9645285/PN OR AU9646060/PN OR AU9646064/PN OR BR2004010358/PN OR BR9510478/PN OR CA2208079/PN OR CA2208500/PN OR CA2397068/P N OR CA2524868/PN OR CA2534306/PN OR CA2611577/PN OR CA2726836/ PN OR CA2750233/PN OR CA2776366/PN OR CA2776471/PN OR CA2776474 /PN OR CA2776692/PN OR CN102076333/PN OR CN102686205/PN OR CN1787806/PN OR EP1250116/PN OR EP1626779/PN OR EP1685824/PN OR EP1919449/PN OR EP2097065/PN OR EP2310000/PN OR EP2391342/PN OR EP2482788/PN OR EP796078/PN OR EP799018/PN OR ES2192586/PN OR IL198688/PN OR IL209697/PN OR IN2002CN01062/PN OR IN2002CN01 082/PN OR IN2007KN04925/PN OR IN2011CN00566/PN OR IN221380/PN OR JP11502504/PN OR JP2003528821/PN OR JP2005314437/PN OR JP2007502326/PN OR JP2011526302/PN OR KR2011033243/PN OR KR9607395/PN OR MX2005012381/PN OR MX2010013562/PN OR MX2012003 985/PN OR NZ520014/PN OR PT801554/PN OR US20030124202/PN OR US20030157138/PN OR US20040228822/PN OR US20040228885/PN OR US20040253275/PN OR US20050031547/PN OR US20050031571/PN OR US20050069566/PN OR US20050074414/PN OR US20050186142/PN OR

Page 154 of 158

Science IP Order: 3550000 Client Reference: 3456-789

US20060088561/PN OR US20060140984/PN OR US20060228321/PN OR US20060257437/PN OR US20060269485/PN OR US20070207115/PN OR US20070292355/PN OR US20090143295/PN OR US20090246156/PN OR US20100040561/PN OR US20100137198/PN OR US20100226983/PN OR US201

FILE 'HCAPLUS, WPINDEX, USPATFULL, USPAT2, EPFULL, GBFULL, PCTFULL, AUPATFULL, CANPATFULL, CNFULL, JPFULL, IFIPAT' ENTERED AT 09:52:27 ON 09 JAN 2013 L56 199 DUPLICATE REMOV L39 L40 L42 L52 L46 (0 DUPLICATES REMOVED) ANSWERS '1-26' FROM FILE HCAPLUS ANSWERS '27-38' FROM FILE WPINDEX ANSWERS '39-105' FROM FILE USPATFULL ANSWERS '106-125' FROM FILE USPAT2 ANSWERS '126-130' FROM FILE EPFULL ANSWER '131' FROM FILE GBFULL ANSWERS '132-168' FROM FILE PCTFULL ANSWERS '169-177' FROM FILE AUPATFULL ANSWERS '178-191' FROM FILE CANPATFULL ANSWERS '192-197' FROM FILE CNFULL ANSWER '198' FROM FILE JPFULL ANSWER '199' FROM FILE IFIPAT D 1-26 IBIB AB HITIND D 39-45 IBIB AB KWIC D 132-135 IBIB AB KWIC D 199 IBIB AB KWIC

Return to Table of Contents

Page 155 of 158

Science IP Order: 3550000 Client Reference: 3456-789

Sources Used For more information about individual databases, please see the STN Database Summary Sheets at http://stnguide.cas.org/

FILE REGISTRY (CAS Registry) STRUCTURE FILE UPDATES: 8 JAN 2013 HIGHEST RN 1416207-43-6 DICTIONARY FILE UPDATES: 8 JAN 2013 HIGHEST RN 1416207-43-6

FILE HCAPLUS (Chemical Abstracts Plus) FILE COVERS 1907 - 9 Jan 2013 VOL 158 ISS 3 FILE LAST UPDATED: 8 Jan 2013 (20130108/ED) REVISED CLASS FIELDS (/NCL) LAST RELOADED: November 2012 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: November 2012

FILE WPINDEX (Derwent World Patents Index) FILE LAST UPDATED: 7 JAN 2013 <20130107/UP> MOST RECENT UPDATE: 201302 <201302/DW> DERWENT WORLD PATENTS INDEX, COVERS 1963 TO DATE

FILE FRANCEPAT (French Patent Abstracts) FILE LAST UPDATED: 6 NOV 2009 <20091106/UP> FILE COVERS 1961 TO NOVEMBER 6, 2009 - FILE CLOSED

FILE JAPIO (Japan Patent Information Organization) FILE LAST UPDATED: 7 JAN 2013 <20130107/UP>

FILE KOREAPAT (Korean Patent Abstracts) FILE LAST UPDATED: 18 DEC 2012 <20121218/UP>

FILE RUSSIAPAT (Russian Patent Abstracts) FILE LAST UPDATED: 27 DEC 2012 <20121227/UP> FILE COVERS 1924 TO DATE

FILE STNINDEX

FILE MEDLINE (MEDLINE) FILE LAST UPDATED: 8 Jan 2013 (20130108/UP). FILE COVERS 1946 TO DATE.

FILE ADISCTI (Adis Clinical Trials Insight) FILE COVERS 1998 TO 4 Jan 2013 (20130104/ED) FILE LAST UPDATED: 4 JAN 2013 (20130104/ED)

FILE BIOSIS (BIOSIS Previews) FILE COVERS 1926 TO DATE. RECORDS LAST ADDED: 2 January 2013 (20130102/ED)

FILE DDFU (Derwent Drug File for nonsubscribers) FILE LAST UPDATED: 22 DEC 2012 <20121222/UP> >>> FILE COVERS 1983 TO DATE <<<

FILE EMBASE (Excerpta Medica) FILE COVERAGE: Embase-originated material 1947 to 7 Jan 2013 (20130107/ED Unique MEDLINE content 1948 to present Emtree thesaurus updated on October 8, 2012. See NEWS for details.

FILE IPA (International Pharmaceutical Abstracts) FILE COVERS 1970 TO 4 DEC 2012 (20121204/ED)

Page 156 of 158

Science IP Order: 3550000 Client Reference: 3456-789

FILE KOSMET (Cosmetic & Perfume Science and Technology) FILE LAST UPDATED: 8 JAN 2013 <20130108/UP> FILE COVERS 1968 TO DATE.

FILE SCISEARCH ( Expanded) FILE COVERS 1974 TO 7 Jan 2013 (20130107/ED)

FILE CABA (CAB Abstracts) FILE LAST UPDATED: 9 JAN 2013 <20130109/UP> FILE COVERS 1973 TO DATE

FILE USPATFULL (U.S. Patents Full Text) FILE COVERS 1971 TO PATENT PUBLICATION DATE: 8 Jan 2013 (20130108/PD) FILE LAST UPDATED: 8 Jan 2013 (20130108/ED) HIGHEST GRANTED PATENT NUMBER: US8353061 HIGHEST APPLICATION PUBLICATION NUMBER: US20120265827

FILE USPAT2 (U.S. Patents Full Text Latest Publications) FILE COVERS 2001 TO PUBLICATION DATE: 8 Jan 2013 (20130108/PD) FILE LAST UPDATED: 8 Jan 2013 (20130108/ED) HIGHEST GRANTED PATENT NUMBER: US8353061 HIGHEST APPLICATION PUBLICATION NUMBER: US20120265827

FILE EPFULL (European Patents Full text) FILE LAST UPDATED: 3 JAN 2013 <20130103/UP> FILE COVERS 1978 TO DATE

FILE FRFULL (French Patents Full Text) FILE LAST UPDATED: 8 JAN 2013 <20130108/UP> FILE COVERS 1902 TO DATE

FILE GBFULL (British Patents Full Text) FILE LAST UPDATED: 7 JAN 2013 <20130107/UP> FILE COVERS 1855 TO DATE

FILE PATDPAFULL (German Patents Full Text) FILE LAST UPDATED: 3 JAN 2013 <20130103/UP> MOST RECENT UPDATE WEEK: 201301 <201301/EW> FILE COVERS 1981 TO DATE

FILE PCTFULL (PCT Published Patent Applications Full Text) FILE LAST UPDATED: 7 JAN 2013 <20130107/UP> FILE COVERS 1978 TO DATE

FILE AUPATFULL (Australia Patents Full Text) FILE LAST UPDATED: 7 JAN 2013 <20130107/UP> FILE COVERS 1964 TO DATE.

FILE CANPATFULL FILE LAST UPDATED: 7 JAN 2013 <20130107/UP> FILE COVERS 1906 TO DATE

FILE CNFULL FILE LAST UPDATED: 4 JAN 2013 <20130104/UP> FILE COVERS 1985 TO DATE

FILE JPFULL FILE LAST UPDATED: 2 JAN 2013 <20130102/UP>

Page 157 of 158

Science IP Order: 3550000 Client Reference: 3456-789 FILE COVERS APPLICATION YEARS FROM 2004 ONWARDS

FILE IFIREF (IFI Uniterm and U.S. Class Reference File) FILE COVERS CURRENT DATA. LAST UPDATE: NOVEMBER 2009

FILE IFIUDB (IFI Uniterm Database) FILE COVERS 1950 TO PATENT PUBLICATION DATE: 3 Jan 2013 (20130103/PD) FILE LAST UPDATED: 4 Jan 2013 (20130104/ED) HIGHEST GRANTED PATENT NUMBER: US8347411 HIGHEST APPLICATION PUBLICATION NUMBER: US20130007934

FILE IFIPAT (IFI Patent Database) FILE COVERS 1950 TO PATENT PUBLICATION DATE: 3 Jan 2013 (20130103/PD) FILE LAST UPDATED: 4 Jan 2013 (20130104/ED) HIGHEST GRANTED PATENT NUMBER: US8347411 HIGHEST APPLICATION PUBLICATION NUMBER: US20130007934

FILE INPAFAMDB FILE LAST UPDATED: 3 JAN 2013 <20130103/UP> FILE COVERS 1790 TO DATE.

Return to Table of Contents

Page 158 of 158

Top View